<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1901256680
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Cisplatin 1 mg/ml VIAL
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CISPLATIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="INTAS PHARMACEUTICALS LIMITED" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            INTAS PHARMACEUTICALS LIMITED
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 540]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ZIMMO TRADING ESTABLISHMENT
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Accord Healthcare Limited
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01XA01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Tinplat is a part of a group of medicines called cytostatics, which are used in the treatment of cancer. Cisplatin can<br />be used alone but more commonly, Cisplatin is used in combination with other cytostatics.<br />Tinplat can destroy cells in your body that may cause certain types of cancer (tumour of testis, tumour of ovary,<br />tumour of the bladder, head and neck epithelial tumour, lung cancer and for cervical cancer in combination with<br />radiotherapy).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>You should not be given Tinplat if<br />&bull; you are allergic to cisplatin or to any of the other ingredients of this medicine (listed in section 6)<br />&bull; you have had hypersensitivity to similar anticancer medicines in the past<br />&bull; you have severe kidney disease you have hearing difficulties<br />&bull; you have very low numbers of blood cells (called &ldquo;myelosuppression&rdquo;), (your doctor will check this with a blood<br />test)<br />&bull; you are dehydrated<br />&bull; you need to have a vaccine for &ldquo;yellow fever&rdquo;<br />&bull; you are breastfeeding<br />Warnings and Precautions<br />Talk to your doctor, pharmacist or nurse before using Tinplat<br />&bull; if you have any symptoms of nerve damage (peripheral neuropathy) such as pins and needles, numbness or poor<br />sense of touch<br />&bull; if you have had radiation therapy to your head<br />Taking other medicines<br />Tell your doctor or pharmacist if you are taking/ using, have recently taken/ used or might take/ use any other<br />medicines, for example:<br />&bull; Some antibiotics, such as Cephalosporins, Aminoglycosides and Amphotericin B and some substances used in<br />medical imaging may make the side effects of Cisplatin worse; particularly kidney problems<br />&bull; Some water tablets called loop diuretics, antibiotics called Aminoglycosides and an anticancer medicine called<br />Ifosfamide may make the hearing loss side effect of Cisplatin worse<br />&bull; Bleomycin (anticancer medicine), Methotrexate (used to treat cancer or arthritis) and Paclitaxel (anticancer<br />medicine) may produce more side effects if Cisplatin is also being used<br />&bull; The effectiveness of oral anticoagulants may be affected. Your doctor will monitor with blood tests<br />&bull; Use of certain antihistamines may hide the symptoms of balance changes (such as dizziness or tinnitus)<br />&bull; The effectiveness of medicines used for the treatment of convulsions (e.g. Phenytoin) may be reduced, so blood<br />levels may need to be checked<br />&bull; Cisplatin may make the side effects of the anticancer medicine Ifosfamide worse<br />Pregnancy, Breastfeeding and Fertility<br />If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor or<br />pharmacist for advice before using this medicine.<br />Due to the possible risk of birth defects, male and female patients should take contraceptive measures both during<br />treatment with Cisplatin and for at least 6 months after treatment has ended.<br />Treatment with Cisplatin can potentially cause permanent sterility in men. It is recommended that those who wish to<br />become fathers in the future discuss the possibility of cryoconservation (freezing) of their sperm prior to treatment.<br />Tell your doctor if you have any concerns.<br />Driving and using machines<br />Do not drive or use machines if you experience any side effect which may lessen your ability to do so.<br />Tinplat contains Sodium<br />Tinplat contains 3.5mg sodium (main component of cooking/table salt) in each ml. This is equivalent to 38.3% of the<br />recommended maximum daily dietary intake of sodium for an adult.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Dosage and method of administration<br />Tinplat should only be given by a specialist in cancer treatment.<br />Tinplat should be diluted with at least 1 litre of the following solutions:<br />&bull; sodium chloride 0.9%<br />&bull; mixture of sodium chloride 0.9% / glucose 5% (1:1), (resulting final concentrations sodium chloride 0.45%, glucose<br />2.5%)<br />&bull; sodium chloride 0.9% and 1.875% mannitol, for injection<br />&bull; sodium chloride 0.45%, glucose 2.5% and 1.875% mannitol for injection<br />Tinplat is only given by injection into a vein (an intravenous infusion).<br />Supportive equipment should be available to control anaphylactic reactions.<br />Tinplat should not come into contact with any materials that contain Aluminium.<br />The recommended dosage of Tinplat depends on your well-being, the anticipated effects of the treatment and whether<br />or not Tinplat is given on its own (monotherapy) or in combination with other agents (combination chemotherapy).<br />Tinplat (monotherapy)<br />The following dosages are recommended:<br />&bull; a single dosage of 50 to 120mg/m&sup2; body surface, every 3 to 4 weeks<br />&bull; 15 to 20mg/m&sup2; per day over a 5-day period, every 3 to 4 weeks<br />Tinplat in combination with other chemotherapeutic agents (combination chemotherapy)<br />&bull; 20mg/m&sup2; or more, once every 3 to 4 weeks<br />For treatment of cervical cancer, Tinplat used in combination with radiotherapy<br />&bull; typical dose 40mg/m&sup2; weekly for 6 weeks<br />In order to avoid or reduce kidney problems, you are advised to drink copious amounts of water for a period of 24<br />hours following treatment with Tinplat.<br />If you have been received more Tinplat than you should<br />Your doctor will ensure that the correct dose for your condition is given. In case of overdose, you may experience<br />increased side effects. Your doctor may give you symptomatic treatment for these side effects. If you think you<br />received too much Cisplatin, immediately contact your doctor.<br />Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if<br />you are not sure.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Cisplatin can cause side effects, although not everybody gets them.<br />If any of the following happen, tell your doctor immediately:<br />&bull; severe allergic reaction - you may experience a sudden itchy rash (hives), swelling of the hands, feet, ankles, face,<br />lips, mouth or throat (which may cause difficulty in swallowing or breathing), and you may feel you are going to<br />faint<br />&bull; severe chest pains possibly radiating to the jaw or arm with sweating, breathlessness and nausea (heart attack)<br />&bull; pain or swelling at the injection site during the injection (may be due to the injection not going into the vein<br />properly, which can lead to serious damage to the tissues around the injection site)<br />&bull; stroke<br />&bull; brain dysfunction (confusion, slurred speech, sometimes blindness, memory loss and paralysis)<br />These are serious side effects. You may need urgent medical attention.<br />Very common (may affect more than 1 in 10 people)<br />&bull; decrease in bone marrow function (which can affect the production of blood cells)<br />&bull; decrease in white blood cells, which makes infections more likely (leukopenia)<br />&bull; decrease in blood platelets, which increases the risk of bruising and bleeding (thrombocytopenia)<br />&bull; reduction of red blood cells which can cause weakness and your skin to look pale (anaemia)<br />&bull; reduced level of sodium in the blood<br />&bull; high temperature<br />Common (may affect up to 1 in 10 people)<br />&bull; severe pain or swelling in either of your legs, chest pain, or difficulty breathing (possibly indicating harmful blood<br />clots in a vein)<br />&bull; fast, irregular or slow heart beats<br />&bull; sepsis (blood poisoning)<br />Uncommon (may affect up to 1 in 100 people)<br />&bull; severe allergic reaction (see above)<br />&bull; damage to the ear (ototoxicity)<br />&bull; reduced level of magnesium in the blood<br />&bull; abnormal sperm production<br />Rare (may affect up to 1 in 1,000 people)<br />&bull; increased risk of acute leukaemia<br />&bull; seizures (fits)<br />&bull; fainting, headache, confusion and loss of vision<br />&bull; loss of certain types of brain function, including brain dysfunction characterised by<br />&bull; spasms and reduced level of consciousness<br />&bull; heart attack<br />&bull; inflammation of mucous membranes of the mouth (stomatitis).<br />&bull; peripheral neuropathy of the sensory nerves, characterised by tickling, itching or tingling without cause and<br />sometimes with loss of taste, touch, sight, sudden shooting pains from the neck through the back and into the legs<br />when bending forward<br />Very rare (may affect up to 1 in 10,000 people)<br />&bull; heart arrest<br />Not known (frequency cannot be estimated from the available data)<br />&bull; signs of infection such as fever or sore throat<br />&bull; haemolytic anaemia<br />&bull; inappropriate release of vasopressin hormone (ADH) which may lead to low sodium in the blood and water retention<br />&bull; blood amylase (enzyme) increased<br />&bull; dehydration<br />&bull; reduced level of calcium, phosphate, potassium in the blood<br />&bull; high level of uric acid in the blood<br />&bull; muscle cramping<br />&bull; spinal disease which may cause a sensation of electric shocks passing into your limbs<br />&bull; loss of taste<br />&bull; problems with your eyesight (blurred vision, odd colours, loss of vision or eye pain)<br />&bull; ringing in the ears or deafness<br />&bull; heart problems<br />&bull; unusually cold or white hands and feet<br />&bull; tingling, numbness or tremor in your hands, feet, arms or legs<br />&bull; persistent headache<br />&bull; feeling or being sick<br />&bull; loss of appetite, anorexia<br />&bull; hiccups<br />&bull; diarrhoea<br />&bull; liver enzymes increased, bilirubin increased<br />&bull; difficulty breathing<br />&bull; problems with your kidneys or urine<br />&bull; hair loss<br />&bull; rash<br />&bull; extreme tiredness/weakness<br />&bull; swelling or soreness where the injection was given<br />&bull; cramps or spasms<br />&bull; burning or prickling sensation<br />&bull; unexpected bruising or bleeding<br />&bull; haemolytic uremic syndrome which may cause changes to the kidneys and blood<br />Cisplatin may lead to problems with your blood, liver and kidneys. Your doctor will take blood samples to check for<br />these problems.<br />Reporting of side effects<br />If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in<br />this leaflet. You can also report the side effects directly to the National Pharmacovigilance Centre (NPC) (see Section 6).<br />By reporting side effects, you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Keep out of sight and reach of children.<br />Do not store above 30&deg;C.<br />Do not refrigerate or freeze.<br />Keep vial in the outer carton in order to protect from light.<br />Do not use this medicine after the expiry date which is stated on the pack. The expiry date refers to the last day of that<br />month.<br />This product is a concentrate and must be diluted before use.<br />Single-use vial.<br />After dilution: Chemical and physical in-use stability after dilution remains stable for 24 hours at 20&deg;C-25&deg;C room<br />temperature.<br />From a microbiological point of view, the diluted solution should be used immediately. If not used immediately, in-use<br />storage times and conditions prior to use are the responsibility of the user and dilution should be taken place in<br />controlled and validated aseptic conditions.<br />Do not use this medicine if you notice visible signs of deterioration.<br />All materials that have been used for the preparation and administration, or which have been in contact with Cisplatin<br />in any way, must be disposed of according to local cytotoxic guidelines<br />If you find the solution cloudy or a deposit that does not dissolve is noticed, the product should be discarded.<br />Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of<br />medicines no longer required. These measures will help to protect the environment.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active ingredient is Cisplatin.<br />Each ml contains 1mg Cisplatin.<br />Each 10ml vial contains 10mg of Cisplatin<br />Each 25ml vial contains 25mg of Cisplatin<br />Each 50ml vial contains 50mg of Cisplatin<br />Each 100ml vial contains 100mg of Cisplatin<br />The other ingredients include sodium chloride, hydrochloric acid (for pH adjustment) and sodium hydroxide (for pH<br />adjustment) and water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Tinplat is a clear, colourless to pale yellow solution free from particles.
Pack sizes:
1 × 10ml vial (10mg/10ml)
1 × 25ml vial (25mg/25ml)
1 × 50ml vial (50mg/50ml)
1 × 100ml vial (100mg/100ml)
Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorization Holder (MAH):<br />Accord Healthcare Limited<br />Sage House, 319 Pinner Road, North Harrow,<br />Middlesex HA1 4HF, United Kingdom</p><p><br />Manufactured for Accord Healthcare Limited by:<br />Intas Pharmaceuticals Limited<br />Ahmedabad-380054, Gujarat state, India.<br />For any information about this medicinal product, please contact us by:<br />E-mail: mena-pv@accord-healthcare.com</p><p><br />This leaflet was last approved in 07/2020, version number SA-02.<br />To report any side effect(s) in Saudi Arabia, please contact:<br />The National Pharmacovigilance Centre (NPC)<br />&bull; SFDA Call Centre: 19999<br />&bull; E-mail: npc.drug@sfda.gov.sa<br />&bull; Website: https://ade.sfda.gov.sa/</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 02/2022.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ينتمي تنبلات إلى مجموعة الأدوية التي تُسمى مثبطات نمو الخلايا، ويتم استخدام هذه الأدوية في علاج السرطان. ويُمكِن استخدام سيسبلاتين كعلاج أحادي، ولكن<br />الأكثر شيوعًا هو استعماله بمصاحبة مثبطات نمو الخلايا الأخرى.<br />يقضي تنبلات على خلايا الجسم التي قد تتسبب في حدوث أنواعًا مُعيَّنة من السرطان (ورم الخصية، ورم المبيض، ورم المثانة، الورم الطلائي في الرَّأس والرقبة<br />وسرطان الرئة ويتم استخدامه في علاج سرطان عنق الرحم بالتزامن مع العلاج الإشعاعي).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحظر عليك استخدام سيسبلاتين إذا<br />( &bull; كنت تعاني من حساسية تجاه سيسبلاتين أو تجاه أيِّ مكون من المكونات الأخرى الداخلة في تركيب هذا الدواء (المدرجة في القسم رقم ٦<br />&bull; كنت قد عانيت في السابق من فرط الحساسية تجاه أدوية معالجة السرطان المشابهة<br />&bull; كنت تعاني من مرض حاد بالكلى أو تعاني من صعوبة في السمع<br />&bull; كنت تعاني من قلة عدد خلايا الدم (يسمى كبت نخاع العظام) (سيتحقق طبيبك المعالج من ذلك من خلال إجراء تحليل للدم)<br />&bull; كنت تعاني من الجفاف<br />&bull; كنت بحاجة إلى تلقي لقاح ضد &quot;الحمى الصفراء&quot;<br />&bull; كنتِ ترضعين رضاعة طبيعية<br />تحذيرات واحتياطات<br />تحدَّث إلى طبيبك المعالج أو الصيدلي أو الممرض قبل استخدام تنبلات إذا<br />&bull; كنت تعاني من أي أعراض تلف الأعصاب (الاعتلال العصبي الطرفي) مثل وخز &quot;الإبر أو الدبابيس&quot; أو تنميل أو ضعف بحاسة اللمس<br />&bull; كنت قد خضعت للعلاج الإشعاعي على الرأس<br />استخدام تنبلات مع الأدوية الأخرى<br />أخبر طبيبك المعالج أو الصيدلي إذا كنت تتناول/تستخدم أية أدوية أخرى أو قد تناولتها /استخدمتها مؤخرًا أو قد تتناولها/تستخدمها وتشمل ما يلي:<br />&bull; بعض المضادات الحيوية، مثل السيفالوسبورينات والأمينوجليكوزيدات وأمفوتيريسين &quot;ب&quot; وبعض المواد المستخدمة في الأشعة الطبية، حيث قد تتسبب في<br />تفاقم التأثيرات الجانبية لدواء سيسبلاتين؛ وبصفة خاصة حدوث اضطرابات بالكلى<br />&bull; بعض أقراص الماء وتسمى مدرات البول الحلقية والمضادات الحيوية التي تسمى الأمينوجليكوزيدات ودواء معالج للسرطان يسمى إيفوسفاميد، حيث قد تؤدي<br />إلى تفاقم التأثير الجانبي &quot;فقدان السمع&quot; لدواء سيسبلاتين<br />&bull; بلوميسين (دواء معالج للسرطان) وميثوتريكسيت (أدوية تستخدم لعلاج السرطان أو التهاب المفاصل) وباكليتاكسيل (دواء معالج للسرطان)، حيث قد تؤدي إلى<br />تفاقم المزيد من التأثيرات الجانبية إذا تم استعمالها بمصاحبة سيسبلاتين<br />&bull; قد تتأثر فعالية الأدوية المضادة لتجلط الدم التي يتم تناولها عن طريق الفم. سيقوم طبيبك المعالج بمتابعة حالتك عن طريق نتائج اختبارات الدَّم<br />&bull; قد يخفي استخدام بعض مضادات الهيستامين أعراض تغيرات التوازن (مثل دوخة أو طنين بالأذن)<br />&bull; قد تنخفض فعالية الأدوية التي تستخدم لعلاج التشنجات (مثل فينيتوين)، لذلك قد يلزم فحص مستويات الدم<br />&bull; قد يُزيد استخدام سيسبلاتين من تفاقم التأثيرات الجانبية للدواء المضاد للسرطان (إيفوسفاميد)<br />الحمل، الرضاعة الطبيعية والخصوبة<br />إذا كنتِ حاملًا أو ترضعين رضاعة طبيعية أو تعتقدين أنكِ قد تكونين حاملاً أو تخططين للحمل، فاستشيري طبيبك المعالج أو الصيدلي للحصول على النصيحة<br />قبل استخدام هذا الدَّواء.<br />بسبب الخطر المحتمل لحدوث عيوب خلقية، يوصي المرضى من الذكور والإناث اتخاذ إجراءات وقائية لمنع الحمل قبل وأثناء العلاج باستخدام سيسبلاتين ولمدة<br />٦ أشهر على الأقل بعد الانتهاء من العلاج.<br />يمكن أن يتسبب العلاج باستخدام سيسبلاتين في حدوث عقم دائم في المرضى من الرجال. يوصي بمناقشة كيفية حفظ الحيوانات المنوية (بالتجميد) قبل تلقي العلاج<br />لأولئك المرضى الذين يرغبون في الإنجاب مستقبلًا. تحدث إلى طبيبك المعالج إذا كان لديك اية استفسارات.<br />القيادة واستخدام الآلات<br />يحظر قيادة السيارات أو استخدام الآلات، إذا كنت تُعاني من أي تأثيرات جانبية قد تقلل من قدرتك على القيام بهذه الأمور.<br />يحتوي تنبلات على الصوديوم<br />يحتوي تنبلات على ۳٫٥ ملغم من الصوديوم (المكون الرئيسي ملح الطعام/ملح المائدة) في كل ملليمتر. وهذا التركيز يُعادل ۳۸٫۳ ٪ من الحد الأقصى المُوصى<br />بتناوُله يوميًا من الصوديوم بالنسبة للشخص البالغ.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>الجرعة وكيفية إعطاء الدواء<br />يجب إعطائك تنبلات فقط من قبل متخصص في علاج السرطان.<br />يجب تخفيف تنبلات بما لا يقل عن ۱ لتر من المحاليل التَّالية:<br />٪ &bull; كلوريد الصوديوم ۰٫۹<br />(٪ ۱)، (التركيزات النهائية الناتجة: كلوريد الصوديوم ۰٫٤٥ ٪ / جلوكوز ۲٫٥ :۱) ٪ &bull; خليط من كلوريد الصوديوم ۰٫۹ ٪ / جلوكوز ٥<br />&bull; كلوريد الصوديوم ۰٫۹ ٪ ومانيتول ۱٫۸۷٥ ٪ محلول للحقن<br />&bull; كلوريد الصوديوم ۰٫٤٥ ٪ وجلوكوز ۲٫٥ ٪ ومانيتول ۱٫۸۷٥ ٪، محلول للحقن<br />يُعطى تنبلات فقط عبر الحقن في الوريد (التسريب الوَريدي).<br />يجب توافر أجهزة مناسبة للتعامل مع تفاعلات فرط الحساسية.<br />يحظر أي تلامس بين سيسبلاتين وأي مواد تحتوي على الألومنيوم.<br />تعتمد الجرعة الموصى بها من تنبلات على الحالة الصحية العامة للمريض والتأثيرات المتوقعة للعلاج وهل يتم إعطاء تنبلات بمفرده (كعلاج أحادي) أو<br />بمصاحبة أدوية أخرى (مجموعة من أدوية العلاج الكيميائي).<br />في حالة استخدام تنبلات (كعلاج أحادي)<br />يُنصح باتباع الجرعات التالية:<br />&bull; جرعة واحدة تتراوح بين ٥۰ و ۱۲۰ ملغم/م ۲ من مساحة سطح الجسم كل ۳ إلى ٤ أسابيع<br />&bull; جرعة تتراوح بين ۱٥ و ۲۰ ملغم/م ۲ يوميًا على مدار مدة ٥ أيام، كل ۳ إلى ٤ أسابيع<br />في حالة استخدام تنبلات بمصاحبة أدوية العلاج الكيميائي الأخرى (العلاج الكيميائي المركب)<br />&bull; جرعة ۲۰ ملغم/ م ۲ أو أكثر، مرة واحدة كل ۳ إلى ٤ أسابيع<br />لعلاج سرطان عنق الرحم، يستخدم تنبلات بمصاحبة العلاج الإشعاعي<br />&bull; الجرعة القياسية هي ٤۰ ملغم/ م ۲ مرّة واحدة أسبوعيًا لمدة ٦ أسابيع.<br />يوصي بشرب كميات وفيرة من الماء لمدة ۲٤ ساعة بعد العلاج باستخدام تنبلات لتجنب أو تقليل مشاكل الكلى.<br />إذا تم إعطائك تنبلات أكثر مما يجب<br />سيتأكد طبيبك المعالج من إعطائك الجرعة الصحيحة المناسبة لحالتك الصحية. قد تشعر بزيادة شدة التأثيرات الجانبية في حالة تلقي جرعة زائدة. قد يعطيك طبيبك<br />المعالج العلاج المناسب لهذه التأثيرات الجانبية. إذا كنت تعتقد أنه تم إعطائك جرعة كبيرة من سيسبلاتين أكثر مما يجب، فاتصل بطبيبك المعالج فورًا.<br />استخدم هذا الدَّواء تمامًا كما أخبرك طبيبك المعالج أو الصيدلي. راجع طبيبك المعالج أو الصيدلي إذا لم تكن متأكدًا من كيفية الاستخدام.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>قد يسبب هذا الدواء مثله مثل كافة الأدوية تأثيرات جانبية على الرغم من عدم حدوثها لجميع المرضى.<br />أخبر طبيبك المعالج فورًا إذا تعرضت لأي من التأثيرات الجانبية التالية:<br />&bull; تفاعلات حساسية شديدة، فقد تتعرض لطفح جلدي مفاجئ (ارتيكاريا) وتورُّم باليدين أو القدمين أو الكاحلين أو الوجه أو الشفتين أو الفم أو الحَلْق (مما قد يتسَبب<br />في صعوبة البلع أو التنفس) وقد تشعر أنك على وشك الإصابة بإغماء<br />&bull; آلام حادة بالصدر قد تصل إلى الفك أو الذراع مصحوب بزيادة إفراز العرق وصعوبة التنفس وغثيان (أزمة قلبية)<br />&bull; ألم أو تورم في موضع الحقن أثناء الحقن (قد يكون بسبب عدم دخول الحقنة في الوريد بشكل صحيح مما قد يؤدي إلى تلف خطير في الأنسجة المحيطة بموضع<br />الحقن)<br />&bull; سكتة دماغية<br />&bull; اختلال بوظائف الدماغ (ارتباك وعدم وضوح الكلام وفي بعض الأحيان: الإصابة بالعمى، فقدان الذاكرة وشلل)</p><p>تعد هذه التأثيرات الجانبية خطيرة، وقد تحتاج إلى رعاية طبية عاجلة.<br />تأثيرات جانبية شائعة جدًا (قد تُؤثر على أكثر من شخص واحد من بين كل ۱۰ أشخاص)<br />&bull; انخفاض في وظيفة نخاع العظام (يمكن أن يؤثر ذلك على إنتاج خلايا الدم)<br />&bull; انخفاض عدد خلايا الدم البيضاء، مما يؤدي إلى سهولة الإصابة بالعدوى (قلة كرات الدم البيضاء)<br />&bull; انخفاض عدد الصفائح الدموية مما يزيد من خطر حدوث كدمات ونزيف (نقص في الصفائح الدموية)<br />&bull; انخفاض عدد خلايا الدم الحمراء مما يسبب حدوث ضعف عام وشحوب البشرة (فقر الدم)<br />&bull; انخفاض مستوى الصوديوم في الدَّم<br />&bull; ارتفاع درجة حرارة الجسم<br />تأثيرات جانبية شائعة (قد تُؤثر على ما يصل إلى شخص واحد من بين كل ۱۰ أشخاص)<br />&bull; ألم شديد أو تورم في أحد الساقين أو ألم بالصدر أو صعوبة بالتنفس (ربما تشير هذه الأعراض إلى حدوث جلطات دموية بالوريد ضارة بالجسم)<br />&bull; سرعة ضربات القلب أو عدم انتظامها أو بطئها<br />&bull; تعفن الدم (تسمم دموي)<br />تأثيرات جانبية غير شائعة (قد تُؤثر على ما يصل إلى شخص واحد من بين كل ۱۰۰ شخص)<br />&bull; تفاعلات حساسية شديدة (انظر أعلاه)<br />&bull; حدوث ضرر للأذن (السمية الأذنية)<br />&bull; انخفاض مستوى الماغنيسيوم بالدم<br />&bull; انتاج حيوانات منوية غير طبيعية<br />تأثيرات جانبية نادرة (قد تُؤثر على ما يصل إلى شخص واحد من بين كل ۱,۰۰۰ شخص)<br />&bull; زيادة خطر الإصابة بسرطان الدم الحاد<br />&bull; نوبات تشنجية (نوبات)<br />&bull; إغماء وصداع وارتباك وفقدان الرؤية<br />&bull; اضطراب في بعض وظائف المخ بما في ذلك اختلال وظائف المخ الذي يصاحبه تشنجات وتدهور مستوى الوعي<br />&bull; أزمة قلبية<br />&bull; التهاب الأغشية المخاطية للفم (التهاب الفم)<br />&bull; الاعتلال العصبي الطرفي للأعصاب الحسية الذي يصاحبه تنميل أو حكة أو وخز دون سبب مصحوب بفقدان حاسة التذوق أو اللمس أو الرؤية أو آلام مفاجئة<br />بالرقبة ومؤلمة تمتد إلى الظهر وفي الساقين عند الانحناء للأمام<br />تأثيرات جانبية نادرة جدًا (قد تؤثر على شخص واحد من بين كل ۱۰,۰۰۰ شخص)<br />&bull; سكتة قلبية<br />تأثيرات جانبية غير معروف معدّل تكرارها (لا يمكن تقدير معدل التكرار من واقع البيانات المتاحة)<br />&bull; علامات حدوث عدوى مثل حمى أو التهاب الحلق<br />&bull; فقر الدم الإنحلالي<br />الذي قد يؤدي إلى انخفاض مستوى الصوديوم بالدم واحتباس البول (ADH) &bull; اضطراب بإفراز الهرمون المانع لإدرار البول<br />&bull; ارتفاع مستوى (إنزيم) الأميليز بالدم<br />&bull; جفاف<br />&bull; انخفاض مستوى الكالسيوم والفوسفات والبوتاسيوم في الدم<br />&bull; ارتفاع مستوى حَمْض اليوريك في الدم<br />&bull; تشنج العضلات<br />&bull; مرض النخاع الشوكي الذي قد يسبب إحساس بصدمة كهربائية تؤثر على الأطراف<br />&bull; فقدان حاسة التذوق<br />&bull; اضطرابات في النظر (عدم وضوح الرؤية ورؤية ألوان غريبة وفقدان البصر أو ألم العين)<br />&bull; سماع صوت طنين بالأذنين أو فقدان السمع<br />&bull; اضطرابات بالقلب<br />&bull; برودة اليدين والقدمين على غير العادة أو تحول لونهم إلى اللون الأبيض<br />&bull; وخز أو خدر أو رعشة في اليدين أو القدمين أو الذراعين أو الساقين<br />&bull; صداع مستمر<br />&bull; شعور بالإعياء أو بالمرض<br />&bull; فقدان الشهية (فقدان الشهية العصبي)<br />&bull; فُواق (زغطة)<br />&bull; إِسْهال<br />&bull; ارتفاع في مستوى إنزيمات الكبد والبيليروبين<br />&bull; صعوبة في التنفس<br />&bull; اضطرابات بالكُلى أو بالبول<br />&bull; تساقط الشعر<br />&bull; طفح جلدي<br />&bull; تعب شديد/ضعف عام شديد<br />&bull; تورم أو ألم في مكان الحقن<br />&bull; تقلصات أو تشنجات<br />&bull; حرقة أو شعور بوخز خفيف<br />&bull; ظهور كدمات غير متوقعة أو حدوث نزيف<br />&bull; متلازمة انحلال الدم اليوريمي التي قد تسبب اضطرابات في الكلى والدم<br />قد يؤدي سيسبلاتين إلى حدوث اضطرابات بالدم والكبد والكلى. سوف يأخذ طبيبك المعالج عينات دم منك للتحقق من وجود هذه المشاكل.</p><p>الإبلاغ عن التأثيرات الجانبية<br />إذا تعرضت للإصابة بأي تأثيرات جانبية، فيُرجي التحدث إلى طبيبك المعالج أو الصيدلي أو الممرض. ويشمل ذلك أية تأثيرات جانبية مُحتمَلة لم يتم ذكرها في<br />هذه النَّشرة. يمكنك أيضًا الإبلاغ عن التأثيرات الجانبية بشكل مباشر إلى المركز الوطني للتيقظ والسلامة الدوائية (انظر القسم رقم ٦) عن طريق الإبلاغ عن<br />التأثيرات الجانبية، يُمكنك المساعدة في تقديم المزيد من المعلومات حول أمان هذا الدَّواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يُحفظ بعيدًا عن رؤية ومُتناوَل الأطفال.<br />يُحفظ في درجة حرارة لا تزيد عن ۳۰ درجة مئوية.<br />لا يُبرد ولا يُجمد.<br />تُحفظ الزجاجة في العبوة الخارجية بعيدًا عن الضوء.<br />لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على العبوة. يُشير تاريخ انتهاء الصَّلاحية إلى اليوم الأخير من ذلك الشهر.<br />هذا الدواء عبارة عن محلول مركز، ولذا يجب تخفيفه قبل الاستخدام.<br />زجاجة للاستعمال مرة واحدة فقط.<br />بعد التخفيف: يظل الثبات الكيميائي والفيزيائي للاستخدام بعد التخفيف ثابتًا لمدة ۲٤ ساعة عند درجة حرارة الغرفة التي تتراوح من ۲۰ إلى ۲٥ درجة مئوية.<br />من وجهة النظر الميكروبيولوجية، يجب استخدام المحلول فور تخفيفه. إذا لم يتم استعمال المحلول فورًا، يتحمل المستخدم المسئولية كاملة عن أوقات وشروط<br />التخزين أثناء الاستخدام ويجب أن يتم التخفيف في شروط معقمة ومضبطة ومعتمدة.<br />لا تستعمل هذا الدَّواء إذا لاحظت أية علامات تلف واضحة.<br />يجب التخلص من جميع الأدوات التي تم استخدامها للتحضير والإعطاء، أو التي كانت على اتصال مع سيسبلاتين بأي شكل من الأشكال وفقًا للإرشادات المحلية<br />الخاصة بالسمية الخلوية.<br />يجب التخلص من الدواء إذا وجدت أن المحلول غير صاف أو لاحظت وجود رواسب غير قابلة للذوبان.<br />يُحظر التَّخلص من الأدوية عن طريق إلقائها في مياه الصرف أو مع المخلفات المنزلية. استشر الصيدلي عن كيفية التَّخلص من الأدوية التي لم تعد بحاجة إليها.<br />ستُساعد هذه التَّدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>ما هي محتويات تنبلات<br />المادة الفعالة هي سيسبلاتين<br />يحتوي كل ملليلتر على ۱ ملغم من سيسبلاتين.<br />تحتوي كل زجاجة ۱۰ ملليلتر على ۱۰ ملغم من سيسبلاتين.<br />تحتوي كل زجاجة ۲٥ ملليلتر على ۲٥ ملغم من سيسبلاتين.<br />تحتوي كل زجاجة ٥۰ ملليلتر على ٥۰ ملغم من سيسبلاتين.<br />تحتوي كل زجاجة ۱۰۰ ملليلتر على ۱۰۰ ملغم من سيسبلاتين.</p><p>تتضمن المكوّنات الأخرى: كلوريد الصوديوم وحمض الهيدروكلوريك (لضبط درجة الحموضة) وهيدروكسيد الصوديوم (لضبط درجة الحموضة) وماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>ما هو الشكل الصيدلاني لدواء تنبلات وما هي محتويات العبوة<br />تنبلات هو عبارة عن محلول شفاف عديم اللون يميل لونه إلى اللون الأصفر الشاحب خالي من الجسيمات.</p><p>يحتوي كل ملليلتر على ۱ ملغم من سيسبلاتين.<br />تحتوي كل زجاجة ۱۰ ملليلتر على ۱۰ ملغم من سيسبلاتين.<br />تحتوي كل زجاجة ۲٥ ملليلتر على ۲٥ ملغم من سيسبلاتين.<br />تحتوي كل زجاجة ٥۰ ملليلتر على ٥۰ ملغم من سيسبلاتين.<br />تحتوي كل زجاجة ۱۰۰ ملليلتر على ۱۰۰ ملغم من سيسبلاتين.</p><p>قد لا يتم تسويق جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>صنع لصالح أكورد هيلثكير ليمتد بواسطة:<br />إنتاس المحدودة للصناعات الدوائية، أحمد أباد، ولاية جوجارات، الهند.<br />للحصول على أيّة معلومات بشأن هذا الدواء، يُرجى الاتصال بالممثل المحلي لمالك التصريح بالتسويق:<br />المكتب العلمي لشركة أكورد هيلثكير، المملكة العربية السعودية<br />في شركة زمو التجارية المحدودة<br />الرياض، العليا، شارع العرفج، متفرع من شارع عبد الملك بن مروان،<br />خلف وزارة الداخلية، مبنى أطلس، مكتب رقم ۱<br />+۹٦٦-۱۱-۲۱۷- هاتف: ۰۱٤۰<br />mena-pv@accord-healthcare.com : البريد الإلكتروني<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            07/2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Cisplatin 1 mg/ml Concentrate for Solution for Infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                1 ml of concentrate for solution for infusion contains 1 mg of Cisplatin.

10 ml of concentrate for solution for infusion contains 10 mg of Cisplatin
25 ml of concentrate for solution for infusion contains 25 mg of Cisplatin
50 ml of concentrate for solution for infusion contains 50 mg of Cisplatin
100 ml of concentrate for solution for infusion contains 100 mg of Cisplatin

Excipients with known effect: Each ml of solution contains 3.5 mg of sodium. For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Concentrate for solution for infusion

Clear, colourless to pale yellow solution in an amber glass vial, which is practically free from particles.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Cisplatin is intended for the treatment of:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; &nbsp;advanced or metastasised testicular cancer</p><p>&middot;&nbsp;&nbsp; &nbsp;advanced or metastasised ovarian cancer</p><p>&middot;&nbsp;&nbsp; &nbsp;advanced or metastasised bladder carcinoma</p><p>&middot;&nbsp;&nbsp; &nbsp;advanced or metastasised squamous cell carcinoma of the head and neck</p><p>&middot;&nbsp;&nbsp; &nbsp;advanced or metastasised non-small cell lung carcinoma</p><p>&middot;&nbsp;&nbsp; &nbsp;advanced or metastasised small cell lung carcinoma.</p><p><s>&middot;</s> &nbsp;&nbsp;&nbsp; Cisplatin is indicated in the treatment of cervical carcinoma in combination with other chemotherapeutics or with radiotherapy.</p><p>&middot;&nbsp;&nbsp; &nbsp;Cisplatin can be used as monotherapy and in combination therapy</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Posology</strong></p><p><strong>Adults and children:</strong></p><p>The cisplatin dosage depends on the primary disease, the expected reaction, and on whether cisplatin is used for monotherapy or as a component of combination chemotherapy. The dosage directions are applicable for both adults and children.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>For <u>monotherapy</u>, the following two dosage regimens are recommended:</p><p>&nbsp;</p><p>&lt;&lt;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Single dose of 50 to 120 mg/m&sup2; body surface every 3 to 4 weeks;</p><p>&lt;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;15 to 20 mg/m&sup2;/day for five days, every 3 to 4 weeks.</p><p>&nbsp;</p><p>If cisplatin is used in <u>combination therapy</u>, the dose of cisplatin must be reduced. A</p><p>typical dose is 20 mg/m&sup2; or more once every 3 to 4 weeks.</p><p>&nbsp;</p><p>For treatment of cervical cancer cisplatin is used in combination with radiotherapy. A typical dose is 40 mg/m2 weekly for 6 weeks.</p><p>&nbsp;</p><p>For warning and precautions to be considered prior to the start of the next treatment cycle</p><p>(see section 4.4).</p><p>&nbsp;</p><p>In patients with renal dysfunction or bone marrow depression, the dose should be reduced adequately (see section 4.3).</p><p>&nbsp;</p><p>The cisplatin solution for infusion prepared according to instructions (see section 6.6.) should be administered by intravenous infusion over a period of 6 to 8 hours.</p><p>&nbsp;</p><p>Adequate hydration must be maintained from 2 to 12 hours prior to administration until minimum 6 hours after the administration of cisplatin. Hydratation is necessary to cause sufficient diuresis during and after treatment with cisplatin. It is realised by intravenous infusion of one of the following solutions:</p><p>sodium chloride solution 0.9%;</p><p>mixture of sodium chloride solution 0.9% and glucose solution 5% (1:1).</p><p>&nbsp;</p><p>Method of administration</p><p>Cisplatin 1 mg/ml sterile concentrate is to be diluted before administration. For instructions for dilution of the product before administration see section 6.6.</p><p>&nbsp;</p><p>The diluted solution should be administered only intravenously by infusion (see below). For administration, any device containing aluminium that may come in contact with cisplatin (sets for intravenous infusion, needles, catheters, syringes) must be avoided.</p><p>&nbsp;</p><p>Hydration prior to treatment with cisplatin:</p><p>Intravenous infusion of 100 to 200ml/hour for a period of 6 to 12 hours, with a total amount of at least 1litre.</p><p>&nbsp;</p><p>Hydration after termination of the administration of cisplatin:</p><p>Intravenous infusion of another 2 litres at a rate of 100 to 200 ml per hour for a period of</p><p>6 to 12 hours.</p><p>&nbsp;</p><p>Forced diuresis may be required should the urine secretion be less than 100 to 200 ml/hour after &nbsp;hydration. &nbsp;Forced &nbsp;diuresis &nbsp;may &nbsp;be &nbsp;realised &nbsp;by &nbsp;intravenously &nbsp;administering&nbsp; 37.5g mannitol as a 10% solution (375 ml mannitol solution 10%), or by administration of a diuretic if the kidney functions are normal.</p><p>The administration of mannitol or a diuretic is also required when the administrated cisplatin dose is higher than 60 mg/m2 of body surface.</p><p>&nbsp;</p><p>It is necessary that the patient drinks large quantities of liquids for 24 hours after the cisplatin infusion to ensure adequate urine secretion.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to cisplatin or to any of the excipients listed in section 6.1 or other platinum containing compounds. 

Cisplatin induces nephrotoxicity which is cumulative. It is therefore contraindicated in patients with pre-existing renal impairment.

Cisplatin has also been shown to be cumulatively neurotoxic (in particular ototoxic) and should not be given to patients with pre-existing hearing impairment. 

Cisplatin is also contraindicated in myelosuppressed patients and those who are dehydrated.

Patients receiving cisplatin should not breast feed (see section 4.6).

Concurrent administration of yellow fever vaccine is contraindicated

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This agent should only be administered under the direction of oncologists in specialist units under conditions permitting adequate monitoring and surveillance. Supportive equipment should be available to control anaphylactic reactions.</p><p>&nbsp;</p><p>Cisplatin reacts with metallic aluminium to form a black precipitate of platinum. All aluminium</p><p>containing IV sets, needles, catheters and syringes should be avoided.</p><p>&nbsp;</p><p>The solution for infusion should not be mixed with other drugs or additives.</p><p>&nbsp;</p><p>Appropriate monitoring and management of the treatment and its complications are only possible if adequate diagnosis and exact treatment conditions are available.</p><p>&nbsp;</p><p>1. Nephrotoxicity</p><p>&nbsp;</p><p>Cisplatin produces severe cumulative nephrotoxicity. Which may be potentiated by aminoglycoside antibiotics. Cisplatin should not be given more frequently than once every 3-4 weeks.</p><p>Repeat courses of cisplatin should not be given unless levels of serum creatinine are below 1.5 mg/100 ml (130 &micro;mol/l) or blood urea below 55 mg/100 ml (9 mmol/l), and circulating blood levels are at an acceptable level. Since the renal toxicity of cisplatin is cumulative, measurement of BUN, serum creatinine or GFR should be performed prior to initiating therapy and prior to each subsequent course.</p><p>&nbsp;</p><p>Adequate pre-treatment and &lsquo;during treatment&rsquo; hydration should be ensured and such agents as mannitol given to minimise hazards of renal toxicity. A urine output of 100 mL/hour or greater will tend to minimize cisplatin nephrotoxicity. This can be accomplished by prehydration with 2 litres of an appropriate intravenous solution, and similar post cisplatin hydration (recommended 2,500 mL/m2/24 hours). If vigorous hydration is insufficient to maintain adequate urinary output, an osmotic diuretic may be administered (eg, mannitol).</p><p>&nbsp;</p><p>The serum creatinine, BUN and creatinine clearance should be measured prior to initiating therapy and monitored throughout treatment with cisplatin.</p><p>&nbsp;</p><p>2.Neuropathies</p><p>&nbsp;</p><p>Severe cases of neuropathies have been reported.</p><p>These neuropathies may be irreversible and may manifest by paresthesia, areflexia and a proprioceptive loss and a vibration perception. A loss of motor function has also been reported. A neurologic examination must be carried out at regular intervals.</p><p>Neurotoxicity appears to be cumulative.</p><p>&nbsp;</p><p>3. Ototoxicity</p><p>&nbsp;</p><p>Ototoxicity has been observed in up to 31% of patients treated with a single dose of cisplatin</p><p>50mg/m2, and is manifested by tinnitus and/or hearing loss in the high frequency range (4000 to 8000Hz). Decreased ability to hear conversational tones may occur occasionally. Ototoxic effect may be more pronounced in children receiving cisplatin. Hearing loss can be unilateral or bilateral and tends to become more frequent and severe with repeated doses; however, deafness after initial dose of cisplatin has been reported rarely. Ototoxicity may be enhanced with prior simultaneous cranial irradiation and may be related to peak plasma concentration of cisplatin. It is unclear whether cisplatin induced ototoxicity is reversible. Careful monitoring by audiometry should be performed prior to initiation of therapy and prior to subsequent doses of cisplatin. Vestibular toxicity has also been reported (see section 4.8).</p><p>&nbsp;</p><p>Since ototoxicity of cisplatin is cumulative, audiometric testing should be performed prior to initiating therapy and prior to each subsequent course of the drug (see section 4.8).</p><p>&nbsp;</p><p>4. Allergic phenomena</p><p>&nbsp;</p><p>As with other platinum-based products, hypersensitivity reactions appearing in most cases during perfusion may occur, and necessitate discontinuation of the perfusion and an appropriate symptomatic treatment. Cross reactions, sometimes fatal, have been reported with all the platinum compounds (See sections 4.3 and 4.8).</p><p>&nbsp;</p><p>5. Hepatic function and haematological formula</p><p>&nbsp;</p><p>The haematological formula and hepatic function must be monitored at regular intervals.</p><p>&nbsp;</p><p>6. Carcinogenic potential</p><p>&nbsp;</p><p>In humans, in rare cases the appearance of acute leukaemia has coincided with use of</p><p>Cisplatin, which was in general associated with other leukaemogenic agents.</p><p>&nbsp;</p><p>Cisplatin carcinogenic in mice and rats (see section 5.3).</p><p>&nbsp;</p><p>7. Injection site reactions</p><p>&nbsp;</p><p>Injection site reactions may occur during the administration of cisplatin. Given the possibility of extravasation, it is recommended to closely monitor the infusion site for possible infiltration during drug administration. A specific treatment for extravasation reactions is unknown at this time.</p><p>&nbsp;</p><p>WARNING</p><p>&nbsp;</p><p>This cytostatic agent had a more marked toxicity than is usually found in antineoplastic chemotherapy.</p><p>&nbsp;</p><p>Renal toxicity, which is above-all cumulative, is severe and requires particular precautions during administration (see sections 4.1 and 4.8).</p><p>&nbsp;</p><p>Nausea and vomiting may be intense and require adequate antiemetic treatment.</p><p>Close supervision must also be carried out with regard to ototoxicity, myelodepression and anaphylactic reactions (see section 4.8).</p><p>&nbsp;</p><p>Preparation of the intravenous solution</p><p>&nbsp;</p><p><em>Warning</em></p><p>&nbsp;</p><p>As with all other potentially toxic products, precautions are essential when handling the cisplatin solution. Skin lesions are possible in the event of accidental exposure</p><p>to the product. It is advisable to wear gloves. In the event the cisplatin solution</p><p>comes into contact with the skin or mucous membranes, wash the skin or mucous membranes vigorously with soap and water.</p><p>&nbsp;</p><p>Conforming to the procedures appropriate for the manipulation and elimination of cytostatic agents is recommended.</p><p>&nbsp;</p><p>Before administering the solution to the patient, verify the clarity of the solution and the absence of particles.</p><p>&nbsp;</p><p>This medicinal product contains 3.5 mg sodium per ml, equivalent to 38.3% of the WHO recommended maximum daily intake of 2 g sodium for an adult.</p><p>Cisplatin may be further prepared for administration with sodium-containing solutions (see section 6.6) and this should be considered in relation to the total sodium from all sources that will be administered to the patient.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cisplatin can be used in combination with other cytostatics with corresponding mechanisms of action.&nbsp; Additive toxicity might occur in such cases.</p><p>&nbsp;</p><p>Myelosuppression induced by cisplatin will be additive to existent impairment or to the similar toxicity of other agents such as cephaloridine, frusemide, aminoglycosides, etc., administered concurrently.</p><p>&nbsp;</p><p><strong>Nephrotoxic substances:</strong></p><p>Concomitant&nbsp; &nbsp;administration &nbsp;of&nbsp; &nbsp;nephrotoxic&nbsp;&nbsp; (e.g.&nbsp; &nbsp;cephalosporins, &nbsp;aminoglycosides &nbsp;or</p><p>Amphotericin B or contrast media) or ototoxic (e.g. aminoglycosides) medicinal&nbsp;&nbsp;&nbsp; products will potentiate the toxic effect of cisplatin on the kidneys. Nephrotoxicity might be exacerbated by aminoglycoside antibiotics, administered simultaneously or 1-2 weeks after treatment with cisplatin. The use of other potentially nephrotoxic drugs (e.g. amphotericin) is not recommended during treatment with cisplatin. During or after treatment with cisplatin caution is advised with predominantly renally eliminated substances, e.g. cytostatic agents such as bleomycin and methotrexate, because of potentially reduced renal elimination.</p><p>The renal toxicity of ifosfamide may be greater when used with cisplatin or in patients who have previously been given cisplatin.</p><p>&nbsp;</p><p>Reduction of the blood&rsquo;s lithium values was noticed in a few cases after treatment with cisplatin</p><p>combined with bleomycin and etoposide. It is therefore recommended to monitor the lithium values.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Ototoxic substances:</strong></p><p>&nbsp;</p><p>Concomitant administration of ototoxic (e.g. aminoglycosides, loop diuretics) medicinal products will potentiate the toxic effect of cisplatin on auditory function. Except for patients receiving doses of cisplatin exceeding 60 mg/m2, whose urine secretion is less than 1000 ml per 24 hours, no forced diuresis with loop diuretics should be applied in view of possible damage to the kidney tract and ototoxicity.</p><p>&nbsp;</p><p>Ifosfamide may increase hearing loss due to cisplatin.</p><p>&nbsp;</p><p><strong>Weakened live vaccines:</strong></p><p>Yellow fever vaccine is strictly contraindicated because of the risk of fatal systemic vaccinal disease (see section 4.3.). In view of the risk of generalised illness, it is advisable to use an inactive vaccine if available.</p><p>&nbsp;</p><p><strong>Oral anticoagulants:</strong></p><p>In the event of simultaneous use of oral anticoagulants, it is advisable regularly to check the</p><p>INR.</p><p>&nbsp;</p><p><strong>Antihistamines, Phenothiazines and others:</strong></p><p>Simultaneous use of antihistamines, buclizine, cyclizine, loxapine, meclozine, phenothiazines, thioxanthenes or trimethobenzamides may mask ototoxicity symptoms (such as dizziness and tinnitus).</p><p>&nbsp;</p><p><strong>Pyroxidine + altretamine combination:</strong></p><p>During a randomised study of the treatment of advanced ovarian cancer, the response time was unfavourably affected when pyridoxine was used in combination with altretamine</p><p>(hexamethylmelamine) and Cisplatin.</p><p>&nbsp;</p><p><strong>Paclitaxel:</strong></p><p>Treatment with cisplatin prior to an infusion with paclitaxel may reduce the clearance of paclitaxel by 33% and therefore can intensify neurotoxicity.</p><p>&nbsp;</p><p><strong>Anticonvulsive substances/Anti-epileptics:</strong></p><p>Serum concentrations of anticonvulsive medicines may remain at sub therapeutic levels during treatment with cisplatin. For example; in patients receiving cisplatin and phenytoin, the serum level of phenytoin might be reduced. This is probably due to reduced absorption and/or increased metabolism. One should monitor the levels of phenytoin in plasma, and adjust the dose accordingly.</p><p>&nbsp;</p><p>Cisplatin may interact with aluminium (see section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy</strong></p><p>Cisplatin may be toxic to the foetus when administered to a pregnant woman. The safe use of cisplatin in human pregnancy has not been established. Studies in animals have shown reproductive toxicity (see section 5.3). Cisplatin should not be used during pregnancy unless the clinician considers the risk to the individual patient to be justified.</p><p>&nbsp;</p><p><strong>During treatment with Cisplatin and for a minimum of the following 6 months, appropriate measures must be taken to avoid pregnancy;</strong><strong> </strong><strong>this applies to patients of both sexes.</strong></p><p><strong>&nbsp;</strong></p><p>Genetic consultation is recommended if the patient wishes to have children after ending treatment.</p><p><strong>&nbsp;</strong></p><p><strong>Breast-feeding</strong></p><p>Cisplatin is excreted in breast milk. Patients treated with cisplatin must not breastfeed.</p><p>&nbsp;</p><p><strong>Fertility</strong></p><p>Since a treatment with cisplatin may cause irreversible infertility, it is recommended that men, who wish to become fathers in the future, ask for advice regarding cryoconservation of their sperm prior to treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on ability to drive and use machines have been performed.</p><p>&nbsp;</p><p>Nevertheless, the profile of undesirable effects (like nephrotoxicity) may influence the ability to drive vehicles and use machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most frequently reported adverse events (&gt;10%) of cisplatin were haematological (leukopenia, thrombocytopenia and anaemia), gastrointestinal (anorexia, nausea, vomiting and diarrhoea), ear disorders (hearing impairment), renal disorders (renal failure, nephrotoxicity, hyperuricemia) and fever.</p><p>Serious toxic effects on the kidneys, bone marrow and ears have been reported in up to about one third of patients given a single dose of cisplatin; the effects are generally dose-related and cumulative. Ototoxicity may be more severe in children.</p><p>&nbsp;</p><p>Frequencies are defined using the following convention:</p><p>&nbsp;</p><p>Very common (<u>&lt;</u>1/10); common (<u>&lt;</u>1/100 to &lt;1/10); uncommon (<u>&lt;</u>1/1,000 to &lt;1/100); rare (<u>&lt;</u>1/10,000 to <u>&lt;</u>1/1,000); very rare (<u>&lt;</u>1/10,000), not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p><strong>Table of Adverse Drug Events Reported During Clinical or Postmarketing Experience (MedDRA terms).</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:614px"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>MedDRA term</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Infectiona</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Sepsis</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Bone marrow failure, thrombocytopenia, leukopenia, anaemia</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Coombs positive haemolytic anaemia, thrombotic microangiopathy (haemolytic uremic syndrome), neutropenia</p></td></tr><tr><td style="vertical-align:top"><p>Neoplasm benign, malignant, and unspecified</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Acute leukaemia</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Anaphylactoidb&nbsp;&nbsp;reaction</p></td></tr><tr><td style="vertical-align:top"><p>Endocrine disorders</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Blood amylase increased, inappropriate antidiuretic hormone secretion</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Dehydration, hypokalaemia, hypophosphatemia, hyperuricemia, hypocalcaemia, tetany</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Hypomagnesaemia</p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Hyponatraemia</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Cerebrovascular accident, haemorrhagic stroke, ischaemic stroke ageusia, cerebral arteritis, Lhermitte&#39;s sign, myelopathy, autonomic neuropathy</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Convulsion, neuropathy peripheral, leukoencephalopathy, reversible posterior leukoencephalopathy&nbsp; syndrome</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Vision blurred, colour blindness acquired, blindness cortical, optic neuritis, papilledema, retinal pigmentation</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Ototoxicity</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Tinnitus, deafness</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>Not known</p><p>Common</p></td><td style="vertical-align:top"><p>Cardiac disorder</p><p>Arrhythmia, bradycardia, tachycardia</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Myocardial infarction</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Cardiac arrest</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Venous thromboembolism</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Raynaud&#39;s phenomenon</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Vomiting, nausea, anorexia, hiccups, diarrhoea</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Stomatitis</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Hepatic enzymes increased, blood bilirubin increased</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and</p><p>&nbsp;mediastinal disorders</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Pulmonary embolism</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue</p><p>&nbsp;disorders</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Rash, alopecia</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal, connective tissue</p><p>&nbsp;and bone disorders</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Muscle spasms</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Renal failure acute, renal failurec&nbsp;, renal &nbsp;tubular disorder</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive system and breast</p><p>&nbsp;disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Abnormal spermatogenesis</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site condition</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Pyrexia (very common), asthenia, malaise, injection site extravasationd</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>a: Infectious complications have led to death in some patients.</p><p>&nbsp;</p><p>b: Symptoms include facial edema (PT-face oedema), flushing, wheezing, bronchospasm, tachycardia, and hypotension will be included in the parentheses for anaphylactoid reaction in the AE frequency table.</p><p>&nbsp;</p><p>c: Elevations in BUN and creatinine, serum uric acid, and/or a decrease in creatinine clearance are subsumed under renal insufficiency/failure.</p><p>&nbsp;</p><p>d: Local soft tissue toxicity including cellulitis, fibrosis, and necrosis (common) pain</p><p>(common), oedema (common) and erythema (common) as the result of extravasation.</p><p>&nbsp;</p><p><u>Nephrotoxicity</u></p><p>Renal toxicity has been shown in 28-38% of patients treated with a single dose of cisplatin 50 mg/m2. Renal toxicity becomes more prolonged and severe with repeated courses of the drug.</p><p>&nbsp;</p><p><u>Gastrointestinal toxicity</u></p><p>Nausea and vomiting occur in the majority of patients, usually starting within 1 hour of treatment and lasting up to 24 hours. Anorexia, nausea and occasional vomiting may persist for up to a week.</p><p>&nbsp;</p><p><u>Ocular Toxicity</u></p><p>There have been reports of optic neuritis, papilledema and cerebral blindness following treatment with cisplatin. Improvement and/or total recovery usually occurs following immediate discontinuation. Blurred vision and altered colour perception have been reported after the use of regimens with higher doses of cisplatin or greater dose frequencies than those recommended.</p><p>&nbsp;</p><p><u>Ototoxicity</u></p><p>Ototoxicity has occurred in up to 31% of patients treated with a single dose of cisplatin 50 mg/m2. Ototoxicity may be more severe in children and more frequent and severe with repeated doses. Careful monitoring should be performed prior to initiation of therapy and prior to subsequent doses of cisplatin.</p><p>&nbsp;</p><p>Unilateral or bilateral tinnitus, which is usually reversible, and/or hearing loss in the high frequency range may occur.</p><p>&nbsp;</p><p>The overall incidence of audiogram abnormalities is 24%, but large variations exist. These abnormalities usually appear within 4 days after drug administration and consist of at least a 15 decibel loss in pure tone threshold. The damage seems to be cumulative and is not reversible. The audiogram abnormalities are most common in the 4000- 8000 Hz frequencies.</p><p>&nbsp;</p><p><u>Haemotoxicity</u></p><p>Myelosuppression is observed in about 30% of patients treated with cisplatin. Leukopenia and thrombocytopenia are more pronounced at higher doses. The nadirs in circulating platelets and leucocytes generally occur between days 18-23 (range 7.3 to 45) with most patients recovering by day 39 (range 13 to 62). Leukopenia and thrombocytopenia are more pronounced at doses greater than 50 mg/m2. Anaemia (decreases of greater than 2 g% haemoglobin) occurs at approximately the same frequency, but generally with a later onset than leukopenia and thrombocytopenia. Subsequent courses of cisplatin should not be instituted until platelets are present at levels greater than 100,000/mm3 and white cells greater than 4,000/mm3. A high incidence of severe anaemia requiring transfusion of packed red cells has been observed in patients receiving combination chemotherapy including cisplatin.</p><p>&nbsp;</p><p><u>Anaphylaxis</u></p><p>Reactions possibly secondary to cisplatin therapy have been occasionally reported in patients who were previously exposed to cisplatin. Patients who are particularly at risk are those with a prior history or family history of atopy. Facial oedema, wheezing, tachycardia, hypotension and skin rashes of urticarial non-specific maculopapular type can occur within a few minutes of administration. Serious reactions seem to be controlled by I.V. adrenaline, corticosteroids or antihistamines.</p><p>&nbsp;</p><p><u>Neurotoxicity</u></p><p>Neurotoxicity may occur. It is cumulative and may be irreversible. It is generally characterised by neuropathies, but seizures and taste loss have occurred.</p><p>&nbsp;</p><p>Peripheral neuropathies with paraesthesia in both upper and lower extremities, tremor and loss of taste have been observed in some patients, generally those treated with repeated courses.</p><p>&nbsp;</p><p><u>Hypomagnesaemia and Hypocalcaemia</u></p><p>Hypomagnesaemia occurs quite frequently with cisplatin administration, while hypocalcaemia occurs less frequently. The loss of magnesium seems to be associated with renal tubular damage which prevents resorption of this cation. Where both electrolytes are deficient, tetany may result. It does not appear to be dose related. Monitoring of electrolytes is necessary.</p><p>&nbsp;</p><p><u>Electrolyte Disturbances</u></p><p>Hyponatraemia, hypokalaemia and hypophosphatemia can occur.</p><p>&nbsp;</p><p><u>Hyperuricemia</u></p><p>Hyperuricemia occurring with cisplatin is more pronounced with doses greater than 50 mg/m2. Allopurinol effectively reduces uric acid levels.</p><p>&nbsp;</p><p><u>Cardiac and Vascular Disorders</u></p><p>Cardiac reactions including tachycardia and arrhythmia have been reported. Vascular toxicities coincident with the use of cisplatin in combination with other antineoplastic agents have been reported rarely. These events may include myocardial infarction, cerebrovascular accident, thrombotic microangiopathy (Haemolytic uremic syndrome) or cerebral arteritis.</p><p>&nbsp;</p><p><u>Other Toxicities</u></p><p>There are also reports of Raynaud&#39;s phenomenon occurring in patients treated with the combination of bleomycin, vinblastine and with or without cisplatin. It has been suggested that hypomagnesaemia developing with the use of cisplatin may be an added, although not essential factor, associated with this event. However the cause of this Raynaud&#39;s phenomenon is currently unknown.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via The National Pharmacovigilance Centre (NPC).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>To reports any side effect(s):</strong></p><p>&bull; The National Pharmacovigilance Centre (NPC):</p><p>&minus; SFDA Call Center: 19999</p><p>&minus; E-mail: npc.drug@sfda.gov.sa</p><p>&minus; Website: https://ade.sfda.gov.sa/</p><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>CAUTION IS ESSENTIAL IN ORDER TO PREVENT AN INADVERTANT OVERDOSE.</u></strong></p><p>&nbsp;</p><p>Overdosage can be expected to cause the toxic effects described above, but to an exaggerated degree. Adequate hydration and osmotic diuresis may help reduce the toxicity of cisplatin if administered promptly following overdosage. Convulsions may be treated with appropriate anticonvulsants.</p><p>&nbsp;</p><p>An acute overdose of Cisplatin may result in renal failure, liver failure, deafness, ocular toxicity (including detachment of the retina), significant myelosuppression, untreatable nausea and vomiting and/or neuritis. Renal function, cardiovascular function and blood counts should be monitored daily in order to assess the potential toxicity to these systems. Serum magnesium and calcium levels should be carefully monitored&nbsp; as&nbsp; should&nbsp; symptoms&nbsp; and&nbsp; signs&nbsp; of&nbsp; voluntary&nbsp; muscle&nbsp; irritability. If symptomatic tetany develops, electrolyte supplements should be administered. Serum liver enzymes and uric acid should also be monitored daily after an acute overdose. An overdose may be fatal.</p><p>&nbsp;</p><p>There is no specific antidote in the event of an overdosage of Cisplatin. Even if haemodialysis is initiated 4 hours after the overdose it has little effect on the elimination of cisplatin from the body following a strong and rapid fixation of Cisplatin to proteins.</p><p>&nbsp;</p><p>Treatment in the event of an overdose consists of general support measures.</p><p>&nbsp;</p><p>If fever develops during prolonged myelosuppression, appropriate presumptive antibiotic coverage should be instilled after cultures have been obtained.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Other antineoplastic agents, Platinum compounds, ATC code: L01XA01</p><p>&nbsp;</p><p>Cisplatin has biochemical properties similar to those of bifunctional alkylating agents. The drug inhibits DNA-synthesis by producing intrastrand and interstrand cross- links in DNA. Protein and RNA synthesis are also inhibited to a lesser extent.</p><p>&nbsp;</p><p>Although the principalmechanism of action of cisplatin appears to be inhibition of DNA synthesis, other mechanisms, including enhancementof tumour immunogenicity may be involved in its antineoplastic activity. Cisplatin&nbsp; &nbsp;also&nbsp; &nbsp;has&nbsp; &nbsp;immunosuppressive,&nbsp;&nbsp; radiosensitising,&nbsp; &nbsp;and antimicrobial properties. Cisplatin does not appear to be cell-cycle specific.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption</p><p>There is good uptake of cisplatin by the kidneys, liver and intestine. More than 90% of platinum containing species remaining in the blood are bound (possibly irreversibly) to plasma proteins.</p><p>&nbsp;</p><p>Penetration into the CSF is poor although significant amounts of cisplatin can be detected in intracerebral tumours.</p><p>The clearance of total platinum from plasma is rapid during the first four hours after intravenous administration, but then proceeds more slowly because of covalent binding to serum proteins. Levels of unbound platinum fall with a half-life of 20 minutes to 1 hour depending on the rate of drug infusion.</p><p>&nbsp;</p><p>Elimination</p><p>The elimination of intact drug and various platinum-containing biotransformation products is via the urine. About 15-25% of administered platinum is rapidly excreted in the first 2-4 hours after administration of cisplatin. This early excretion is mostly of intact cisplatin. In the first 24 hours after administration, 20-80% is excreted, the remainder representing drug bound to tissues or plasma protein.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In non-clinical repeat dose toxicity studies, renal damage, bone marrow depression, gastrointestinal disorders, ototoxicity, neurotoxicity, and immunosuppression have been observed at exposure levels similar to clinical exposure levels.</p><p>&nbsp;</p><p>Non-clinical data indicate cisplatin is mutagenic, genotoxic and carcinogenic. Thymic lymphomas, mammary adenocarcinomas, fibro-liposarcoma, and lung adenomas were reported from repeat-dose studies of up to 19 weeks duration in mice. Leukemia and renal fibrosarcoma were reported from repeat-dose studies of up to 3 weeks in rats.</p><p>&nbsp;</p><p>Non-clinical studies in mice showed that cisplatin caused direct damage to primordial follicle oocytes, leading to apoptosis, and ovarian depletion. Cisplatin causes testis damage and decreased sperm counts in mice, primarily through effects on differentiated spermatogonia. These findings suggest potential clinically relevant effects on male and female fertility.</p><p>&nbsp;</p><p>Developmental toxicity studies indicate cisplatin is embryotoxic in mice and rats, and teratogenic in both species at exposure levels similar to clinical exposure levels.</p><p>&nbsp;</p><p>Studies in rodents have shown that exposure during pregnancy can cause tumors in adult offspring.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium chloride,</p><p>Sodium hydroxide (for pH adjustment)</p><p>Hydrochloric acid (for pH adjustment)</p><p>Water for injection</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not bring in contact with aluminium. Cisplatin reacts with metal aluminium to form a black precipitate of platinum. All aluminium-containing IV sets, needles, catheters and syringes should be avoided. Cisplatin decomposes with solution in media with low chloride content; the chloride concentration should at least be equivalent to 0.45% of sodium chloride.</p><p>&nbsp;</p><p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p><p>Antioxidants (such as sodium metabisulphite), bicarbonates (sodium bicarbonate), sulfates, fluorouracil and paclitaxel may inactivate cisplatin in infusion systems.</p><p>&nbsp;</p><p>Cisplatin should only be used with those diluents specified in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Before opening

24 months

After dilution
	
Chemical and physical in-use stability after dilution with infusion fluids described in section
6.6, indicate that after dilution with recommended intravenous fluids, Cisplatin Injection remains stable for 24 hours at 20 - 25 °C room temperature. The diluted solution should be protected from light. Do not store diluted solutions in the refrigerator or freezer.

From a microbiological point of view, the diluted solution should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and dilution should taken place in controlled and validated aseptic conditions.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Undiluted solution:</em></p><p>Keep container in the outer carton in order to protect from light. Do not refrigerate or freeze.</p><p>&nbsp;</p><p>A crystal or precipitate may formed as a result of exposure to low temperatures, in case a cloudy solution (i.e a precipitate or crystal) is observed inside the vial, see section 6.6.</p><p>&nbsp;</p><p>For the storage conditions of the diluted medicinal product (see section 6.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For 10 ml</p><p>&nbsp;</p><p>10 ml type I amber glass vial with a chlorobutyl grey stopper, sealed with an aluminium flip off transparent white seal/ 20 mm flip off seal transparent.</p><p>&nbsp;</p><p>For 25 ml</p><p>30 ml type I amber glass vial with a chlorobutyl grey stopper, sealed with an aluminium flip off transparent white seal/ 20 mm flip off seal transparent.</p><p>&nbsp;</p><p>For 50 ml</p><p>50 ml type I amber glass vial with a chlorobutyl grey stopper, sealed with an aluminium flip off transparent white seal/ 20 mm flip off seal transparent.</p><p>&nbsp;</p><p>For 100 ml</p><p>100 mL Type I amber glass vial with a 20 mm, S127 &ndash; 4432/50 grey rubber stopper , sealed with 20 mm aluminium flip off transparent white seal/ 20 mm flip off seal transparent.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Preparation and handling of the product</strong></p><p>Like with all anti-neoplastic products caution is needed with the processing of cisplatin. Must be &nbsp;diluted &nbsp;before &nbsp;use. &nbsp;Dilution &nbsp;should &nbsp;take &nbsp;place &nbsp;under &nbsp;aseptic &nbsp;conditions&nbsp; by &nbsp;trained personnel in an area specifically intended for this. Protective gloves should be worn for this. Precautions should be taken to avoid contact with the skin and mucous membranes. If skin contact did occur anyway, the skin should be washed with soap and water immediately. With</p><p>skin contact tingling, burns and redness have been observed. In case of contact with the</p><p>mucous membranes they should be copiously rinsed with water. After inhalation dyspnoea, pain in the chest, throat irritation and nausea have been reported.</p><p>Pregnant women must avoid contact with cytostatic drugs. Bodily waste matter and vomit should be disposed with care.</p><p>If the solution is cloudy or a deposit that does not dissolve is noticed, the bottle should be discarded.</p><p>&nbsp;</p><p>A damaged bottle must be regarded and treated with the same precautions as contaminated waste. Contaminated waste must be stored in waste containers specifically marked for this. See section &ldquo;Disposal&rdquo;.</p><p>&nbsp;</p><p><strong>Preparation of the intravenous administration</strong></p><p>Take the quantity of the solution that is needed from the bottle and dilute with at least 1 litre of the following solutions:</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;sodium chloride 0.9%</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;mixture of sodium chloride 0.9% / glucose 5% (1:1), (resulting final concentrations:</p><p>sodium chloride 0.45%, glucose 2.5%)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;sodium chloride 0.9% and 1.875% mannitol, for injection</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;sodium chloride 0.45%, glucose 2.5% and 1.875% mannitol for injection</p><p>&nbsp;</p><p>Always look at the injection before use. If the solution is not clear or an undissolvable precipitate is formed the solution must not be used. Only a clear solution, free from particles should be administered.</p><p>&nbsp;</p><p>If precipitate or crystal observed inside the vial, keep vial at room temperature ( 20 - 25&deg;C) until till clear solution obtained. Protect unopened container from light. The product should be discarded if the solution doesn&rsquo;t become clear after vigorous shaking.</p><p>&nbsp;</p><p>DO NOT bring in contact with injection material that contains aluminium</p><p>DO NOT administer undiluted</p><p>&nbsp;</p><p>With respect to microbiological, chemical and physical stability with use of the undiluted solutions (see section 6.3).</p><p>&nbsp;</p><p><strong>Disposal</strong></p><p>All materials that have been used for the preparation and administration, or which have been in contact with cisplatin in any way, must be disposed of according to local cytotoxic guidelines. Medicines should not be disposed of via wastewater or household waste.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Accord Healthcare Limited
Sage House
319, Pinner Road 
North Harrow 
Middlesex, HA1 4HF 
UK


8. MARKETING AUTHORISATION NUMBER (S)

10ml: 29-5223-19

50ml: 30-5223-19


9. DATE OF FIRST APPROVAL/APPROVAL RENEWAL

26 December 2019

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                03/01/2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="data:image/png; base64,iVBORw0KGgoAAAANSUhEUgAACSMAAAZ2CAIAAADVZbb1AAAKQ2lDQ1BJQ0MgUHJvZmlsZQAAeJydU3dYk/cWPt/3ZQ9WQtjwsZdsgQAiI6wIyBBZohCSAGGEEBJAxYWIClYUFRGcSFXEgtUKSJ2I4qAouGdBiohai1VcOO4f3Ke1fXrv7e371/u855zn/M55zw&#x2B;AERImkeaiagA5UoU8Otgfj09IxMm9gAIVSOAEIBDmy8JnBcUAAPADeXh&#x2B;dLA//AGvbwACAHDVLiQSx&#x2B;H/g7pQJlcAIJEA4CIS5wsBkFIAyC5UyBQAyBgAsFOzZAoAlAAAbHl8QiIAqg0A7PRJPgUA2KmT3BcA2KIcqQgAjQEAmShHJAJAuwBgVYFSLALAwgCgrEAiLgTArgGAWbYyRwKAvQUAdo5YkA9AYACAmUIszAAgOAIAQx4TzQMgTAOgMNK/4KlfcIW4SAEAwMuVzZdL0jMUuJXQGnfy8ODiIeLCbLFCYRcpEGYJ5CKcl5sjE0jnA0zODAAAGvnRwf44P5Dn5uTh5mbnbO/0xaL&#x2B;a/BvIj4h8d/&#x2B;vIwCBAAQTs/v2l/l5dYDcMcBsHW/a6lbANpWAGjf&#x2B;V0z2wmgWgrQevmLeTj8QB6eoVDIPB0cCgsL7SViob0w44s&#x2B;/zPhb&#x2B;CLfvb8QB7&#x2B;23rwAHGaQJmtwKOD/XFhbnauUo7nywRCMW735yP&#x2B;x4V//Y4p0eI0sVwsFYrxWIm4UCJNx3m5UpFEIcmV4hLpfzLxH5b9CZN3DQCshk/ATrYHtctswH7uAQKLDljSdgBAfvMtjBoLkQAQZzQyefcAAJO/&#x2B;Y9AKwEAzZek4wAAvOgYXKiUF0zGCAAARKCBKrBBBwzBFKzADpzBHbzAFwJhBkRADCTAPBBCBuSAHAqhGJZBGVTAOtgEtbADGqARmuEQtMExOA3n4BJcgetwFwZgGJ7CGLyGCQRByAgTYSE6iBFijtgizggXmY4EImFINJKApCDpiBRRIsXIcqQCqUJqkV1II/ItchQ5jVxA&#x2B;pDbyCAyivyKvEcxlIGyUQPUAnVAuagfGorGoHPRdDQPXYCWomvRGrQePYC2oqfRS&#x2B;h1dAB9io5jgNExDmaM2WFcjIdFYIlYGibHFmPlWDVWjzVjHVg3dhUbwJ5h7wgkAouAE&#x2B;wIXoQQwmyCkJBHWExYQ6gl7CO0EroIVwmDhDHCJyKTqE&#x2B;0JXoS&#x2B;cR4YjqxkFhGrCbuIR4hniVeJw4TX5NIJA7JkuROCiElkDJJC0lrSNtILaRTpD7SEGmcTCbrkG3J3uQIsoCsIJeRt5APkE&#x2B;S&#x2B;8nD5LcUOsWI4kwJoiRSpJQSSjVlP&#x2B;UEpZ8yQpmgqlHNqZ7UCKqIOp9aSW2gdlAvU4epEzR1miXNmxZDy6Qto9XQmmlnafdoL&#x2B;l0ugndgx5Fl9CX0mvoB&#x2B;nn6YP0dwwNhg2Dx0hiKBlrGXsZpxi3GS&#x2B;ZTKYF05eZyFQw1zIbmWeYD5hvVVgq9ip8FZHKEpU6lVaVfpXnqlRVc1U/1XmqC1SrVQ&#x2B;rXlZ9pkZVs1DjqQnUFqvVqR1Vu6k2rs5Sd1KPUM9RX6O&#x2B;X/2C&#x2B;mMNsoaFRqCGSKNUY7fGGY0hFsYyZfFYQtZyVgPrLGuYTWJbsvnsTHYF&#x2B;xt2L3tMU0NzqmasZpFmneZxzQEOxrHg8DnZnErOIc4NznstAy0/LbHWaq1mrX6tN9p62r7aYu1y7Rbt69rvdXCdQJ0snfU6bTr3dQm6NrpRuoW623XP6j7TY&#x2B;t56Qn1yvUO6d3RR/Vt9KP1F&#x2B;rv1u/RHzcwNAg2kBlsMThj8MyQY&#x2B;hrmGm40fCE4agRy2i6kcRoo9FJoye4Ju6HZ&#x2B;M1eBc&#x2B;ZqxvHGKsNN5l3Gs8YWJpMtukxKTF5L4pzZRrmma60bTTdMzMyCzcrNisyeyOOdWca55hvtm82/yNhaVFnMVKizaLx5balnzLBZZNlvesmFY&#x2B;VnlW9VbXrEnWXOss623WV2xQG1ebDJs6m8u2qK2brcR2m23fFOIUjynSKfVTbtox7PzsCuya7AbtOfZh9iX2bfbPHcwcEh3WO3Q7fHJ0dcx2bHC866ThNMOpxKnD6VdnG2ehc53zNRemS5DLEpd2lxdTbaeKp26fesuV5RruutK10/Wjm7ub3K3ZbdTdzD3Ffav7TS6bG8ldwz3vQfTw91jicczjnaebp8LzkOcvXnZeWV77vR5Ps5wmntYwbcjbxFvgvct7YDo&#x2B;PWX6zukDPsY&#x2B;Ap96n4e&#x2B;pr4i3z2&#x2B;I37Wfpl&#x2B;B/ye&#x2B;zv6y/2P&#x2B;L/hefIW8U4FYAHBAeUBvYEagbMDawMfBJkEpQc1BY0FuwYvDD4VQgwJDVkfcpNvwBfyG/ljM9xnLJrRFcoInRVaG/owzCZMHtYRjobPCN8Qfm&#x2B;m&#x2B;UzpzLYIiOBHbIi4H2kZmRf5fRQpKjKqLupRtFN0cXT3LNas5Fn7Z72O8Y&#x2B;pjLk722q2cnZnrGpsUmxj7Ju4gLiquIF4h/hF8ZcSdBMkCe2J5MTYxD2J43MC52yaM5zkmlSWdGOu5dyiuRfm6c7Lnnc8WTVZkHw4hZgSl7I/5YMgQlAvGE/lp25NHRPyhJuFT0W&#x2B;oo2iUbG3uEo8kuadVpX2ON07fUP6aIZPRnXGMwlPUit5kRmSuSPzTVZE1t6sz9lx2S05lJyUnKNSDWmWtCvXMLcot09mKyuTDeR55m3KG5OHyvfkI/lz89sVbIVM0aO0Uq5QDhZML6greFsYW3i4SL1IWtQz32b&#x2B;6vkjC4IWfL2QsFC4sLPYuHhZ8eAiv0W7FiOLUxd3LjFdUrpkeGnw0n3LaMuylv1Q4lhSVfJqedzyjlKD0qWlQyuCVzSVqZTJy26u9Fq5YxVhlWRV72qX1VtWfyoXlV&#x2B;scKyorviwRrjm4ldOX9V89Xlt2treSrfK7etI66Trbqz3Wb&#x2B;vSr1qQdXQhvANrRvxjeUbX21K3nShemr1js20zcrNAzVhNe1bzLas2/KhNqP2ep1/XctW/a2rt77ZJtrWv913e/MOgx0VO97vlOy8tSt4V2u9RX31btLugt2PGmIbur/mft24R3dPxZ6Pe6V7B/ZF7&#x2B;tqdG9s3K&#x2B;/v7IJbVI2jR5IOnDlm4Bv2pvtmne1cFoqDsJB5cEn36Z8e&#x2B;NQ6KHOw9zDzd&#x2B;Zf7f1COtIeSvSOr91rC2jbaA9ob3v6IyjnR1eHUe&#x2B;t/9&#x2B;7zHjY3XHNY9XnqCdKD3x&#x2B;eSCk&#x2B;OnZKeenU4/PdSZ3Hn3TPyZa11RXb1nQ8&#x2B;ePxd07ky3X/fJ897nj13wvHD0Ivdi2yW3S609rj1HfnD94UivW2/rZffL7Vc8rnT0Tes70e/Tf/pqwNVz1/jXLl2feb3vxuwbt24m3Ry4Jbr1&#x2B;Hb27Rd3Cu5M3F16j3iv/L7a/eoH&#x2B;g/qf7T&#x2B;sWXAbeD4YMBgz8NZD&#x2B;8OCYee/pT/04fh0kfMR9UjRiONj50fHxsNGr3yZM6T4aeypxPPyn5W/3nrc6vn3/3i&#x2B;0vPWPzY8Av5i8&#x2B;/rnmp83Lvq6mvOscjxx&#x2B;8znk98ab8rc7bfe&#x2B;477rfx70fmSj8QP5Q89H6Y8en0E/3Pud8/vwv94Tz&#x2B;5fBhlYAAAAJcEhZcwAAHsMAAB7DAbyXl9oAACAASURBVHic7N1Nru7IfdhhdrvtFXgBtmVA8Mg7EAQNNdcaPPMkkLOGRMhEM62h5xoKQu8go0CAOtICsoJEzs3gjSmKn8V/Fcmq4vNAg9vnvh8877m6t4o/VvGrL1&#x2B;&#x2B;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&#x2B;X/33DkQAAAADAFb768uXL08cAADRvK6rth7TYswAAAACgEkobAHDO1XlMfgMAAACgFUobALCpnuhVz5EAAAAAwEhpAwCGoc2U1eIxAwAAANATpQ0AXqfvQNX3dwcAAABAVZQ2AOiZ7PThcwAAAADgCkobAHRCTDpr6xMbfGgAAAAApFHaAKA9otqlfLwAAAAAJFLaAKBqqk8l/CAAAAAAWFLaAKAWWk5z/MgAAAAAXk5pA4AHKDQd88MFAAAAeA&#x2B;lDQCupbuU9Zv/9tvpf/7kP/34meM4yR8DAAAAgC4pbQBQjJpS1iyqpZPfAAAAALiH0gYAERpJWeGolk5&#x2B;AwAAAKA4pQ0ADigfxd3Q1RLJbwAAAADkUNoA4M/0jOLqiWrp5DcAAAAAEiltALyUSlFci1EtnfwGAAAAwJLSBkD/tIcr9N3VUrTS3gb/FwAAAAC4jNIGQFcUhSuIaunkNwAAAIBXUdoAaJVOcAVR7Qod5LfB/7MAAAAA1ihtADRAVLuIrvaghvLb4P&#x2B;DAAAAABuUNgDq4oT&#x2B;RUS1JshvAAAAAG1R2gB4zNZp&#x2B;v/z/X/fedZf/cM/XXM4/RDVOiO/AQAAAFTrm6cPAID&#x2B;7dz5aT&#x2B;qrfr3//k/Zl/R3qAeq0Xt66/&#x2B;ZvXvAfkNAAAAaJ01bQCUFFumVpz2NmOVW1vaWsQWZvUbAAAA0AGlDYCgSqJaIu1tRnurx0u6WiL5DQAAAGiL0gbAsbaiWiLtbUZ7u4euFiC/AQAAANVS2gD4C11GtUTa25L8lkNUu5T8BgAAANRAaQN4rxqi2je/&#x2B;L7gq/3p5z8o&#x2B;GqD9rZGe9uiq9VAfgMAAABuprQBvMLjUa1sUUunvd3gne1NV2uI/AYAAABcR2kD6M3jUW14rqul0N7u0Vl&#x2B;09X6I78BAAAARShtAA0T1XL9r/86DMOf/suvyr6q9raqofamq72W/AYAAACcpbQBtEFUK&#x2B;l//df939fe7lFJe6u/q/3yxwd/IP/1t/9yz5G8k/wGAAAA7FDaAKojqhV21NVSaG&#x2B;3uTq/1d/VPgJ1bfkUBe46W39RDwocAAAAvIzSBvAkUa2wElEtUfH2NshvG8LtrZWolu4wv30cRjgF7joWwAEAAMDbKG0ANxHVCrsxqiXS3m6z2t7q72qrnaxI9EoscFvvOD5dgbuI/AYAAAAdU9oAyhPVCsuIal&#x2B;&#x2B;/S72xK9&#x2B;9qPwm460t9fK3/vx/gJX6k1JJL8BAABAH5Q2gCyiWnnZi9XCdW2pSG8bXRHeBu3tMluZKpajSi07ix3A5&#x2B;njE/dfbf9Q1bhLyW8AAADQHKUNIJWoVt75qPapaIkBbJrcvvrZj/YL3OEDpo9MeVgK7a026TdCy0xfZ99x571mFe3U&#x2B;86&#x2B;kcO3Wz5YeLuB/AYAAAA1U9oAVohq5eWtVIstU9tKYlu5bnyX6W&#x2B;lvLX21o2z3WuqbHMKHMkV0evsUrxSAZJD8hsAAABUQmkD3q6GqDboaguV7ACZfhj7VS/nMLS3GjxV4AL3e9t5Yv6&#x2B;l6v7Tx6aFjj57VLyGwAAANxPaQNeRFS7RHZUWzXb&#x2B;HHrATvr0pZKJbfxdQI5sMjqN&#x2B;2tEjn5bcjuXocbP66&#x2B;11ObXm55KrwtP8aOE6D8BgAAAJdS2oA&#x2B;iWqXiEa16zZgLLX0LRzAzh5AwX0mp7S3Z83yVT1bUA5nktjnrcPZafnE8IK8ixzemm558PIbALzT1j&#x2B;UM/7dBAA&#x2B;lDageaLaVS64s9pXP/vRFevAckre1tq41mlvzyq15Osj3HuKHEaRd68hWS0/jVgWreF7uYj8BsALhaeTf/2Df179un83AeCFlDagJaLaVa7ZAfJjmcGmWetUeEvsYem3Rjt8954KnPb2uMy1brOnP5Lfpuveco4hxexdLlpktprflr9V8PNvjvwGQB92lqkVnE7KbwDwTkobUKlKotrQX1e7MqrFhHeADGSwrfdKX2ynvR16pL3949/9/fjr3//xD/cfQFhK91ptP8vfLXgAiYu97iltZ13RIN/T1RLJbwDUrJ655MdWfhv80wkAvVDagOfVNhHqJ63VF9WWpn3rE7FmxevUhpOnFrGtvvLsFV616G1op71Nu9q&#x2B;tqrbR8GdJ3P60M5ir7OvcOnyu9kyu/2HcamdtQJOIwJwkdrmkqdYAAcA3VDagFvVPBFqPrC10NVSLPd&#x2B;3OphW7eCu&#x2B;Jg0mlvKXLa21ZmG6Pa4QOas7&#x2B;NYaIbUtPqfo8Fj&#x2B;eXP/5V4NvfeYr8dg8L4AAooua5ZEHyGwC0SGkDbjWbHdUzKWoss/US1c6aRbj7F5zFNrqcHW3rKa6e9jYWtd//8Q&#x2B;x/NZoezvc5DC9RZVNTSlpbVYNb3jfw0PiOv/&#x2B;P//H&#x2B;OvleUNnDAHY8lRU&#x2B;&#x2B;Y/x8cGFw2SP&#x2B;Q3AKic0gbc6uuv/macHS1nCw&#x2B;Gt3pL21uj2qFT0atU3FrubBk&#x2B;pKV2C1w97W0qfYfJmUbz2&#x2B;jZfRRz1tvNnut2ay3aT2vDf/xD/9c/&#x2B;GdnBgH4eCSq5RS1U&#x2B;Q3AHgJpQ241bS0zVQS3h5ObrpaVMF7ueU7vBvclnZj20yd7W3IyG8frUe4Z&#x2B;Xcf266A6RaVpXEtDajtAG8U99RLZ38BgD9UdqAW&#x2B;2Utpn&#x2B;w5uodo3YzdsSY1ishH1evJuKFlNJe5uWtk82m31lmeKmX5yWttUvdq9I7spJbkvC281iaW1GaQPonqh2lvwGAE1T2oBbpZe2mbbDW8tRbZmguilGmZs9fly0L&#x2B;V1b1SPCttbKT21t9W0tprKMotX&#x2B;hsVfFNSFElrM0obQE/aimo7o&#x2B;4Kx9vyGwC0QmkDbhUubTNVh7fWulp&#x2B;cKpwUpqiSGmbyvkcAgfT6Me&#x2B;o5L2Nuzmt&#x2B;VKuEQt5rdSi89K3XFNV7vHFWltRmkDaFRbUW10dqRd&#x2B;TBbfgOACiltwK1KlbaZWsJby9uVDNnlqfIZaaLwh3Ddt3/pzpaVq6e9DQl1bXXzyZ0HNNTethax7Zew/VAnm9XjhrQ2o7QB1K/RqLYqZfeItta6LclvAPAspQ241UWlbaaS8Da8vr0NjcxLl1K&#x2B;8eW3FrtFXJGDSdToj2Oqqvb2kbn/ZEO9bSl90dvY1a7YeZKz7k9rM0obQFWai2qZVWz69P3Gtnzl8cFNjKvlNwC4jdIG3Oqe0jYjvOUrtePK53WamJeedeojOvsJ7DS8rfcd32L/wFr/WVx3&#x2B;uDB9jY0nt9mdmqcwHabx9PajNIG8JTmotrH1dtOvOr6QvkNAK6gtAG3eqS0zQhvAQXXeM0e/&#x2B;Xb7xqal6a4NLldcQzXHcYjqmpv&#x2B;cltpsUCNy1t0tptaktrM0obwA0ajWo7it9ledgdBhd5u1aG2Y/kt0GBA6AjShtwqxpK24zwdoXAvLSVWeiO5Xc9/aauvlT2cO/KlAd08FNY0t54g8rT2ozSBlDWI1FtqGP&#x2B;cuetpmdbR1Z4g&#x2B;eyLs1vgwVwAPRFaQNuVWFpm6rq7GQNE9ccpa45bWUiumr2IczuA5F4W4jrPoFn3/1Bfbe3QX57h7bS2ozSBhD25qiW6OYeFnv95bG1MuqW3wBgldIG3Kry0jZT1bnLhia3h87ur7jsVaWPqFKZN3s/9YLpuvz8q2pvH4EC9/s//mHnWfJb66ZpbahpQXaA0gaQQlQ7lH4T6Jxh8M4uEft3py74jpWPwOU3AFDagFu1VdpmhLeyLHqb2e9qRW69dvgis2e9dtHb0Et7mxHb2tJTWptR2gBmRLWPrcHn/uq08HD06t3dd94rMLw/&#x2B;46Pk98AeBWlDbhV06VtRngrpey9zRuafM5ccY/3j5zPRBAdVdjeRikRTmarX8dpbUZpA95MVNuROPJczVRbK8/OjkLvvPvadL1a9&#x2B;HtQ34DoFdKG3CrnkrbTFXhbWhkLv1xXWEaGpx8zqSvQiu&#x2B;1WT6MZzV&#x2B;g9ldOmZgrP5bRbbdLUmHKa1oaO6NqW0AS/xVFQbmpoLHLpz5Vklx1B288nKx95Xt7dBfgPgFkobcKuOS9tMbSdMO5hsv3xxVebN6nL2gVx97uFVw9eVv5pV1d6o0GvT2ozSBvTnwag26mDAH/DgbudFdne/7u2KH8Cd5DcAmqO0Abd6T2mbqe10ah/z8Je3t0O3Tf5XK&#x2B;DO9bNnbxfXtC7b27h&#x2B;zsq5Q9LaKqUNaNdWURsWJ&#x2B;hn/wRcrY/hfRGnxsBlh537e1qWNb5X&#x2B;JZvQ2ujbvkNgJopbcCtXlvaZmo72druzLzgxoZtzTMP1bnlY/q9N/Lfq1rNtbfpvpSftLZ6WzjV7UNaS6G0AU3Yimrhv8EubW/tjucTTW9plvMKU/2NOcdPKTbqbnFTCvkNgEoobcCtlLZVtZ2KbW6ivjXxfvmit8S9dLYetvyt4p/Dg1ccV6X&#x2B;9raa1qZ&#x2B;/8c/7D&#x2B;m4w4nrQUobUBtike1RMXbW3PD&#x2B;H2He5iXevGd4DTu1rD/ajWPVA&#x2B;H9Olj8pq/zSn5DYD7KW3ArZS2FLWdqO1jxr41UX9b7Mn/fnfOSlxxDFs6&#x2B;FnsqK29LbeLPGxvM8vFcO22N2ktn9IGPOipqJZIe5s6VYCmuykWf/2UA1h98cqHrDmfQOXf2tKD&#x2B;W2o5m8YAK6jtAG3UtoCajuN2/R0fVi7qDM9wjU3nzx0KpuVveF8&#x2B;qvZc3KouL2tSglyqxtR1pnfpLXilDbgHo9EtcSLUdL/yXt5e5v1qsBwNLN4pQ9Em173NpUZIFv5Nj9uyG&#x2B;DBXAA76C0AbdS2vLVdpK3rbn6x9XFqK3pZbrArPvUR/Hl2&#x2B;9mJym2dvJ5z43fd9TW3obk/Hb4yOXj7zc9rVnb37odUNqA4mpYqba8fOTUEvAH29vQ4JD&#x2B;zqGgHemHk8PvlNu/1fxpyG8ABChtwK2UtuIqPAXc3ET90Kuu69xXcI&#x2B;dUeYlxlvr3lKufR5PGfTxM6qtve2fcNz/z&#x2B;H20iat3UlpA3LUENW2nN1decvZfwS1t8RdK7bkr0izB8Po6ovzniK/AbBPaQNupbRdrcITxG3N0re8/FLWUfEtH4eLP5OXn/WovL1tuaexSWsPUtqARDVHtXQ5&#x2B;W222fKpfyJfvu3kqvwh/dkNG3aeW8louTj3fitOfgNogtIG3Eppu1mFp487mKLPnL1gdvmU5qaUo5TbvJ2dbO/cOe/U6wxrhxf4YXWmtvZ2J2mtHkobsNRHVEuRH97CtLels1dl5W&#x2B;HkHjhWut3fStyneL0e2xoAiW/AbyT0gbcSml7VoUnlzuYnw&#x2B;2l1xzxT6TH0VuaJ8S3rr8ucxcfSLg2fYmrVVLaYOXe09UO2VZ4MauFlvTlkJ7Wyp7R&#x2B;fY6ydqdLBaPMI1QX4D6J7SBtxKaatKhaeem56cF9kBprkbhifa/75S1sYNJS4i3tHrJ39W0&#x2B;1NWmuF0gbvIaoFfLrazfcrHWlvw&#x2B;7QdGvAv79xxc4dhVNefOvtEn359rtWxrSZm2G08m2O5DeAnihtwK2UtppVeGK69Zn5xzgDzJxRb73C2zS0dUzT7pn5D3ntTVprlNIGXRLVmvCPf/f3Zxue9jZVw4q0w&#x2B;vDdg6yuZFzwQVw40tV/iHIbwCNUtqAWyltDanwtHXT0/Itdp5M1&#x2B;t946t1W2yb2Wlv0loflDZonahWucRbwf3&#x2B;j3&#x2B;I7UupvQ23bIG4uhbtoh3aWxk8l/r2W/l&#x2B;R/IbQP2UNuBWSlu7Kjyp3eKcfEsNl8eme/A62dX9YVq/Y3y1niptO5Z/Efk3pUVKGzREVGtRYmlbFdu1snh7G3oZ6qcPU4sMaGNziqaHyq9tb4P8BlAZpQ24ldLWjQrD29DFhLz4ZaplJ42Vz94teiulnsYmrXVJaYM6iWq9yg9vgVvHaW9bwqP92PD18BZxKfeQa&#x2B;teaLN9&#x2B;xM/8P077TVEfgN4itIG3Epp65XwVlbgNuxblpPMnBlj5WvvynbKFqfW&#x2B;WpobLO/Tx7/m4TilDZ4nKhGkfymvRVx6r5rh/tJHu5IGTnExbE1V6Ru2O2zZs/mt8E/LsA7KG3ArZS2lxDerlZJUlqdY586tuLz1f1TFVvHlnIP&#x2B;Xan1ocer2sWrr2N0gZ3EtUe8csf/&#x2B;pff9vSyDMnvH0Etp3U3nbsj0hj49WdC&#x2B;9SBvDLwJb4vtUKX8KY8gr1fya3TQEsgANeQmkDbqW0vZPwdrX88DadtGdOC0sdTP67r77O1imGZwPhzaQ1nqW0wUVEtUf88seb/6q2Fds&#x2B;xuT2&#x2B;z/&#x2B;ITO/aW&#x2B;ZEu/cdli/wuvP8kNUcxI/q463rJffAMKUNuBWBUvbbMr0&#x2B;Ilj0glvN3g2dxU8jKl77jmXclMHc&#x2B;azpDWmlDbIJ6o9a7WufbraTnhbfXzl8te6jQLhbdDeFmrYBTF9Zdv&#x2B;0TY3os788Jv7fkfyG0AKpQ24VanStj87evycMqcIb1eIzQN39oQZyt2GPf0dCx7GUuLqt0anxI//NSitsUNpg1NEtZpNu9q//vZfZv&#x2B;59cgtb2tvg3VvF0gcWl80xA3PQYofyZ3SP/PlIxv93u&#x2B;ca8hvQCuUNuBWRUrb2YnQ42ecOUV4u8H9S80ybwtR8Eh69fhfdNIa6ZQ22CKqPWhWwsLRK31N244mktvobHv71LV//Lu/39qg8mx&#x2B;u6K9DR2N/&#x2B;&#x2B;8rK3mDS2uVsmeIvf523&#x2B;bfeFPP//BbW8uvwEVUtqAW&#x2B;WXtswJz&#x2B;MnozlLeLvHcoHXI/ctq2E/nFY8/reZtEaY0gZbRW1wlvB6iSVstkBtyK5fy/edvuD4u201ti1l170N2tsF7tkmfXaxnRu/NfwdLbpaIvkNeA&#x2B;lDbjV46Vt5vFT1ZxVZ3gb&#x2B;pp4f1Sy1Gw5O025OfzqYxqe2Q7DUMHfV9IapShtvIplalUpsuBslFPFPkfSR1dL8Wlv02C2X&#x2B;PGdW/7D0invSU63D59Z6eKxBffd2q3jMBzSRVNaynkN6BLShtwq9pK29TjZ7EJEN6esnN55s7tB/LvfPaqHWke/0tJWuMiShu9EtXalV/g3tPMCgovfVvddlJ7KyJnsH310Dr92MYL7yof7dflyrSWQn4DWqe0AbfKLG13zlseP8dNgPB2m6e2eSy70q6qe5LX8HeOtMY9lDY6IKo9KyWMxdLX9JVnr3Cqxl0R3h4/gHuU3XnyVH7T3rZk7vp4xQ6Kj2x035Wnu9q&#x2B;O6vbSH4DMiltwK0aKm0zNZwE5yzh7UH7m7rkb/lyOGOv/5ZvNfytIq3xCKWNRs3qmj/Gd0pMa/v3Qrv6GKYHUDx0ldr3stECt5rfDneY3HpKOu0tUQ3da/8Yet1e/oS609rMI6Vt1eopBQMAYJXSBtyq3dI2VcP5cQKEtztVss1j/mEUnH7X8FeHtEYNlDYatbqOzR/m21Ryi7Wtw/i84HWlLf1IAlrMbzk7T&#x2B;a8r/aWInMN3HD93eCW7z59Vif5ram0NlNJabPKDThFaQNulVPaqp1&#x2B;1HD2nADh7U6r&#x2B;zTmT8LzD&#x2B;OKdxnV8JeDtEaFlDYa9RnHbp13&#x2B;/Bn&#x2B;07TrDXLTqvr21bdHJn2Q13xlz2rxeQ2pFW3zMC2Q3tLcWoQvrX47GwMS3/T1d0yrtj08lotp7WpBzPb/j/xwzB8hgH&#x2B;rQdWKW3ArbosbVM1nFgnRni7X6l1b&#x2B;E9J88&#x2B;/VANfwNIa9TPGQoatTqOFd7O2mlCj9SmS9tSZgDLP7bVA5gtv7v0AB7xCW/XpbVDF7W3obt5Qc5c4M4dLyptbL10tY&#x2B;n6lpKWls&#x2B;xT/uwCqlDbjVFaWt5n0eajjtTozwdqfD2yocPmb5&#x2B;HvU8P9xaY3mOENBo1LGscLb1Kkbmy1/64ojeTYd5YS3gtUtfcHfRUfyQtpbop0B/9lFbBdtO3m48O7sm54grZUQSGvLV3jbv&#x2B;ZAIqUNuNXVpW2mqvBWwxl5wqoNb0N3E&#x2B;xhY6vJIg/OV8P/kaU1WucMBY0KjGOFXps9rwAAIABJREFUt4/8vQ1rqDvLDSoLvlpMzjFUct&#x2B;7N&#x2B;t128kv335XfDT&#x2B;GfCfmhFsKfIi01e7MLlJa4Xs/1sc&#x2B;Jf9Pf98A6cobcCtbi5to6qS20cN5&#x2B;sJE94ulbmrZNn/v9fwf1Vpjc44Q0GjcsaxH8LbUp17GJ46qoIL5tLr1xWfifb2uOba2207MZbac/7SY8idg/TV1YaO0tryxd/57zVwSGkDbhU&#x2B;Q7EzPWi0tM3UcDafMOHtIo/sGFnJ/xlnf6gq&#x2B;eMERThDQaPyS9uM8Pbxyx//anbnsAcjTcHaVHbR2zLsHb57kc/z8VvNvVzl7S0WwFY3YMwczAf2udlZeze&#x2B;mt0gT&#x2B;k1rS3f6z3/QAOnKG3Ara4obaNWtpE8VMmJfsKEt7ZU8v84C9f688Of/HQYht/95tdPH0h1nKGgUcVL24zwVptSkSm/eJ29m92y0k2/cufau1XyW44629thmkpZEFaqb53qf7fed01aK&#x2B;fOtLZ8a/8iA6uUNuBW95S2z4C44CVyz6okAxAmvNWmkv9PSWvdC5S2z1POPqs5zlDQqKtL24zwVqc6I1PsqIofTJ0fTvfqbG&#x2B;rEhvYcvJ&#x2B;eJ&#x2B;28HslHkCQtFbOg2lteST&#x2B;CQZWffP0AQBcpem6NjWd5FRSCDhlNu7/TBIq2Rtw9ieq1/BWyf9xpLUuZS5cG9MawMzq&#x2B;GH09Vd/M/1PZ/1uM61BOTeZWz63VGdavs7Wca5&#x2B;/Z7cNVtmR46/&#x2B;od/mn2lSHtbjp/zZwr7C8hG6ZFs9sjlGYCUcwLFrtDtrqsN0hrAGda0Abe6c03b6lfOqnxhXCX9gBxWvF2hkv9rSGtvsFPalr&#x2B;1XLK2VdqsaYMK3bymbZ8VbxX6pKPZPedSLJ9SKnel9LycXhg7hoIvTqKL1r0NheYLKXtL7jwyMeCVn85La0W1ktaMY4EtShtwqwdL23LYfesFbreopC6QQ3iLqeQPv7T2QumlbRbVPl9X2qAhVZW2GeGtNtPqlvLIFNfltzvfnUpU3t6GvO0fl8rM5aW1olpJazPGscAWu0cC7/Xl2&#x2B;/qj2en2GeyA7aaDBzJg6S1joVvmbba3g53iew7rQFXs9Vkbfa71H7rGp&#x2B;7fNjsK7H6Ne7cuPr09K0mtbemXbTn5FBu28nEqfpOkMud7PfY1QZpDeAy1rQBt6pqTdvyt8Zfr25A0XSWq6dMkKPmFW/Dle2tnj/A0lqX9tvYfgPbX7j2&#x2B;a2dhWuZt3lrlGuBaVTNa9r2WfHWkMCCszu3mqzcb/7bb3d&#x2B;9yf/6cc3HUcv6l/3VliPae3BrjZ0mtaMY4Et1rQB/NnY1QLL3bYSXSV9znK3PtS84m3IW/RW7R9LaY10iQvXDh8GUJYVb604vFXbaofbinNnO1lnXe3w8cLbofrXveWS1krrMq0BJFLagDfaWeI2OhXbdl5t9ls1hLfZNKbawsGhtsJbK6Q1tkwLWWAV2tsWrgHVEt6qtdW6Vlva8sGzh3WwRm3qbFcLvKD2dqj59iatlSatAYyUNuB1clpXfjb7BLzZArhnWe7WjcrDW7WkNVLMFqL98Cc/3d9tcrlwzVI2oE7CW/1OFbhuFE9rgXfU3g5V3d567GqDtAZQK6UN4C&#x2B;kLHcbTbPZ8nWG3bVuQ2iPyqtZ7tYT4W2LtEYRy9gG0AHhrUVNL1b7uL&#x2B;rpbDhZMCd7W1Y5rce61rNaW0wkwL4D0obwJ/Nutesk61ms9XHzF5nVt3SS97jhLeevDm8SWtkSl&#x2B;ONra33/3m1zvP2k90Gh5QD&#x2B;GtZu0Gtjq72iGL3mKua2/D6tK3X3xf6sWfIq0BtEhpA5g7taztCtN3r2rRm30me9J3eJPW&#x2B;vYpWI&#x2B;0qK2dIdOf&#x2B;3n61rdgh0mgcsIbAY12tRTaW8y17W2Rqepvb9IaQAeUNoBUs/ur3VPjxnepKrkNlrt1p/XwJq1RxH7oSlyvBvAewhtLHXe1FNpbzNvam7QG0B&#x2B;lDeCE1cZ25xo4y924R/3hTVp7m/A6tlkS23mFsvFs&#x2B;Wr2hAS6J7y90Mu7Wgo3e4vprL1JawDdU9qAfuSXpy/ffrefzQ6L2p3163O0t71dOsvd&#x2B;lNDeJPWOOuRZWf7OW16SKsPk&#x2B;KAnghvXZLWMln0FlZ/e3s2p01JawD3U9qAngVWm&#x2B;VktqstD6Da2DZluVt/7glv0hpbDm9vtt&#x2B;6DmtWzs3YVo8n5e0Auie8tUhXu4H2FnZze6uZtAbwOKUN6NwYou7c4zFHtftDFmG5W5cKhreqNqikZtNglpK1Uu6sll689l9q&#x2B;buzd5&#x2B;&#x2B;kcwGvJbwViFdrRLaW9il7a0q0hpAbZQ24EXOhqutOLd6t7YrfN5iedjTA2tiWdsW4a1Lp8KbhWsvEb7L2urr7H9lWCxcu6dm7cc8RQ1gn/B2P12tIW72FtZNe5PWACqntAEvlVOn0uPW1sNOLbBruqWdYp/JLh2GN3NCDiWuWlt9ZMHE9Ql46TtDqmsAYcJbcbpaTyx6y9FKe5PWANqitAH82TSA7cetwIK2srVs1uq2Vr&#x2B;1y3K3Xk1Xs5kcsnQqlY0Pvq1pbW0CefNhALyN8HaWrvY22luOStqbtAbQNKUN4C/sxKqUhWj5y91yXrbje7xZ7ga9mm4smXgrtf1NGtPXnBWhrgHcT3hbktaYseFkjmV7G67Jb8s99m3&#x2B;AdAopQ1gz6xXlY1tW&#x2B;84LlDLuRXc5zASl&#x2B;i1xXI3aM40R22VsKr62f4BqGsAVZmejF4uCnlneAOKK7L0zcI1gF4pbQDnjMlqjFizplXwLfJj2/TXPcW2Kcvd4DqfO5MVeZ0hOZglrm&#x2B;7mboG0IT95W5Dv&#x2B;FttmLJEjcsYrtBSnvbT2u6GkA3lDaAYNBqLlxNY1uXa90Gy92gqMzWlfn0GtaxPfjuABQhvH0Ib28grdXgr/7hn2Z/q8xIawC9UtoAhqFEcCqVrDIb2OdZ&#x2B;&#x2B;FwttZt9tyeCG9w1vSuaZkvsmO2am36dpkL2mpbCQdAVYS3D&#x2B;GtA7paPaQ1AAalDejGrC31F41KKbjLZXPsMwn7Aplq9pTDRLfzgAc3jbR8DeCdhLeR9lY/aa0e0hoAS0ob0INlPergtmRFkljKEreUY2j9w1yy3A3y5dx0bXVBW85Stuluk8oZAAGvDW&#x2B;DRW9VktbqIa0BcEhpA7rVQWzbUarDJb5O35tMDpa7wa5pABsj1moV&#x2B;xSv5YPPvsuQdp&#x2B;26WMSt6wEeJxRRyuEt5HwdgNdrSrSGgBnKW0AdUmpXwWXu6XHtum7l70pXW3pznI3Wrcaxs6&#x2B;wlZRm60eG0K7Pu4vPsvcRnJ8TWkNqM1sjLH8ilFHzYS3kfBWhLRWlf20NqhrABxR2oDmLe/QNn6l0WVty/pV23cxfrBFjrPyBXNOgfESsbJVvGbtv&#x2B;DyIFezH0CjLHdriPA2Et5S6Gq1kdYAKEtpA7pSYaeJmca28ZtaXX9W1bc8TZuxzFl/HHUKjM58MtVhoDrcyzFls8fpO&#x2B;Y/ZvrW6Q8GeMpyQdupxxt1VE54m9LeBmmtPtIaAJdS2oB&#x2B;7Bep5qwGpwe/teVbrx7JLLZNn372HStf2Dc4BUYLZjdOS&#x2B;9qO/9ZyurLLhvb7Fu47ngArnM2s&#x2B;2/giFH/d4c3oa3LnqT1mojrQFwJ6UN6NOsylS&#x2B;P&#x2B;Epq8vdAk6tHgvf1C32dsNaxrPcDVLk3N5s9bk7WStQvJZ3fUt8oroGMHKtT3OEt&#x2B;l/9hHedLUKSWsAPEhpA17nk3Aqbzb7Ch58kRVyq/dsO/sKHSxDnHIKjP6k7w&#x2B;Z6HA7yoLvVcRydR1ADVzr0xzhbfqfrYQ3aa1C0hoA9VDagP7tJJwii8NqcGp12vhdl4pbs9VmiYvPAptD1r&#x2B;sbYtTYHRpWp7yI1zlEatsZQReJX/ryPB7GXU0QXib/mc94U1aq5C0BkC1lDbgpZZxaPx1oy1nqvi3sExcKfdsO/X6Q323pruIU2CMzebStjQuQat8JVbNxwbQOqOOFglvs6/c0950tTpJaz2ZXrhmCgD0R2kDXiSx2UyrUgdbTQ6L3R2LtKv0F0n/9MZPvmxaqzyjOgX2HpnFa7amav&#x2B;lbp67nlrvZV4N8BSL7Fv08vA2XLboTVqrk7TWn89MITYFEOeAhihtQD9SCtmpyDTbZbHCSHNKZsS6Z2HZ6v6Qs59aHz&#x2B;OLU6B9Spn78H0596/w2Fi/xu/boYMvM2dW0ee4lqfRglv4fAmrdVJWutbbHqy&#x2B;qzKN&#x2B;oAUNqA5u3Es5zbei1fM3Y3soKHVFypBWSzwHmPwG3emuMUWDcSZ5ir12wWiWfF56Xj1pT7jyn4jmWZqAOPq20k41qfRglvW&#x2B;FNV6uWtMaUVWtAN5Q2oCufjhXoPYnNafb6pxZXVXizsVKHNPtYEj&#x2B;Q8SmrS9ZixxB4YkOcAuvGbA55xTWb9y9umx5tbZPk2Y3xTn0493&#x2B;SwDtVtdm1a33aJbwJbBWS1voTu&#x2B;308lLC2UjbxXBA05Q2oDf3B63l3cUePz&#x2B;yo8hN2pZmqSw9thU8quUr1PyDyPTNf/6X4W//bfzPP/38Bw8ezEvE5pOHL7UfcpbXeJYNP1uvljLLbXQaLLMB9attSOlan3YJbzxCWutS5mxoOa5OudzwihkQwEWUNqAHF9Wj8cWHxT3bZpYbS86e3rrZJ/z5psp&#x2B;7Jf&#x2B;ELv3zS&#x2B;&#x2B;H3&#x2B;tutUsPEuc3udsJ4&#x2B;lH0ajnewi1&#x2B;3bCdAZy92aJrxxEWmtS/kXGhpOA6&#x2B;itAGdWO00s8r1SMgJb2h5nZTPavVZ6a&#x2B;f8rAi12vvf7Zv2FJyaVrdBuGtAukzzLLXbM5ebVnXAm/UdJ9bfvurH/jyg0q5KR3AWY/c5rY44a1pwhth0hpbAn3OwjWgD0ob0I/VdVcFX/zzi1kfCpwcCeefgt2o7OsU&#x2B;djDp5mWP/emz1gVJ7zdaTY/jN23IN9sx5WtjVlWn1j/PcnDs/chedea5buIbcANOmhv9plsmvDGDmmNLbGlb4bWQH&#x2B;UNqArq5nnhjuT5T99P1BVfsIls9u9c&#x2B;XZU&#x2B;wzWdZnirh1Gebq6qjVRxaUmcfqrGuZUj7waUsz8wdKmS35StTHuMhyt9YJb&#x2B;zXNWntbfJnGVuX&#x2B;p16nYI3zwYoS2kDXmEZ286ewvg8/dQOiqfyWH&#x2B;16dQnsPzpxOJiZ5/h1V613K34lGy55eDWI&#x2B;9ZDpXyFp/yV/&#x2B;qteEvE2b46fuvsLzXuoVrQCWK7LBd5EUKstytdcLbG0hr7IhtLGF0DbyH0ga8xXSfw1NnHKYNLDH/LF8/JR0F7p12tcwD2H96Yk6rfD1fT775xfe9xracCd5yXdrM8ndnq6PK1qzYzdWaqGunbN1zbvbNzj7/5e&#x2B;uvghAPabBLDCOrZPlbh0Q3vpgT0iWDIkBYpQ24F3CN0jbeqlAB0o/hk/kK7VNZSvnZVo5zi61HtsKZq2dHjMsruhcXuBZ2/WbfdS1j&#x2B;n3kn7ftX1V/bAAVo0jum5620h464Dw1gpprWNFpkL3j4qXu24ANEppA15t5yTFYeKarnXLP9mRvsDr7IK88HNvsKyVtR3hC7UY24pPzPZf8JF5oMnnyL0ZAEZjdcvMb1WNEu0z2QHhrR7SWq9mW1acnSxkbtVeVmzTjiuOBCCH0gbwZymnGKZJbPqL8OmJ/GV29ZwZiVk9/tX02Pp32ooWY9toeS3nzsxt&#x2B;Vtbc7bV6evywcV72KlpswnnaLbW8NSzPmwsCTQkZ7nbbLhV2wjTcrc&#x2B;CG93ktbeIDxSXT5xf7uI62xNcw7vsmzKA1RLaQPYtIw9l55xmF6PvIx5U8tzIjWcCikuf&#x2B;dMwpqObYkSZ5KtzOVaOc6LxNLa7Omrr6CxAfW4eWhUW3UbLHfrhfBWlrT2Nme72s5Ad0fxHR1zFq69fKYDtEJpA9iTvtyqoGXeO3y7w9jWaLWq5LQO/dma6aXf3iDlYUXmhLNZrtsYHLriYwdoyOqwMDObzW4eXMMIzXK3bghvZ0lrjLaGrLN7Tu/s23Hq62UtD15aA5qmtAFEzMJVkdMNKSUs/Y063nqx0WrYnDcsa/vYWQ61M8dbnbLOdl8pdf&#x2B;DpzZ1aUWRe79Pp/rm9kBz9kdHW9shbA0XWxxoWe7WDeFtSVpj1epW9qvtLf1qwhxutwa8nNIGNC/zDvBhT4WrWeFLvFfcU5/SRbr5RrjC4UzywaBy9qZrXbafrWtX7zc9E7F6H74uP3&#x2B;gV6cuRVqOG5df6aO6DcJb494Z3qQ1UuRcgffs4NbQGuiS0gZ0ooZ7lSWe4Djc0ueKN916o9j2QTlPv0Ilh9GfDpa1Jc4/Y9PUnaRXfN5bT50KmK7tq2dN3taPb/rFtj5ngEulbGY&#x2B;/c96hmfCW096DW/SGokOx9I7m&#x2B;RfcDgnGFcD3VPaAEoqck4hPZ6d7XPLx58tlMvdh4aazqR8jMfT4lXY3CBzM8adO3gtN2w5nFJ2POecfUr598a7wtmfF0CLxrHlnVtw1zlKHOwz2Zd2w5u0RorMi&#x2B;3uufHw/rsYXQPvobQBXGW5A8&#x2B;d4Sd9w5/lvTo&#x2B;h5q&#x2B;8K6GBYWrPkfV7t5HXKrItHNZibbu9xbbh3B14nrRfDWzeJ36Bh9c37Zz63WAjn1Gd8tlZ/cMkCx34x41hzdpjbPyrwgMD7bDTzSuBt5MaQPeZRqT7n/3nTed3XHtorc&#x2B;tVSu2n4W09P3cqe2NpAc55azaLSMK5mNZ7kQaiuwrf46/F7XzV1zPpDlZ7u1K&#x2B;N0G8kHPX4AU5V8JsCDbhiipIwA7xwpVTvItNytM8&#x2B;GN2mNHKuD89XLxR7fFnIwlAUYhkFpA15lepbh8Rl&#x2B;&#x2B;N2nTS7Qz5YvMoQ&#x2B;jfxXgKslTjsz56ifsHTpSqnrFrHlv3jK57b6Cd9/UsApAKAVgaVmNa/dr/nYdlju1p&#x2B;rw5u0RqKcWcM9G0KmHMbThwBQHaUN6Eq1N4RIkXJWZecBmans7HNjr/DsmkL4KHJfrhY3IZymtcAUPf373d&#x2B;I8razA&#x2B;Mx1P&#x2B;jAZgZR0r5GzzeH7q6HOZZ7taf/PAmrRGQMhJO2TwjUeYNqrdeCoAlpQ3o0Gzx1oNHctb0aBNvsTb99W2xzQq2V2lrA8lTxulibNr5qtnm/g42mZ9k&#x2B;gG86jMH&#x2B;JgOujLD2z03Zku59K3pwaTlbl06G95SXoQ3S9/p8aJr1AJX1y13yI&#x2B;9NcA7KW1A58ZpfHP5reBZlcx3XzWeQ2l0RyB6Nb1V2/iV/aecnX&#x2B;Gj60Jq7PrlBtFbNn6xFI&#x2B;ybNnFrr/6QAMCYO0/IFuYBS6fMyypZ3a9rwhwluXdsLb//n&#x2B;v4//Ka2xlH/lWZEbsC1TX/qu7wAEKG1A/5bz/Bavol1&#x2B;C7e91/Trs/dd/SRnj2nuo&#x2B;Y9NLaZ5a3UZt/1/tW4ie&#x2B;yDHg5e3jGnvi4Gm6wAXRpOe6ajt9iA8izmy5MH3y4sm3obqxon8kuLYuaxsYoZUy7Oq7eGRDGxopGmAAPUtqAl4rdMKye24wto1fKBc5X9LnZOZSUK5rPvv5QwQfOq7TbbxJNJ&#x2B;H7&#x2B;9UM2&#x2B;cOpsHszll9Bz8dJ0GA4m4bKV3xRs3tPJHOcjfoz/7&#x2B;ipm7PuRbDXhbw3gAClLagG6dCkst5pzMfBULb6vPWt2is4jlErrxMMq&#x2B;Ea&#x2B;ynH9WPtu8&#x2B;RZlh3vLZN5Z/dP2AmvgnhVbgXfnrewApg53gFxeLJUzvhqHgpmXds1eobMhn&#x2B;Vu8CrjiHe5LcT&#x2B;gHAW8zJHj&#x2B;MotJJBNUCvlDbgLVKm/S3uKhkWPgmScrIm5XcPr1/u7zYe7frmF9//6ec/ePooUk2nozs3Cbs5X4WFp9axMvR5cOKU/tTtH6a/e3iv9Up&#x2B;LoG71m89N/FZABcJ7wAZeJfM/SqnT&#x2B;l4cG65G9Qpf3vz5UtdqrmLCAF6pbQBfdqfkx9Wt17vNJZzlfEyjO2/VOC9WlxZSFum084Kp6ClYkzK7dYKnkQo9SK12b9zRuxbnn3s1rcBj2hrrDWNbS/ZZ1J1g0csh9BDoVHu/tAxcSP3FF2OyQFaobQBzO0s2GpuSp94wCkPW70z3FZLW72iOfFgLGXjCvVPO0tFl5zXSfyUtt7i8K27vOR29TtKv0WH2AbkyB&#x2B;alhrc5u/3ePZKuF53mBwsd4O7TC&#x2B;BunpItjNizL/YroMRNUAHlDaAEzqY0i&#x2B;Xo2Xek&#x2B;OeMPYJdbe9Ha3rfra51asezDaP3/79IrMDXr3YefaV5dJJOQ3Y0dlWCrH9HpdPmY363jwCFN6glK27phV0Q7RrbjgN8BJKG8CmlCVZjba3zKMdP42bz3q8&#x2B;SQL&#x2B;5qYcJbasPGw7gy3Bx4ladXWT6GJP67APc7e&#x2B;7YJ&#x2B;QO2/JFqkdepk30mIeDsHoz5u0SsjgBXb1p8eACGjgBNUNoANn3OdOycLFheadv0fP7UijHRi3q8avKZMu0fP5CyF9V&#x2B;el76Njvd/1x2brpWwypDoH49jaa2hpGxvcRj77XU8X3dPix3g6UijSpnHHt25dzqe3U/kAboj9IGsGenn6XcSaK5Kf3&#x2B;AZ86r5H5vSe&#x2B;V2cbLsEpswtj9/c5LPUu&#x2B;48s8o7VOnX18c6Dxx/W6l6U3X&#x2B;MwKEOlrVtKRUXAzuKF/xUqx3nW&#x2B;7Gy6Vs/HDqdXKe63IrgLdR2oDmFZ/lLqfu6TPz2SO7v5D2WVdsuORHRis&#x2B;M//VvWVumNiP7371G90jJXFtXR&#x2B;9&#x2B;qzAj8DpGHi5Dm5Gu/wWPkOpst9azvBsa//z2GtWfr2X5W70LT2GxWJb&#x2B;nNP3avYtpAAHVPagK4Ebh6W2GaKJJzaZuABO1sDDYsNgsq&#x2B;b&#x2B;Ijp5/z2bt0hAsrXGH1stzPL3Y2J7wi2PR6UiDls8r8PLfap64GLC/u6SO2DWlLvqoaYs1Gj&#x2B;HwVtU3NSO80YHV4dPWVgHV6mYgDcCM0gZ0aJzl7pyw2GlCZ89xzPJe5dPsfMucmfL93vmZLH8EVqrRisRzBFsPm3095T5tidf5dnBSoNTejOmv0MGHBhCwHGsVjIhnR9qrm1Xsv2zmYrXK17p92GeS5pwKaYF7FW89ZX&#x2B;ovHzK6usYEwK8gdIGdC5nclv8yuKeItzWN3Lb5djLsxi33UMO0j11dW2R&#x2B;XxPJwVm98y49Ftbvfva8B9narb&#x2B;SAROCQH9WQ5RurlaaDpUu/kbuXOx4BV7m1/Ncjeqsrxu7OyzVvdpTLGzaUTsdQB4FaUNeJHAFanpM/OdbRVb3wjorK27dBw&#x2B;LOcdT71gyimPys&#x2B;JUK3pda/3hJPl2xU5gErOERQJY4efw87rLz/MrUubE7eInJ73mb6OzAYsdbavdamDTx9A7pfLYbHLxdkj7HKcb7kbN5sO9lZHU/mD0lMbhv/uN7/eGq2NX9ka4&#x2B;UdJgBtU9qA90q5qVuRyXOXk/B9mdvs5AucK3nbz4iypvPt/GRyGGBSCs3skGaT/y5vvbZ6EfThRkD5Ge/sK6SEPYCdTQ6ni8NSbopWrfTDjg2nr2iTgc0h202klrtxtdgQuviN2c4exn6KA&#x2B;CdlDbg7abz3vFUhejSn7M/1nbPiXC//Qn5qXMBRebqd75XEfnXBSeeE0l85NbTt5a1LZtlYOMju0cCAZ3dJ/j&#x2B;byFzzL&#x2B;TObucUFju9nI5Ow2sXuAVG/kEDmA5yip7YRwADEobwNQ4T07c//Dj1CaTLzf7GG&#x2B;7udrZ7SVnb718Kd4p/fbmy/n8RR1lejltzh6JT4l9JoGLiG/&#x2B;3mNvV&#x2B;ogi&#x2B;yzBFwtf4vymelg6ak7opUVHjde8e47xk8&#x2B;fBfhrZcNHMxtLHd7m7NjtrN7J&#x2B;yMnIsPbFaH9DaEBCCT0gaw7tSEVmYLqzxStnhbey5yaqHY1fvJHN4A7NJ3v8fnrMr&#x2B;Vc&#x2B;ru2KODy67peewtuVmPR&#x2B;49XDQh601UrPbiaW8yPjrPsYt4eFi2fq18y6Hn3PT&#x2B;3weEt76dmqYsXWvtZ1ydsWu5meHRlWN6wBokdIGELQ1Ue91/nyd5Qae49d3ToVk3sF&#x2B;/wX39XfNeE&#x2B;KJK70F7l58dDhwrWmbxqxuu9izj5FlxpD4LNHKLBBH2YjmdWBzc7I8/Cuw6ubpecc4bNS7rWc/joft1349ZLNEuwzWbmyw8VTWyycesGCT290&#x2B;wcAGqK0AZzw7CY2bxA&#x2B;3VD2B3F4Bmd5vklyq02sgS0zzzL/7EzUn5qfT9&#x2B;3knMEpy4Knh1/zq3Uij9y&#x2B;cTHr3duN6YC&#x2B;4oMZlZfZLnVeXpvq3CsW&#x2B;qQZh9L4hBuHCXOhouxo5q9TpfDSMvdanNdDMtc&#x2B;naRnc3e7zkAAF5CaQPIMjtt0eX0&#x2B;EHhz/OKH0TgLinUbLkUKWV/ws&#x2B;vL7rpWoordtcpbmvXoFKvv7r67dSzco6nzs/8o&#x2B;ZjA5ZO7Qm59Qr5h9HE1ULX7fo4/XX6J1Dws4oV0Hb9Obz97b/96ec/ePRYiAgPosLj55S3s2QNgMcpbQC5&#x2B;p4MV2V27fCdawo/b118y0oeMbt9V8oWkZ9flFp6lam20wQ3b58YPrlT/EhukPjZNvrdAYmWK9JSpGyxuLqx5PTprVu9JK7sANIWFzm&#x2B;&#x2B;cX30/8U3ioxGx6H89jOEw&#x2B;vG9u/r9upw4g9EQDOUtoALmHWfZ3pqZ/Vz7mPc0MEbO39uPOY8WHLCX8ld8Cq/ATB6uc5/jrQIyv52Ienb71W&#x2B;c8dKCVxJJM5qgyMS2N571KxUd/qA3IGkEWWAO5/tq&#x2B;9nGsa3lS3R0zj1ucXpwYk&#x2B;X0u8KazZ9lkG4CnKG0AV3nnDPl&#x2B;y4VuDx7Ja8&#x2B;MtCJlzj&#x2B;blldya/cWzXbaPLV8cCh0fmT67stjq9AL/5wAW9Hl7Ne3XjzzFUbhjQ0Ljo4KjrLyd4DPjJHLA6iqaz7OcrfrzEZB&#x2B;WOP4i&#x2B;YM2yrdowHQPeUNoA7qC9Xq&#x2B;QTruQwOJSyaq3IRP3UuYYKTw3sn&#x2B;kolYXkpYLK3hIPuMfN44fljcEOH7b1xf0jrzwdFf/Y1bLrCG8FZV7YtP&#x2B;Uw9F1wVGfAQ8AVfn66QMAgKt89bMfSV8vtLVxzXIzmeX8PH3GXrzSVXiyYP/kOHDnAAAgAElEQVR7vLRTXvppTP8AVPWxh889/fAnPx3/V/aQgGcthzHpA5tP8vny7Xen2s/ZgdP0/rWnnlitU6PHUt&#x2B;18epZ3/zi&#x2B;/F/Tx/LJab/sj/&#x2B;j3t4eJzyxJ1h&#x2B;erXqxq5AcCUNW0AdC588mJ6YfLhxkdOkTwudnsw0/Utqx/guF7q0pM&#x2B;ZX8o0wN&#x2B;8Mf9&#x2B;AEAjSoywCi1w&#x2B;H&#x2B;i9ewlXepA9h5hZ1dPaf/2U16rF83d3crO7gKL1wrteys7PK1wSAKgOopbQC8SM6ZF2dMXijzXu7F7zr2iBvS2vSNWnzx2zx&#x2B;VTtQv9l1QoePSf/d2Z1xd2TewGx8ken7VsUukdX65hfftxjb6tmOe3aT3czX2fqtrRefjTn7GLwB8B5KG/BSBe/NDtQsfNuq5VmAsyu6OjhBEP4WTn1WxT&#x2B;o2j75lA9h5zGPfIZAzQKD2J1&#x2B;dkPT&#x2B;rxFbFfGOgfts89zPEIR7nGNxraz0nPUIyOEzIvVCh4JANxGaQPeq855Ow9aXqy9c7rEH54urWa56bW3gftPtCg9JWb2oYKe/Vk8e/11r38OgUSzMclh7Jl1rMw3nYa6w&#x2B;V0q3WqUenH3/p32pyeYtvyn/jZ&#x2B;Cp8SdnNtsbYjxwM9bPvOtAipQ0A/sLZ01XUYHrS4VTg2XrwqVVEL5wEVvItN/EjKH6TEntIAoe2VlwdPjL2XkOo2J1d6NYKQ8caNB3bdkY1&#x2B;7fRbUVbR8v9jHWBRiltwKttLWvrdeZPzPKMiT8bnTlctbbMG32fI5h9d6cWbN2Wgp76Eex/GrOzXYkfxeHDzn6zLgQGlmOV6wrQ52WXg6XZVwLv3uiIq9HDpgZnM9v4W7MnXjcGOBX2DEVYMkwFeqW0AcAxZ0yatnVG4FQQeudsMNbMxtg2vVVb5gf4hs9/K1K&#x2B;4XsH7pG&#x2B;1i1dSj/bWfe2vO6t1wVh4cV/xDS9rK1R44iluWV23MBKNaB7Xz99AABP2j&#x2B;/YCbMIQWuTr/7za8//1v93c80L2WNmnMEM&#x2B;kz5J3P/5RSrxPzw5/8NOVbzlyR5rwDvNYjQ82vfvaj8X&#x2B;nnvjl2&#x2B;9KHXD6Wxd800oEPnleazoOWQ5cnx0g7T/AEJqZ2HDXIBloizVtAJDF6ZLHndrbcPaU6bOmK4p6OkFw876XsxVsZsixD9zF4PASNexYXnCtVfoGlWe3sszfx7vCncBrOIa&#x2B;tbis7dStgp9VyWHQGXMHoF1KGwDQv0&#x2B;3eOEVuMtvOXZ3jbOT3heGovEP2PR7P/UhOLMAPCi/&#x2B;pxaqXbqlZeP37rX8nWvcIPajgdGvV6Oxs2W07FX3Qkb6J7SBgC8xXJ219N07tIzICmdcut4hu1D6unzB&#x2B;jGNPmcWnx258K4MZUdLlbberUKY9vUeGyd7Z95sxaXtdXJmI2w9EnE7OJIf&#x2B;qAtihtwIsc7s8zm2/XPPcGUvSd1kbLi0M/3&#x2B;asdU1v9dHl5/CIixaiJf6Adh7mRww9GVvLI6PT6ZvuVJ8rglBgZ8saNuQsq6fvhXz3/PtuFMEV9he0AbROaQP4/z7T8sovbgVmDq95rPNMQealmtN7oaXfz&#x2B;PUurTZ7dbSzd6lzs//IoGVf&#x2B;MTP79o6O4swG2mnenxkWrs3VevZguUudkTA5/GbMFc4is8/rHzNjv/1l90vZTRBfvCU4P0wa3wBrROaQNe6jPN3po2T3&#x2B;3vwtjge6t3irsbGbb/8qOXk/WHH4IsVWDzpcBQ8srsdI3e5z&#x2B;evxOr/iW91/z1H6Yo3Z/QLS1gWT6v&#x2B;CZWSJ2T1nYF5hu&#x2B;BMIdENpA95if3q8c/&#x2B;G8Rdlp9am6/AG4cs/z77ILKfN9orMefcir1C5/al&#x2B;4rd/xafk1AO8zXRE2tAoMXF7yamC69JOsTqNDiyHHKcGDEYXPGV1&#x2B;4fuJxrAeyhtAKkyZ&#x2B;bjCjnTeyio5pMFgXnj2as7M0&#x2B;1nH395YvX/PmfVc/3Us&#x2B;RAA&#x2B;abq7w0cQYcrZL5Oz4r7iX29a7bxlH41cfDECvVucIq3Of8ObqAM1R2gDus7wVnPAGfCzvEH4qtyTeGi3xNfueEs9y5tmNMaePXy2dny/GbqOisQE7Whw33nnAW&#x2B;&#x2B;1LHyfT3L2&#x2B;Nljmvuoea3Z4MFYgqvtD57DN13zRxdondIGvEvKRazLa4d39rdJ3AQy/ZpZu0rCC63ORVNSzdYeLNMnTn&#x2B;9XDOXHoTanf1urRQs&#x2B;L23&#x2B;&#x2B;EANVsOIGNL3MZnPT7CXEavpw5pNuRe/agzd7MYKvjA&#x2B;WjrVm2rtq6C2hrywZ1yLtFb7oFf5pgAbvf10wcAcLcv3363nEvv3L9tZ5o9LXAFj3D27le8MtC3lOnuD3/y052H/e43vx4nutNft2X2PS4n8CnbdcpswJ3OtpnmhoufxWTj/049d9wfIvCmhy&#x2B;b/vVDyyV0zf2YqFDfm3hT3GcYXHybipSNNHK20M98HYAHKW0Ax6YT49gkOXYeAXiD2Xx1tQPt&#x2B;H/s3U3O9Lh5MOpyxwtxYgONbMKDHvbcazAQZHAmPjlbaGT64QN6DZ73sAfeRNCAE3shb&#x2B;AzUCKr9UORFCmR1HXhwYvnrUelUlWpVDd5kzdPO1nmnaQuArc9npvV7h24me4wINJqqbOYu7wndMx&#x2B;pruJvYy9zWmz4vk5ODUFZvPP04fDUFIzc9uypdl1IwHGoHok8BZHa7DPU9biF2lPbT/vLgUR/yg9rskBZFjOIUtdPGz&#x2B;fZlO2&#x2B;bY2pdXNyZ&#x2B;VfZ5g8iV7eIf9GjnVx4CYCmpBPqn59KFq7A8PkrftSyeebqrjMdSKBJox5XFnuP3cFTBPv5xl2sbx&#x2B;wcoH0ybQD/k8qqOv50tT7c3BTXJodXqTdD682JnMiV6u5ssb/57QDasRyt1V3MuTrg3Vg970kFwv7t8Lv4EW&#x2B;msgGPOw13S7Udwg&#x2B;UHXsvxx3mHRjAg2TagBeZc13bxc&#x2B;Plpev12ae2vCB1nvt5B9wm9tyPEnVJh8cLpq94HnGRLSjzYyWBQYTLt4wwLyr7US31D1klLK4aFnZQmDPEUkFalidV6u4N3Xq26lVDi&#x2B;yVXK9yARAO2TagNdZLX1xWkBm&#x2B;qV22zgw163rPhEY0m6twovidxKzYPi0t1VDN9zevk324&#x2B;52EBy16k8rZy5vv9LXoFMAaE1MGuliyuop1w/1hlIWuw9658Ox65f//p9f/vDrp48C7pM6fS1jItr1uhECaWAkMm3A20UOj71notsnYq7bkU57TKA71xNUBWdTxewq3ILtpX0b&#x2B;YrNT6dqHrGXFw14p6Q026f/JYFTM2fyXsDYIldQWw41Sw1uwyF3TG1JgPHItAH8vX0e2cuw2iyyuX5nL8Zy4fd7HhFGtapzeNpMPXK6welOVlO4sh8oY8sM2fUhTy1fhNW8tHmDozsG9hY/rU3vANCmbcIpPg5cFZlMum8Lwkcbn4q7Hq5HPlb2OwVwJL6M/PURaYHI&#x2B;Wjny5IbAEOSaQP4fK61b5N6MeZfbm5RD7A4B0S6Xu4/pt5gktTDSKr32Eh79cr66qmLt4czjoHannP&#x2B;L/6tbOTlBYZUOzDbDTjjc07TL2NEj3cm21aPu/sQu7dceVzFLeBtMqrZV1qY7XOQwMueMAfQqa&#x2B;ePgCAl8orXDMVlsx&#x2B;rLy7Qy&#x2B;&#x2B;/ubb7VJeqemxyNGg00/a8bEnI3&#x2B;Zl0yNz&#x2B;dl7Bzgol/87rfTT9K9TqdGRS5IHNhymNBx97WdbsyrV1HPFLHHH8a2HGiFgwIaclqecTvUbLVBjaOaH1dDCXgnmTaAhwUa0qsyPoFmc9KfNL8ZUl7CZpuZS9pD8ZGhu6nB1aP0m&#x2B;fLSHzG7GH31VgV/AzUmTTeFmhQTMptm19JivEyqjL0bpXLjHkFis8PSw3aU7NuwGDmBsJu&#x2B;fTlZveEsoGo&#x2B;2gDgJdQPRKgvGUFmBortIfL2sx/utgmv7/EJWTb1iqJry44t0tXM6UCawzsLjNevFW53GEjTdb4EpExdS8/0a95jMCyE6eP0sjLC7B0sbZ5ZBwYv&#x2B;Uwjia33f&#x2B;KJTUWRObQkStl1T/Rg/&#x2B;yF127OPRtGU6LogFmMm0AtezW87mhDszcDg&#x2B;0xk/b6m/rc2EYy/lJy4GfqxlOMTtZpWTCw0iv6DH3s8os7qYePynt/5gF2FYbrx466RVr/OUFWFrFbPfkxjJGjPVu&#x2B;8Lek9m6uIbcI8cMBOQ1FmLutYzAn41mxdIAWzJtALeKWQ9jK7WbY3dZ9Yx&#x2B;GYNn6UL85LPAzKrd5mJG4ifPMiOl4XoknNvb3rh6&#x2B;xrpmAC4bg7qltHd8vdXZcgKurhO3nVib&#x2B;hdpSWiY&#x2B;pDVCV&#x2B;Bjgl0wZQXuSQ2FJlHuOVGgS9m8mDxx1ly6ZfdpMu2a3T5R5KlY4cvgV7NMUt8omHX2dJNeBV5jAse/KZpE778mrRe1uhEeFANKlE5PaW7FaMwo8Alci0AVSxGmIc2HLZeC5bDqhsSzvy6UBTwrm3&#x2B;LscbXA9UTe8Go351T5vG8wL0Ky5cniNFYLJLhRRJBrPayCoKgllpRafOGoyRLY14tecjjmS6S731OoAeC2ZNoBa8hq0eRPddosIlXK0Q2NmaU1qAzh7EQVN0KfsvmVWZQeYncZm9yzzNrzGX8btsalIAU/ZVrNfxatXho7tFpaMaa0sNxA/AxTx1dMHAPBqgSb6L3732/lnviWwq3nLsk3oljsRYLJqHE7lHOef5WbTz7zNlUf5XCj5Mob56V9/JfPusuogmN9cAFbkV2pYxurLV/g0Yp9/LxJm5725f/vjn6af6wcA7ApMIytVjyGyrPp2S2k2gBrMaQPowDLZpkkMSVaDOk9btsvtI9ceP2qgarjuCgy8je938NoCJFmlgrbxpGzcRdkZr&#x2B;s7Wd090FjYVqRY1bG/8ugwgNQKGbt337U7&#x2B;SzjsbKLqAueAWqTaQN40rLqY/xdtjcWX0StYBeMYjXc4KjtOslI5LzTlcKY4bcg5qFP95&#x2B;9cwBWVikZcVpZp9Pa7hw5Z6AeFHFa3yKwwfSni9EyAI2TaQN4WDtdGzVSYnPDfjmEVu6NGvImoh1VdNltCR/dmHfArUkaEqubAGAAgrF7PPg6z7Xld2NyYCkyvo0vIF81YA6vXjxMCwWgIzJtAEMxZBVOa0We5uQCfxqm1boaY5u9k&#x2B;yKN/Ojh8vsZB4ZAFnMf7rHbplHCTBoWUwG64bhaNuHWN0ifgZ4ikwbACG7Y2CL9MIYUUtrhp&#x2B;qFUiMZT/xmKqPgQXhtxvnHQYApQjPbtPISz0F9o0cDPQlpkB91fh2rktZ7yEAiCTTBjCCmNRXeINKFR0zFqKDDBllUsIVV3b/27U53dVaU7y14wFgJn57CW80LEUGzE8FsYJngDbJtAFE6TFdVOpoLy7t0NeLRo9Sk2Hxw047TbOdLs&#x2B;&#x2B;2jijuZ5Upmbs9e0AoKw7g2eBOmPIW5xsGQY3HvaLnAHa99XTBwBAGb/43W&#x2B;XTeX594vt57/98U8XC0Ve3wPkycjATT&#x2B;Vjuce2&#x2B;OPf0b12vDznn/68Yfpp9IDAcB4kuL55caCcAZ2JW6f73tD8H9l/2JmgI6Y0wYwlMh2eL3hq3N7frXS&#x2B;8XlH3qcU8j95nGpkZO6Am3XjvJtGUugP/Ls9BQAQLbsMFiyDWaBGHhZg6FS1Jq0f5EzQHdk2gBi7bZvu1g/PGYVt0nM04nfVcbOw7tapfFgK1ClML69mlR98Yq89vxcHic8fW25QTi1ViPxpncAoAZjj7jIycMYTsPXG6qpx4sJtgXPAL2TaQM4N3VqHCWK5tuvZN2WO/lUaAPH7/DKuNfI&#x2B;8Zn/sIPpKeAyW7OqeDOK&#x2B;051eo57uYUV6m71S3bHoeyr1s7rxUAvMc2JL4ebENfVlFofGaraqWH8FrFImeAwVinDSDf7rStjJ3Mmbwyh/U&#x2B;02voBXyz3ZZq6npg241LNYBvWAEivuJNqSPRTQDwFDEPp3ZHpBmmxqiWwfZurHtbyYowYTPAwMxpAzg3Dwu9bSrV/WUSj4a&#x2B;XlxTPalw5Sfr&#x2B;S73b67bmxVpuNZo/WZktmKWXiu&#x2B;mMRqYK8FJAB61EVhc&#x2B;6xWjXZicGQahd&#x2B;vKjlYwOgLJk2gGTL9uppGinc39HUkOTt01kd&#x2B;fzf&#x2B;MPOXtRtl0o4DG936bVVE/3BFrvOAoCWCZPYkmBjPJHj2G6oDwkAM9UjAfLN3RlH/Rqn/R2tNX2XxxM4tl/87rfTz/LGmM6d3W22k9LCR7h89NMdQkfyOgLis1/yZABvIBDiVGttEAiYKkNGFmPflme4OQCeyteLugFeyJw2gCins6kCf52mtR0VNpz&#x2B;1E5zt/aRXOn9uV4ccvno7bzmsLW7gvpHtgwAMQwlOIto35ViD3dOZROfA/Axpw0gXtnm6Grht7/98U8vXGNsftbhbSLvlbqk3LQf475JFT&#x2B;oNnW30y93DoPdPpCeAgAAbrabVDvauHa8GhPni5kBWDGnDSBBoGLh0fbLjNps98Ya7s/eHT1W7SdbZKLbq9KcpGp8ufVd2/o5s&#x2B;Uty98tZQHQsnl41m7QYkVboC/LyDMcuF6JUUvF8NN&#x2B;umsRAHAPmTaATKlZt5s9dWC3df3kldyMeddeOLmQUwXzT0krTNR7iNluZ4EeBICmhMOepuqQA0SqOnVsO5IsaVfxZSoBYKJ6JECaOUkz52Pmn8i7V8qBhReKq/GIK6evQNILtbpX5EOk2h7P6v2FT7k0W7jm5Fw0Mvvhjtr/q&#x2B;lrFmkH6EvMCCFxC3CDSkXUdx/o/l0dlXwAgBjmtAEUcNS7kdrrcTpg&#x2B;RPMNvUyonm1oFrMPLNlsq1eX5JeKlItm&#x2B;7XG&#x2B;Q1ui1Sj0q3AsAYFMcGSskooh4oBbk1bzPda/Vwd9Y2FwkDkM2cNoA0296K3TXY4hWZ5RaeiXXaw1Jvpt2pevPVoLZVsz&#x2B;1ZuOqJb&#x2B;6e147X5UbgNcqNfAr&#x2B;4GAIaUmulaT3q7kya7Mn4ucfqfeAwClmNMGkGyaVnU6t2zZDRG/qFupzovTgwwcwFNJr93H3b6M8JSM8bwrSaN66z0EAGMrmAxbRWLSbDCewDJmReaThUPooz/lPfRPP/6we0eVIQGozZw2gBxHKZ/59t38UMYqZZHdGbszw6bekPj5apYoOzUvhXJxIiN3yl5PYi5fU&#x2B;pItOoBeESpQCUcKwqHoEd5se4cYBecwRZwcdrZfF/T1wCoR6YN4KpVlus0lzbl2&#x2B;JTbqfZsu2f5oRQ5EMQ76iP6ehdoEdzl0FkwZlKx3C6jc4CAJaWa7OFQ82kwVhJDw3wuRymLpd5m/ZzFBtvb1dNHYBHqB4JUECgLyPmT0X6JsruLa&#x2B;GZI3qjss6ReF0Y&#x2B;3akqcv7PIY9Dd1Kpzfuqfdvj2G61UrAehdUmixOwDoepRyWj1yWUFd0W8YSTgcnf66TI/Nv8zD1&#x2B;6MZkXOANxPpg2gvNSeheX2y8HIxdd1W&#x2B;485QD39/OeDpT4NN6Dq9y92TI1Fd&#x2B;ujrzX0WIP99NlAMBTlvkzw4ngJS7GwAVD6FWBym1ULE4G4HEybQBtqZSn6bpPpHifTniHq78e5T5j3qlA4u1t2crWrFr&#x2B;bbbYHz8AAJo1xxjxYVJqNLWKVTIWGxbnwMACRR2z136b9zz/frQrcTIArbFOG0C7YtbYyNtzqQqT13cSafs6bFfFSzqepKXytg8auO/F4k5cFNOwL9gjUNC8CsX0i&#x2B;4DACbhUTv3xBJlF3UDunOxiHq48mSpXQHAg8xpA2jdabme3f6XpEXFtnu&#x2B;Pga5&#x2B;EDmpL3lbRzThbTa8/Q0j6bBHdndwNDve0Q25p9qw/fVd5BXtxOAVFOksR1gdDTbPj4rVir8UFUSOhIfD18cixYZH24fZfXQ4kwA2ifTBtCNi10h033v7AS5J3VUsGcnkHoMuPg0Vyk6ybbrIldcn7d5cDbbs70G0xNPOobAa3XzQvcAb7OKEE5LYc&#x2B;/F4z9toHK9WrYgh&#x2B;42Q2h7zImXNaETLqvwBKAvqgeCdC9yOloU9mf056X&#x2B;xNy1237norv82gWWt6D6lF6SmpTn8nX33w7/Tx9IADsC4QW0&#x2B;T75Qb3xCHxjzLFqApUQllz/LYM4W4O57LTbADQHXPaAEYT7qS4bTGP&#x2B;ZfWenOynT6XpCSlIktVtTa/qqmDKet6WSEA8syBR2QUtEq2RcYh4RrmxV2fJAdd2w2rUiPJ7U62sfH03xaiuIHjZABeRaYNoAOnvRvZvRIq9iRZTWJL7XVavdo9Th9s3DLr006yrZHDiJS0JEZfTw1gSNmB3Okdl3HOaSC6TeMVCTLnxxWvMrDTdFdSWJuUPKs0ZKqFBB4A3Ez1SICObSscLvsjIrskMmr1xHTNJO2wR0evW/i5r1Zl&#x2B;2wGmJc7QMobu9dgWx9yd3V62TWAlwiXzk4dbJQxtGgbNcFr7U5Ty67vXSmcO9qt6BGANzCnDaAPeTmY&#x2B;V5JBYICf0o9jAFSR6XKJR11V8XnRIlRe1pbkZI&#x2B;ADCA1AApaZbbducqMfAec2y5G3kGikNu10V7cJG21ZEAwNhk2gD6FpkHSk25ZRi4vM89a5NYmIR7nHbZHGUrdZQAjG0ZimRk0S7&#x2B;qVQIJCFHv2JiraNsWSOF0&#x2B;eEXwsHAwB3kmkD&#x2B;vDlu&#x2B;9/&#x2B;W&#x2B;/f/ooGrXtEAn0Lyz/FN&#x2B;HomJPZK9TYPz1Kl3nJa1nlSiqsf/i&#x2B;7xHzKsxPbtKi3YA0L5ViHKxQEJqtHlahTu&#x2B;TDcM4GJIVjCcS0qe9RstA0A2mTaAQWSM3k3tOolf&#x2B;G27gFzSHpoVyFOmDuW&#x2B;Z54cp&#x2B;KTTz2ant3p8W8LDd3woAC0JhycZIzWylubbRUuZoRMprUxjMAaurv1IcNlJ8sezOoR84gYARiGTBsABWpLxne4DNPxsXzRkl43VSJvcDr&#x2B;d/vXZtv5GYmryCU9AGBlldY6CleyQ8eYULBIsu1ozx8xGH1ahYKByPCGkK9U2Nxs&#x2B;A0AGWTaAPi7gl0PU5/Ia6dtnXYJHf11pGRkR1pbiix7kln8FD2JNwB2zTFMfJ3GvKXd7jFMZQXe5jRUi4zldsefzaUgT3eyvHsjcTIAtEmmDYBbjZdJ2g7r3l2Y7Uib3VID2O1WOLrxroOKUjUHtswpSrYBsCsvVMuY6Dan6GpU1TaqiR5FVmg8iuK2lSRXt2QsZtxaqAwAbZJpA7rx5bvvf/lvv3/6KF4tvmMiY5jzAPV8tgff8hDv11plmJ7tO9hWhow8tlXnSLgnZbt9VbpjAF5uGxGFY6GkIUqRRF/06MpCaPHlJQGAGmTaAEhw1G0R6ByZ8nPLDbYZuxq9Ie0MWK4xTJsYR9O2Gul6CGe/dgtaxpcJ&#x2B;hSatRbzWjXyegLQrKOxR0cDrbIDp4JBVzuRJBw5jcFMXAOA28i0AVDdbsdKRomh1EdssIuk6rMmoIvug93ekO28t/B9izzT&#x2B;PXeAHinKaeVFGgdbVw1YLuy5wYjSV5oXlNtaXck1mqzVTg37WdVCEE4BwClyLQBcO5ogPCyA6LIIOLiPRotdJHsvixSbvd4vPsgMk&#x2B;2EjmTrHhNyKQ5cwC83OMh1iRcgTwvFNytxDBAqXMal1HJ4Ehk7QQAoJSvnj4AgARfvvv&#x2B;6UN4r0D/xeqXSH/745&#x2B;mn9R7JW3fvqm05vTz9LHwpKT&#x2B;lLk&#x2B;ZJGHO9rP8nY9MgDUs4oJrwdFu3sQa9GRyKzbaQA5B41iOQCoSqYNgFjL7ollZmibMKuaN1o&#x2B;1mnirYUulfhjkG&#x2B;7Ypjug0aeiDQbALXdE/ZkjNMKHNh4o77o0dfffDv9zLfsDsO6PjYLAIikeiQACVb9DrsVI5f1JOcb6/VK7BYFKlLKsqDWjmcwA3QfJK2WkfF851KTRwOfV7UoB3hJARhDOIIKVHQsEn0ZAsWDluHZvMrabixngBQAPE6mDejMl&#x2B;&#x2B;&#x2B;/&#x2B;W//f7po&#x2B;DvInsx7l&#x2B;WLK9nZNVfU3CZNz013Cx1eQ/9MgBDamHN2oBtJFnwaOedZ7wILb9osCSEA4AWyLQBcNWyi&#x2B;S0V2Kbcssecby618Vl6ldFKc1C4zYXV7y/bZ8AdKeLYGY3krwYiV1/4hcDSyhid1rb538jvd5zbAoqADASmTagP6a1NSijG2K16lveEhqn91pukD3LTScLqbK7P6Y&#x2B;lIxHVB8SgH5FxlpHm8VEa&#x2B;FtVqm&#x2B;&#x2B;b/beyWFhdJ1VNJ7ILeNV7NjYABohEwb0CXJtvGs&#x2B;jXCYjYLbJPa6yHZ9mYZObPl0OMqx5RL/wUAky4yQEkjsSKTbRn7Wd0SHxYu03XzjY2/5jRI/AYAXZBpA3ol2TakmOKT216SmFs&#x2B;m5qQ8R0l&#x2B;kTeY86NLSvz5O3hyjHoUgHgNtlZt&#x2B;08sOIhU8YEsgy7Bcl3D6ZIUUqBJS&#x2B;xiorn&#x2B;La1sWgMadWsA7iBTBvQMcm2F0oqF3n612Vnx9R7cr2mJS&#x2B;x23jL7jhYJfbykm3bdTt0ZADwqZPd2c1OxS/cW1sXUZy5bgwspj7kKvdmtBlbqfVFNH&#x2B;AB8m0AX378t330y9SbkO6XtooqShl9kJu2felR6v2226nQFKiq2yfgvHCAGxVLZ39YE4rkFFblXwstdulK5nFwPAv3maM9FLkFCIzjYhXpDkjgwvc5qunDwCgjC/ffT/9PH0g1PK3P/4pox9nda9f/O6327U3rjzQ7gocjCe89No8Dnf679yWS23UXZwe9/U33za7RBwALZiCnOJBy7Mpou2j796yDQIDUl&#x2B;i8Pbbxz2qc570oNCsZSAaiIen2FXUSrb5FHIWAS0wpw0YjVlu49n2OyTNVNu6oaBQO9WTSBo5292Ax&#x2B;0BHy2JAQAr4XlUMbOsGinSGL9QXGTSa3eb09FaSY8LXYsMsKe//vTjD9t5RVIjzFJLRC7vdWQ66y4dFkAimTZgWFJuAzjqvlndOHde5K3iVrZcTwv9TVwxt/R2l5eYf6&#x2B;0ENrycQN1KQEgxmkmLDLPFJg3Nv3SQsqtdjZrWckg6bGuD8Cyohu9O41ghbgvlJRgO212LZtOTifgEapHAuNTWLJrMRWBln&#x2B;6stZahiujmye2X2EAACAASURBVOe71KjjRJ7UldVubsUlPdxPP/6gkQlAdnQ02S4ntrpxmBgmL3mWtMHujanryc2h4zCvPAM7Le43x6sKAJJHewdohzltwIuY5dap5SjpmE6Q&#x2B;CluS9kz26bDM774Qdkrq8ff8bRIY0HztLa53k78HSsdEgC9y5tzdpouqpHseaQE9zwz7&#x2B;hgqj5utt2ylrBbFyH&#x2B;vsv/FgwvV0d1tOfswJ6RJA1/VCgSaIRMG/BGUm7dyc6BTb9E9pKUmtkWuJEW7JaF3K3TuNzy6Pca9CwAUE/GerfToKKjuxQccrRK490QTU3P6&#x2B;ixilfFzHtSp2&#x2B;Z8pJ8SgSokUHyqaPMR/hGAfCQUt/f09N4VWz/yrEBlCXTBryalFunUqeRpZbl&#x2B;SR29BhQ3IubG2PafgA06&#x2B;KApPhILBwmtV8YICOM/CxyYxl5zfidF9wnvcsLO5dZkLKB65xWOdrtlMMTLb9ZXhI377GS1oQDyCPTBvD5SLl1KLtTJq&#x2B;2ZCUtHAOTjBG715tqGnsAPOh6HFJkylf7ybZZannJefvic&#x2B;PgitRpQ1dC1nkZtt09h&#x2B;/F2LbZr&#x2B;UpkZqIdc4Aj5NpA/gZKbf3KJ5yyx7rrfPlKauWf9K9JrvlUJLWFQCAFizjltplt7d72I2aTuOoFooKtDC9TBjJKj&#x2B;x&#x2B;9dw5Lndw5UJZ0cFAwPHMP9JhMwn&#x2B;jRYTp28mBIGuE6mDWCflNt7FEy5pebMliOdLz40qYq3xBTAAaBlq&#x2B;Lb24hle0t8Gil7vNHuI0Y&#x2B;6PYAngqownPdhHncZhXfbpcZ3l2Z&#x2B;LOXGysV1m73s42ZJUi6k7G6XjgfXORgAJ4l0wZwQsrtPfLW4djuJDxAu6MSSQO70rqbx0vGNOp0HADQjmUEEj88qEiAdLTn3R1ON0aGTCKrU9NLtE1GilTHs0yn5UWqZZMWR3sTIXft&#x2B;kkSnn9W9vSY52gW3CfALpk2gFhSbq&#x2B;SNKR67ryY&#x2B;iZOu650YfQosKrEttyN6iUAtC88y203Vsme5ba7wRw1zbu9WFK7zRCrheqO23Fgu&#x2B;nMFg71nWIKPGbscPf2GjGq8WfM6s1dS30spxxwM5k2gGRSbq&#x2B;S2l&#x2B;T10PRwkIjFKRdB0AXjma5hWOSwICkpFTZnGzb3dVtagRgka/DDanBo8NYDRSregyEXZwhFL77lWqQMQHt7m5X9SEFxkPafVtX58N2eGKRSZOB/TjZgAfJtAHkk3KjiHC1SVowjf/dbdRpzgEwjNQ4JHs6VOQYo9Ust4th0qsGNh092d2nLwTtRczyZst4NS9M3SbnMvYjQh5VIFUWmfStwfkGtOCrpw8AYARfvvt&#x2B;&#x2B;nn6QHhGxijsZXat9OFQ0bIVN&#x2B;XeHjwYAGjHPDvtSs5mGxctb&#x2B;kraop8HeKf1PQKZ2dDi&#x2B;TS/vbHP/X1Loxkm8aoMQIscg9Hm4mN3yOQV7t4Gkx7Ps3bLX&#x2B;uPBxAKTJtQDe&#x2B;/ubb5c/Th7NPyu0NVl0MuhteYjmqV4sOAAIyEkJ5j5Jxrzsjt6MpZTdPINsmQS9mNEW/96uX1Th9xJj9C49fIn5BvuW/lR4IoDWqRwJ92B3B13Ior7Dk8Ha7GGLW5FiuilHlyNiTXTyn8UsNADRrinm20VFSFcfV3WvXOSy&#x2B;/6S9ZW&#x2B;cF1VuX9vw9kf5OZUnC0pd3qx4pDrtMD6hQnemNzfy7Ys/IWvX2He&#x2B;Ae0zpw3o2BzMmeXGnY56E&#x2B;bBwnm1fSbSb2VdvzJo1AFAnnlo0dHaYMv/BgKnmJiqYLLnnmCseD4vPv4sMuRrWeNB&#x2B;FrKKnBdtnbnG&#x2B;Nnj5lOxFbSm3t0Qk5qtJK2&#x2B;zRXEuiIOW1AB7aVK3qM/s1yG0nM3LXP8ZrzFY6IMjTkAKC4KxPF5llTy7zOGJOoVvFkjSd1&#x2B;lpNf42MTiMDYOpJilSTprsdzWMTG7/W0flQuyvGKQf0y5w2oEu9p9zMchvAqtviqBdjt1wSZR1dEJKuDxp1AFBJTJgUjpHuCajun6R1sRZCjNUCw0eHEbm3MXKcjVsGpdvgtt6y5bvTiYo/Ct25Mjmyx&#x2B;4agGzmtAE8xiy33kX2NcyjibOXdiNDfLtOJwIAlXz57vs3h3lHQc52glpGLJQxs&#x2B;3NQdf8xKesXtLrsHqpk6bBkWqKS4vPHNoWiQk8Oi8ROCu2hSKr5syceMAYZNqAEfQemUm5DW/bGbHqsNBbUUpM3ZverxgA0Iv4ZcNWd4kJjYqHT28IyY6eYPi5L5Nt0&#x2B;/T9qa4lZUao55ub0YRR5bnRqDQ6Or2&#x2B;DMqZkuNMmAwMm1ANwJ95VMYN0CgJuU2nqQV3Ybv3HnE8sowwFUCAAY2Z26WeZ3Te4VTRJ/0mocDJJBKZQ13dzIn2z4DLZvXkSmgnUvzJS3Gtvs7FBTOsTnxgIHJtAG0SMptJNuejqP&#x2B;CP0U2aziDgAdic8DJaXcMizLKtbY/4OSkm2RWwYSbwlHRpakjNo2MJZme6flmVB80uRq492zzsRK4D1k2oChbOuJx2zfcktDym0My54OPRGVrBpyLX&#x2B;uAYDthP5wjLT8a42s25Dposg85fav86vxhoqavViW&#x2B;DvNXgiM&#x2B;WzOk93ekqRMWFLmbF50MH7/AF2TaQO6EageXvAuzZJy6914fTcNGubzDgAvkRcgJSWQsmOwkYZJ7eYpU9Nvn03iTRLuEZEpNIHx26yGEd9fxXGZh3P6AS8k0waMr/2Ja0mk3AAA4HO5tuTRvVa3DzbdLW954ItpS4pQiI&#x2B;t7cS17Qr3eWfOvKvUeWwA7/TV0wcAkO8o4Pvpxx&#x2B;2Ed60ZPS8cPQAvnz3/fTz9IEAALBPqHaPX/zut9PP9f3s3v6SyVunL&#x2B;BqPpzEWyWRE4Pmv07tX0mOFzrq3FidQlcKOQ7TfwJQm0wb0IFARLgb9p3GgoMFi1JuAACwKy9JNnwOac5NLn8&#x2B;KU/8b3/800sSkLcJDCSNvJG&#x2B;pPZLXBk6fD3N5pQDCFM9EuhJ/CrQpVZoW44Fa78K5ZRsU1USAABmU/nHbVoovOrY9q&#x2B;rLNRIC7ktXazJyRXhZNtIy5CTlDALl4iM7CSJFyg46QwEOCLTBnRmiikDYd/8p90C5Z/oAgvhA0g97DtZyA0AAJaylyW7M9vUZknGm18EZttWZ&#x2B;PtUMpKLdWz3b7gCePcAzgl0wb0YZVCi9/yKCJc/Wm5z/bnrkWSciuuze4PAADibWenBbY8umO95FP84VW1XJLNLLf7DdAaJU/evLTiK2g4AwFSWacN6MZpefq5anmpQvbDLOdmIbcMVp6gd//wT/&#x2B;8/Xn6oADeSAz2lEC&#x2B;Krvw4258WDxobDYKXS3qRlk//fjD/PP0sdCKVZXIZaHI&#x2B;b&#x2B;nZXsAuIFMG9CT3WqQu//dViqPLA45262E3nuzR8ot0nIMb&#x2B;Cv0KBwUk2yDYBX2SaEVtOzMuK6jPFYQ0aPUm6lDNDMpJ5wP0ZkLk3KDeAGqkcCnYlpgWQvpVZkIbcuKCy5siwLeVtXiFqUFCSFBgC7Yma2rbasEQ2uajCGI8AW4sP45dlaOFoYz6p34jRbtruefcy9cg8QgJ&#x2B;RaQPGdKUK&#x2B;Ryh7oaq8/7HCEml3C7KWOdDZwSlxGTXfvOrf5x///Nf/zLd67//6z8qHhYAG1&#x2B;&#x2B;&#x2B;16s1Y7dHNIyQlv&#x2B;XmkM1m4MGZ/cusd0PGJXKKXs3LLVUOC8VBwApci0ASOYk17b2HF7y25wmRGVLv87QNbtzSm3ixPaYjogArud764jg0imrwHARRkTtkrlwML7yYgGV8O5ylZNEJ1CKQWzXKeptd2Okc8QHRcAzbJOGzCaQOxYbwDXSEPDrOU22e1WuNLXEF7Koqnxy7QpvAAbAI0TXLXmaBJbYPtlLFcqBXW06lvkanDLbY5&#x2B;B2729Tffzj95e9h2ayzX89vuefnfuUJPYG8AFGdOGzCg1GRbkTzZMPUkZ2&#x2B;e5fbZm&#x2B;h2Mc1W6sB4G6k1AKgkL0JbJdtSc1qn0&#x2B;lWCTNhJPTiqLdhOcMsstLj9cf9SLAB3EumDXip3aBzvjE&#x2B;8H1DrfOXp9xmSb0eZev28EISbADjsVrbkCLnw2XMUZtvWSbn4sNLWTrItp0WVlZ2N8IyY7e7B9k1gKfItAFvVCr6nGudD59sm7wh5bYaZayHgptJsAGMTbKN2W5SLeZekdGpIBbq2V0FbXXLtpfgSkfE7t4GWzweoGsybcCLHIWec4S6KuzAkSFTbnO3ReSo4YyEXMZgZF5Cgg3gPaY4aqQgilOnKbT4epKfn0eeU&#x2B;AqtoSCTjsETjeonfSa9y&#x2B;7BtAOmTaAn5FmSzJYyu3mpeNPV&#x2B;lgeBJsAK81WBDF0qqKeEa8l7QC3LzxdtBY/EHCq6xWTcu77z22Q4Fl1wDa9NXTBwDwpJ9&#x2B;/GGuAPn0sfTty3ffTz9PH0gV2X0Qq3lvu78fbc/A/uGf/nn6efpAAHje2EHUm01x3TK6S1pibXXH1X13g8b4SHLeUvAJ2ebOhO3txR8o/IgAtECmDRhfZDAajpLNdYvUY29R5Dr22z4OiDdn1yTYANjVYxDFrqTZbPEVyGsHolN6b5XkgzfbdgIcTYZL7S5I3V6ODaB9qkcCr5CabFsu21bxsIbWV02kbZmdo76MyK4TlSGZ3JlX&#x2B;82v/nF1y5//&#x2B;pfbHh2AUvoKoogXGW3G3Pfz89XaLoadeXe3PhxDSsqBZSTY9DAAjEqmDWCH8LegXnqLsnNjuhjYunni2jbHFr4dgC70EkSxtTuK6yjUzE6Ypa7NFnMw8Q/9kWyjPVPqK745n7cE2nbttHind9QXAdApmTaAE1Okq3rkdY33Fq26G8IdB6tF17ZbnnZe6JgY0j0Jtil/Ns9Xk04DGF7jQRS7pkgvqfBjRsotu7CkQBRObZNeOgcAOCLTBhDFyLKC2uwtWo3tzajnk9o5orzkMG6bwbZNqkmzAbxKm0EUAacFycN/rRpVbgd&#x2B;Sb8xtpgZb6fz1fLSbLu71ckAMBKZNoAcV&#x2B;pFMBust2jqrQjUBQp0gljXrUeNlIhcmea6ycCxtPzC0qcDYxgsiHqJKd5LymZdSbnFPNZqG0UXGFJMwcbIldq3MVV8t8CyD0E8BjAemTaATILjghrpLbresxBerF46bQx3JtjmQpG7mbPVjXM9ycBdeCHjQmBsjQRRRMqONlf5sEKHk&#x2B;nxA4Ajq0Z6TBSU167PKyOpDwFgYDJtAAWY4lZKL71F2yHJMT0OeiW6dvMMtk/ivLRlmm2&#x2B;RbLttQJfSaeDtYFO9RJEcV3Gcm7x4qe1mf1GbXkzwOZQp16aLYm4C&#x2B;AlZNoAyhBAl9V&#x2B;b9F2WYtVZ8d8y24nyGp7Sbg23Z9d2xUzoQ0mR51KRoTAe7QfRFFKkZRbuP55&#x2B;HGhnry4ZfdelaKgmKKUxR8UgGbJtAHQtI56i5adFFMHxOnabKe38IjbEmz/5/9&#x2B;v/zvv/7L&#x2B;Uk&#x2B;z11bZtq2E9rm2yXk&#x2B;PxvR49kG7xNR0EUF12vLbmMWnentVnCjTvFRCzhZWhX8&#x2B;GKR0FHKb2CDwFAX2TaAOhDF71Fu8mzbX&#x2B;Hfoo2PZVgW94eTrYdZdR4rXAfU2Bj4FW6CKIoJT7OXBVgOJ3ZJtnGI3YjnFVU82BxbNk1ACYybQB0prveolW3xW4PhW6LB91cIvIozTb/9SjZtkyzxUxoY3jhzNly7LYcGzDpLojiTqmT4Va1HKCGmDRbPdsE3mpunDQbADOZNgB61VFvkQ6IBj2yBls4zTZvE1NGkpGsChwl3WV5y3x3/T5AWEdBFPVcXN1t&#x2B;btYl0c8UhlblAXALpk2ALqnt4h4jyTYJjFptiMmrr1cYPR0fB&#x2B;TddqALUHUe8iH0aPtrLKkBdhkxQC4jUwbAOPQW8SR&#x2B;9dgW81LO0qz/eu//P5KBi5sWWSSBk0dQ6nrq2XULJo2k2YDAgRRb7BMtuVNaJv2cGUyHK&#x2B;St3xaasQSeIi8AzA4CYAMMm0ADEhvEZP7E2yrW47qQC5vn35f7kEByVEtR2FH9uCcbqYnCChLEDW2bZIsMvc2J9ik2YiUEeokZcWqrpdmMhwAqWTaABiZ3qJ3urNEZHhG2pQzW20ji8aRyCqR8xy1Uuk6oKrVZ7CXDlxB1GBO56KpLcn9thP3t/HP6i67w5VO567FxEK9XJwBaNNXTx8AANzhy3ffTz9PHwh1/cM//XM7abYkxdNvSkeOZF6J5HO5FKReJLjZbo/wI0eSTRA1jG0uLT67ZiobxR1dDPNilaO9RY5MEiABcJE5bQC8iwHaA7szx/aJS7Nt82cZGbU///Uvgb/&#x2B;5lf/uN1Amq0jgY6h7Y1J3UDbQd96kaAR8/SLyPUaGyGIGkDMKmvzBhcXdYOAQPxzekmMGXUUrtTdy1UXgI7ItAHwUnqLiDGn07LnnC0TcvfUjZRma1&#x2B;46yd&#x2B;bbbTnqZtzUngTtuSsN1NaNsliOpa0jy2VWZueV/pN2KcjieY/5R6ecy&#x2B;IwDUINMGwNvpLRpD8Qltqylrq5TbdkLbMotWsKrkrj//9S/LdNpyWttpmu2//&#x2B;s/Kh4Z12Qkw057lyTYoAXzJ3HOf8fM22ifIGpIy&#x2B;xaIJ02Zd3k29gVjk&#x2B;uDAM6um94RbeYkUwAcIVMGwD8D71FTMJ5sv/zf78/rQn5r//y&#x2B;93N6jGPrV9JXT/b&#x2B;TEALRBEDSamyOS8Ze2DoRePTKM/rSF525EA8HIybQCwpreoOwUntMVMR1tts5tRuzPNdmSe&#x2B;hZe6Y1UkTNRAmukFRlYfX0hN&#x2B;ARY5d1FUQNY5tsk1QjQ72rXNK0uYGvugA0QqYNAA7pLXqbmDTbNF9t&#x2B;d&#x2B;aR3RoVUByd4PPJsemdORFeZPPaj/61Guv5wiatVvTbPrldAWjfgmiBjAn2&#x2B;TY2ArnrupVa9zd87JC7&#x2B;pPikYCcA&#x2B;ZNgA4p7eoZaUmtB2l2VaptUoysneBZNvuJDZpttsU79NZFY3c1pAcspse3iZpykVH&#x2B;XVBVNfk2Ghf/MWwl8smAD2SaQOABHqL&#x2B;rVNSp3WVJwzXnOy7Z6sW7xtsk2hyFLiJ5oE1k5bFSxKdTQeXD8R9CUmK7b8sMeXqO3rajAFUSIo6EtgAtlTYg5gG0Q9ftgAjE2mDQBySLn1IlBi8Te/&#x2B;sc5L7XNn60mlu3m2EqVjrySvYtMrZnQVkkgi1ajQ0cnEbzElEUbsrakCAo6clvpxRrrqA128QSgcV89fQAA0Lcv330//Tx9IOwIr2QWsJtCe2pJtov&#x2B;&#x2B;7/&#x2B;Q5qtkm330&#x2B;qWr7/59mIX1bKTSIcRDG/3Yz5dScZbakgEBZ0qeDmadjXe9Q2AF5JpA4AydBi1JibNtrtNvYza7ty11Y2lHn1KsMmxncruvw4XjTwq/Jhh2ps0G/To6JObNx121M5oERS0KRDq3PMogh8AOiLTBnRjHs87ai8Dw9Bh1IKk2WwPLr1W/KEl2O43dQOtOoPiv6qOttS7BCM5nQIbuDFpg4vbP0sEVcnf/vinpw&#x2B;Bvu2GOtd3GN5AIARAX6zTBvRhW4/roxeS5lmJ5Cm7abZ5PbNwEq7g0mu7uwqn1lZ3iVyD7WMZtudM30S7X1LzBqk93b7dYGzha0KpKHf5KDUWQKpKBFXc3/74p1/87rdPHwWtWF2FjurWBv563SpA6uXqBABHZNoAoDodRs9a5av&#x2B;/Ne/ZK/flmRKtv3rv/w&#x2B;cuJaRppNgu02Rz3j4R7z&#x2B;G4jHUwwqrk3&#x2B;fRyscqNbZdpnPdzNIl2vCuJCCrJPHdNUo1dgWCmdnHI3f2Pd8kC4M1k2oAOPNIkgBp0GN1glUWLnxZWUEZNyKS5dBJst7kyHW13utvyr&#x2B;ZnA0t56ztu564NeVURQe2aUmvbvNruDDbT2gAA6rFOGwA8wEok99hNsxWc0LabUVveOP1&#x2B;mkWLTLNZg61lc15tt2LbZy/lZg0SeInTyRzzUsSrG2P2s5V9xy6IoI5UXYxtufO//fFPFn67U8ZS5csFzgMjfspeGfpaFRIAijOnDejMaoqAaW30rosx2l/&#x2B;8OunD6GY2nUjj2azBWpInqbZpNZqyOgP2p1uMn8Hbf80dmc3kGQVwa6uBsvLS97MtsC9pmh5vOtPFxFUsyLnt8moPS6jNuxuQLK95lw/tvCDVn04AGiQTBvQEzE6A9NhVNv1HNvuumvzrLXdRNoyizb9Pm8mwfagpF7s1K&#x2B;eo/5uX2HA6XXgyhiyQMXagRdy&#x2B;7w4glqWjlyu0BaZHksqJhmoRakoZT0Xy8nGyEvtRz7okBccADgi0wZ0adkkCK9IMfB6FYzqtR1Gxc2lI4vMYwsvvRa/MJsE21Pmr4OyabapWzywT19AQJIry0PG73/IS5MIarZMv/3id7&#x2B;NT7/t7ifApLciTnPh29tT0&#x2B;dFKsGsrk6GFgHAkkwb0KtVwa7dxoNi8XRNh1Ge5dpsxWtFTtPaIjeO3/IjwVbN6ougxvfCcp/TN5E&#x2B;JiDSfLnY9llvbwnPVws8RKC87ZDXqzdHUFJfwwh8tLerwG6ntAaqW2ek51eXkdO1JwHghWTagAFZvI3BPNth1O8ibUdptj//9S&#x2B;pGbjVlLXAomvLbWL2LMH2lECZtYv7BMgTXmut0oOOHTa/OeU2S8q9LStS8qBAWivmalDkQ72tIlPpgQBgDDJtwGjmKW5PHwiUp8MoXiDNFr7jdtba0QJsgWRbTJpNjq2GO2dpxIzvBkiSVwryorGTbZPhI6jI&#x2B;pDZiTSLsT0lMs22/RRHXhwyriHDXy4AII9MG9C9ua/zDd0EMPl7h9G//&#x2B;ezR9Km3TTbaY5ttky2hdNp27lupzuXYKtnVUxp9Y2wnMQWKNeWxJcOcL9w3bb4a9rFC2Cnxku5zTmw&#x2B;MXYUitMTttLtt0madZaRlHZ&#x2B;FazQUXN2lYbfupIAJjJtAE9WbYKkvJqkRvL1dGdubRjpZRbj6Ujt2m2&#x2B;Bzb7CjBtsqlxa/EJsFW2&#x2B;4qRC7pwGBKXdbmRSVfmGybjJRyq7o2m4XfHnQ0TS31OnDluiGUapCgF6BNMm1AB456AQoGlK/tZWAYtVNu/dqm2bapuJh11/JIsN3j9Bpetm8a4GZHF59VaQcBbYaRUm4r0xS0gqmyaVpb/OQ5MsR/iiODn6&#x2B;/&#x2B;XY1of&#x2B;zuWIIbzriOg/QLJk2oDOrVsEq2baqbrE72mv5X40KxvPylNsqixYzm226y//z//5/p1uawdaC7YV9eSVflojM2xtAF7aBrgvaRd2l3I4yXqsaj/N/66XHFJasIdBQDX/YI1u4rhjt202RLjcwwAKgKV89fQAAybKjydPEG4zkyx9&#x2B;Pf1c2UPB47nfbpptdwm3T0QWLXINtukn5vD4LMZZx28fuNHgCeBV5gqQTx/IaL589/308/SBnNsm1QIZr&#x2B;mv4ZSYhNmzVivOxt/xKBkTEyO5hrRpObZ4&#x2B;9effvxh9RWgZwPgcea0AX0ID9fa/nXVYAi3H0SljC1vllvvabZdR2m2yVENydMcm9RannrX3tMRvjFl1nQ8AY&#x2B;LvBBtO9mXVzmBbrYuZrktZ7adzi1bTmvb3VJZyL5cb&#x2B;SKdjoSzpt6KwEeJ9MGdGO3VzQ&#x2B;oDxqaewW3hGnMqT4lNsL02yT&#x2B;PqQHwm2cnYX3QyUx0ktEXn0oFfuDtAmxcRqaDnllp0bm&#x2B;6YOolNKu5OR6uS785gC9QYDO&#x2B;Bx23fxG0fhVmJAO1TPRLoSakgUjDKy4ULSw6TZptSa7/51T9OP6V2q0RkEadzzk5vmcrm7F7P9TIDb3Z0beS6BgtLXqz3uMycyaKNygWhZYGSofMb5x0E6II5bUBnCibb4vt5hbaMapik2pHdBNvu&#x2B;m2npNZuUzVPtrr4u7wDA7N&#x2B;Tz1NzXKbCkguy0gm2d5rWYUye7fkWU3cD09mChQAWO2QNu2OLQu/Zd5QgGbJtAEDSo1Nt22SpHINq3uJfaFlqWk2CbYH7VaJvH6NdZUG3sZ1r55GUm5TYux0ftsybTZtfJRFk2xrx7YpGkinzbGTT/0ADJIA6IvqkcAgri/YNu8nUIvs62&#x2B;&#x2B;PY13BcTwoHAiLT7NpkTkPWLmWwSqRO7eMbxcPMDLqS1ZSYOFJXf94ne/nX4CG0y/zNk1abbblKoW6DPemqkbYf6Zb5x&#x2B;2V6Wl/8tsj4xADcwpw3oXkzQOQ3ruxiermJiDRjoS0yaTWqtHfEziY/&#x2B;CwD3a2SWW6TwfLXtn3Znwl1cK45TU2P2qD2rWdq4yAA1u8K5QWYAjZBpA95itdRwZL37bbybV1gSuM2UUZtXaIucxybHdqdAj0OpbJk15AFiuEjW00vKbZsnO0q/LetJVj&#x2B;s11s1PHeTbRmfXx/5m51Gtt4RgGGoHgmMZltpYVd8Z26gZNmqpKQoGR6xmyT781//Mv2c3leVyCSrujdlN475627JndXGrsYAtKOXwpJLkbk0KbeqduOZuaq2NFtflm9ZxsCyUotlAFCPTBswuMjEW94OV&#x2B;TboBcSbHnim&#x2B;7xCbbTa&#x2B;Z2V9tbil/qAaC4vlJuqyzaUVJNsu0ewpuu1Xv7ViPPpNkAHqR6JNC90wXYUuPawA5jakWqJwn3&#x2B;&#x2B;//&#x2B;o9/&#x2B;Kd/jtnshoMZVVKaLWaz68tnflSJBKBD/RaW5GbCmyFdeVv1NgA0S6YNGEF8rLkd6rW6b17kunsXSxNDIyTYitteObc3hjf&#x2B;pI&#x2B;63WbmXF0B6FovKTcgw7YqQ9X9A/AsmTbgjcKdszGrFp&#x2B;uRL1av/r0QXkP50MlUzptObNNgi3P6YCD5V9X17rVHVPP82kP8xKYy4vttKvtLQAwACk3GM9RzHzRdldqPAC0QKYN4PM5LmJWcP6EOg8snZ4Pc0JOZi6J7NpFMUMNAhtnXOgCq0rs3uizAMDApNxeSGwzvCJptqMuC&#x2B;cPQCNk2gB2hFcPUqWBqrYTIj8ytTRjlQO&#x2B;IrXwLwC8h5QbtC&#x2B;v1kLBlp0gGaAdMm0A/&#x2B;OGIFWyhM&#x2B;FFMXq/HE6cafASRuYlBZwdPauikYGtgSAN5BygwZt12A7DVmvD&#x2B;cVFQO0TKYNYF9kPcnPWVSd1wfN2LLbSPPJ5oziWdmLYgs9dQAAIABJREFUpR2durJrABAm5QaPC7T9A38S2QK8wVdPHwBAu1YBcZFqabxZZO52OvHmfzXMaMrROakGDgDc48t3308/Tx8IvMuysH/eHraBrh4GgGGY0wYQEp6sFh8W6zsmJs02r4C1TLZ9fn6yKRrJI24YauDEBoAkZrnBbXYj4dRyI6dNQvEwQL9k2gASBEpKiom5KLUwKZRScFhu7TsCAFtSblBWTKX0mIB2HklZ6sAAaJZMG0CaZZQcP8lDyoTPcRNr9/RYnVrL8ZLT9iqNUESpEylmP05aAKhKyg1WInNd8YsQx9eQ3K1fMrNKMcBgrNMGUNcyENfLTMBu42o333b0V0h18yk0VUbVjwAAtVnLDeItQ&#x2B;JVZi7cHIvf/25SbfsLAP0ypw3gkviSEbzZ0Tlgahq3CY&#x2B;ZTV1kYt6nfgEAaJlZbhBWpIb/7vYxbT2xdHEqdgJPMacNoJhVYckHj4TuTOMcY06hvIwILxeuXVNw/y59ANAms9xgK34xiN3b54IN8QVsRMsAozKnDaAkcTMBp6Mjl8uw3XVQjO&#x2B;o2b9Nj2VMsgz0OyTtBwC4h1luvFPxAg9HFSZX2zQ1Iq2pgwEYjEwbQC3bPmvhLJHyphxJ0TGJOX9qTIu01AQAdETKjffYFnjYzYGtbpzHQa42S9JOYLxajq6dAwMYg0wbQEWCVyardlrM&#x2B;Mc8mkxDin9bwyNqT7eJZyQBAAxDyg0y9BUMv231Ae1i4H4ybUAf&#x2B;opiIWzbzonPgpxWAmQwkafE/VdF12EAGIyUG1077TRYjhXLbj1llFt/xHZy3naD8eL5Lt4aYFQybUCXhgwKGVu4SbatSbLdONxs6KXJx22Wq01Enh5OIYCywssCQbOk3OjOaRw7XYQrNZraucKfthlPt&#x2B;mOxeeARnz19AEAnDsagXX/kcAVMaH/sp0w/Xz9zbfTT3j7yNsZQMybu2pFOx8AHhf&#x2B;Qoc2ffnu&#x2B;&#x2B;nn6QOBkEqX1qPm2/L2qclW49FTnX7FNHKckSLf09Xic/PvfT1ZYAwybUD3dFvQkTl/trwlbz/z70fn/7bVcdQOoQvbNzFbXo9AO/0IvfOdBS/nIkCPek&#x2B;5ffnDr58&#x2B;BGqJya8UXPN4/m93sXFHPScZabZJX&#x2B;8IMBjVI4GebGdpCKToVPypG2guRmbOjjI0PkEdSWoSh7sY5gb2fAp10d4GAFqgsCTNqlofsjWBRemWr8BIr8aqSuQwzwsYhkwb0BOJAYY0tX9KndvhJocPUV9KNSC96QDP0i3IeKTcuEfqKlwZV9qpibT7QGVbaqVcH0PZ2jMKWz3f1ZOdv2H7elLAeGTagM6sgmAYw5UakuHZbPOefXC6UHtB79X&#x2B;t2eFBipAPa6xDEnKjUrC&#x2B;ZWV1MZOfIGQepfuvHXFTp9moEFxVOIi6QBuMx9kYJtla/eOYwI4JtMGdGAbBK9ukULgzcL5tmW11aM9xLRhyHBlBO7uUM0rR3J0nTQIFAAoQsqNgo4Wog5kj1J3uxseNxUSh4fEpc6WbuqpBWwzrE8dCUASmTagS6sIW&#x2B;wFn8S2lvx0bakv71ERmCtv0/Lu4f300vAGANon5UaGvAle2/sebRCzzztD4vipaXm7PXouLU9iC1u2drVkgQbJtAF92HY378bKpubwTnN746cffzhNQkc2RH2arrieZqvK2/oIPQLwZv32bMIVjaTcvvzh1w8&#x2B;&#x2B;ttkVCbfHXC22sNpfY7TjXczeS1ck3ebb7sHlrc0wLzlIxUyYxwlWZfvZuRpMN9dxQ7gfjJtQAe2NcRjtv88HS/C45Ytjd0NAuUKKSWQ&#x2B;7xY/Sby0a3EVlVkTlqaDZgEegzDVxLxLV1rJOVGbcUDnqQrXvFA&#x2B;janucZtmYqL9SrayTXujqgOvyAAbZJpA7qxDblOEwMm5cAktdmpJVNKeIrh6rKW0eKNeadcA2uQmQauOKrN4MLC8P6ecvv3/3z2SHhExrCz&#x2B;JlbkcfQ2pX2eo33o&#x2B;GVR/0hj78C1xub266hizsEuE6mDehMjcWljBGmd5Gfi6QpbhSROiWX9p226gMljPodag1cFPnxl2zjPeaKjrVTbkpH3mYZ8OQVsT9aHiLmQbf/XdVaDO/nZqfZtciSidOW24zabkbz8YHIp0/kdA/bSpjiaqAdMm1AT&#x2B;ZlqJLCKX0WvMFLKqt0Kmmpicgdyt61KWZJUeC1AkUjA53FLiOM7baUG4&#x2B;YY6Gj3FupuWhHgXFfl9DVa5W0slpGIrMR04GFWzerg9/deN5PhWMEOCfTBnQmMhbfBl5WKoLP8QdBzqagexYb330UV7anxOQ&#x2B;vTvAZHeOxe4yPPN/XUB4gxopNxPaHhG/6liMOfm0OyUrsLd2rpyBy3jSILyMkXbPvgiBUSN5owYDJ1I7bzfwWjJtQAfyanCHQzcVI2HJLLeLApeU08R/YIfLVKiLVTtiFpn3aQJOWT8Vdpnl1pSyJQdjZi&#x2B;tNs57iEYsh1Acja44tco1Lnd4VLGznQTbrozDOxpl&#x2B;HhJTICZTBsA8D9McStu1aL&#x2B;pKTZtjc2uJ75Cx29j6tsq2QbcN3ulcRwMd7jYsrNhLZ71JvTH1/PJvsh6ikSB25bZ4EJ0J9WX4pJwamH2xYWQAtk2oA&#x2B;6LKEIqoOIH2VwPDJ7YtccMqgt&#x2B;Zx4RG1gW3Ce/POwtgyPuynW5ruzHuY5faU05AmaQxZ9iVLvBRWe32yK/PGrvTkqJYP9EWmDejGUef19f3Aq2icXHdxUYHiO&#x2B;eK4jVnvINAwHzN2XYcxyTy4eXiU24mtN0gMEup1IWriwvg6dyyi3FmuHBC7cbdlbcg5tjmUSMxp5OWLNAymTagJwWrw8cs4VbwEYGuXUzGbEcJHNWHXG125UEp5ehLIaYXafv2ddFhBJQSqDcb3xO92smqdJivCd4pkHKTY7vf8jJV76LU5uWuxppk83W&#x2B;YMXFsm7uM3n8&#x2B;QLEkGkD&#x2B;JlVLKv/Al5uu/D4lb0VLBpGVdtJJ6mm&#x2B;y7PmcCuvN0wtvB1ICnrNu/waPuYnm6TAxiJvNo9YsLggpeUUvVsRtLOKxDZZzLfePodt83bzXdp51kDnJJpA7pXu6iOZBsMILVXsfZVZflflcFaE1hnPoavDOBIYIpb2QeSSwOuezZAvfnylZfX2aaIwnPR4t1cIjJGxriQ&#x2B;Y4ZD9fCUwZIItMGjEAQBgSktu7KdivEdHdafqC2QO9J5JyzK2dRg30lwIMih/mfLl0TY&#x2B;4YdeUB6kmdf9Za3FskMVbkSGrvM9V2&#x2B;tr8&#x2B;/XBgmYuAoORaQOGEtMfEdnXYJYJvEd4EGupFXHClxQNy6ecDmHOeGu277UaOMCuGwLO5QQLlyBg12nCo8jVo6/2dXwS6IWX1lWNxyv78fUEDOOrpw8AoLz4MXThbU4X1Zh&#x2B;Mo4QaMHqU7z7cZ6bkWUfWmOycVfeoKPpaz/9&#x2B;MNuv5WTAV5uug6sLhfTL1dCzd1ri8AV2DoqaVtqYbbAaLb5l9YiohvK/HYnr7Tm6fzF1t56gGwybcDIdvss4gmmoRcZme&#x2B;jDPryv0VafVqV3Sn1vnh/gSQFvxdcf4BI1&#x2B;ckha9dfbWpnzraZ3ONgZZUuPR6zJ4vHRlAV2TagMHNAevFIO&#x2B;0E9/8NnjK8qMXOf70wU&#x2B;rBFtfIt&#x2B;sbVlR7zJwRdlLiq8e4HM2NG11oUiNlsPXme01rZ2LUrj5UPU4W3gRwi2pshqcvAhQkHXaABKcltGw4Dx053oy/vS&#x2B;Lgsv4Y0GCrp&#x2B;SdldQcfIMPJo5vRulVBZBcDLQo7xV4lV6/jojtPD9Xj&#x2B;ZK9GFnOXqi9IzAf2zq&#x2B;DHt99gFQybcDrRPaqBzaLXOZtuR&#x2B;gTT6hndLfB1CPayy7kk4MZ1Ej6mVTlksdbxNLy1uaOhPCteK3y0/sZigjd/6U2w4j8oGaOgEA6pFpA14nstW33Cx1FNu2AoPgEtqxbfZnN0cD5XfydkiMRnoxPt5o4Eb3XHCWXee3PSjtW&#x2B;VUAhusbnQKNev6u7NsI&#x2B;&#x2B;WW2zw3T9aimy3gmLS3L4Gn&#x2B;xSTH6x&#x2B;PNt/DUBKM46bcAbBYLI3dr013t12&#x2B;kXhuElLTZghUUAquroi0apSY6k5k6OBjM5o551VMJx7IzIfBG&#x2B;vnhzeBWJ3Tl8Lby2Sdf2yBfk6PkCvJk5bcBbBOalxQ/I0jiEAcwf5&#x2B;xP9G6FnAJHRq7bFq6vsf87Dx54SvEeyZsvF3pUyViqatL&#x2B;dJ/WVAoya7wLq7OitTc63PyPP5/zugIefzUipyY/fpwAw5BpA14ksnM8sNnujLekR/zoqoAGXM&#x2B;aN/j5fW2lr&#x2B;14&#x2B;UovQo3d3nbwQCO6&#x2B;JivupXVRWcSeN/DebguTvvHHb2ARx&#x2B;6m1NcR29im&#x2B;9skTZ4TNu/wVzj0UTS60OHjxbky94hwGBUjwTeZaqYMYWD4bZikYfbdkysbjFJDm4Q/kQfFdLpRaAezhvc9sS7PkkA4q0udxe7ZS8fDg/bbbActWhimlrOiq3UVuF2&#x2B;9O7x4cxgYzUSO9d9irsW/Np/2ysOJ0VBc&#x2B;EGMJjgCVz2oCXurOKwtFCBUBZ8yjL8NDpKyNPa7cnU&#x2B;cKuKrMsqtahfdZdoer93fZmeWthLFtP&#x2B;aVpkHc0&#x2B;85f88GvrZc1oZx9P6ubg&#x2B;fe6a11XblFe763TmdYrWdyxW/FFkXL0tMkcz7v2W6eOkAyjKnDeCq7dixpLHAqd0QZsJBpPhBnZHFYO9Js9XbfjyrYddlBxTf3EGgPwKGF7hGtXk9Xx1t4AIbOZeC7uy&#x2B;p6dNm9UUtypHNq7lBKnd6oWVPmhHNRJWF4EaD709kvjnGJ5wuTS/nkmzvlbnc&#x2B;RRPav4ce4upXHzMQB0wZw2gCpWI5d3R32m1uJfbSN&#x2B;hSJ66RkMt/NHvSBELgWRekkMvJj1XsnwiGNgSOFgb3VLjatBjS7XwPRxAeobHC1EffTWm7cdbzcsOY0fSr28RxNtW/tQJ11nYtZa60s4Nq70ZrV2DgC0yZw2gEypo3rNVoFHhMtI7n7QWlhrYWDxUx&#x2B;SLqTzbmO22f3rs2&#x2B;6az6M7ej6c&#x2B;dl57b5KJ&#x2B;Ua5qrX&#x2B;/iMxne6&#x2B;vumV/VZgy8vbYk1eCNH7y1e3sjr8npinG3HQkAWzJtAPlOZ5ZErhSl2QmlZA/vncsPlj&#x2B;mn4vMM8XkjSajNqojS3pef6CyCbajNy6Q0/3c1XEGtOnmZFt8f3R8DbdwYcnTu4uEOxWfOfbt1qw7J/cvJZWcnbcMp8EiWwGnl8FpzlyNyuQXFblUut4C1KN6JMAl4YB&#x2B;CtOzw9mvf77a/EczFeq4Lc0WaZukaefYsp3WxT260EUuqpGqxkt69MbFj/Ef470GApYf86c&#x2B;7zHJtsA2igEycyYM4P4LUdLErNMavHmB4m0jurKtZuwF/luKEBTgInPaAMq4MpI3clep2wC77lnPoLhVXr&#x2B;vvq3TVFN2LaB5rHHSih03pNkAPonXqMcvIxcXNArUdVjO9338aVLJ9OamTmtzSrxNZF2HyI0/WafQ0XTMdmawBZ5R3gDBVfOhhecIMB5z2oAO9DLGfzlCOabgW3y5jN0bT6terI4KmPlcPChmqHJM6cXln5oaoHB0eY&#x2B;87PfylQekmi8Cp9e0z9klK/7Sd93ysDPmjuweZAsT&#x2B;4iX9MUkbdaFFj53kXPXlhvH17ONucyGj&#x2B;dB2yOMD4yTdtvOUwYYg0wb0Ic7OxSK2Mb3R80DFXigrOVnqtPpa5&#x2B;9GWwdHfyp3Uv67mUzvu5i2J1ptk/ihT17cUGgfdkR7FNDpm6LS5d5u5G&#x2B;4EZ1NILk6E&#x2B;Re&#x2B;ARTX3ikqo4hi9Q8wkZn5CLO8ZbhatEJl2i288pAgxGpg3oSV/5tmXjc3vMSTUxjuwm84CtUT8d2&#x2B;HAjT/TozG5qwRV6rSJpIKT2QLfQUkrjgC0bHvJipmNF7/n3ekarpNtiuzWD39re8er6jeFuXsaLE&#x2B;5jIRZg2OwAsIjKrb1ePNKrW7XeEs&#x2B;UADiyLQB/emrLuLFg0wKi/vKRMKrXK&#x2B;19Qn2dfbbz7LS5gSv7TJyta&#x2B;0rucwkit5hWZ7SJMOZtVlHK4b3NTTJJBsW2ZElqtbBfIBgXffHMeLUlfIG8/yGtJypcSyjYIrOwGgrK&#x2B;ePgCAc0frEueN6nrW6YC1wGZApHbWM590d6UqpdQciPjOo0be9PhSWi33BAEPypg&#x2B;W9X1S1N83D5t&#x2B;dqvzgbFxFSpKeHdxKo3fesoA93pxyRc&#x2B;7H3ECh7zlnMjeGqkkk7B6ASc9qAbpwOgexF7QUwuntBoDtJn7LuOkFKOVrTJSa3FD&#x2B;z4YbLXdIKItm7fe15AmML110Mf5vsXjAfDPOuPG5e1XQxbVO2mZ7AX3frSYb3sDWdAMvTwITvI82&#x2B;JoG3rNQxNxJBnU79LPV8Y/bT7PkAMDaZNqA/qev3NCgj9g20T&#x2B;ZWaIEjgw7d3JhM7SUs&#x2B;&#x2B;jLD3uzM7quCJcUu/MAwmuH5O1hd2&#x2B;u3vA2qWHbxdD38eTExTWJB/hqG9JyadVArcj4Ha5qUa7&#x2B;9M7TYHdwUi&#x2B;z4VeVt0&#x2B;DotR9Hp14P/3v0r&#x2B;xB1pT&#x2B;EXIe9YfoSNAq1SPBHo1QH2Jgl7b/oQbLEvBBFq2cxmfo2b/latWzNSuZy8C4ed&#x2B;cc/F93n0QNv12FZps9ovsis5jKfqZI7ZUx2vNa5au99o4S9ZHjG/U9mL9p16fPzNg44KcuZla262Ox/387I46uhFuLKTcEMjdecAlGVOGzCmx0fvXhcz3nnbKQw8YtsMLnL98bm&#x2B;M81Wdj&#x2B;l5i4DA1jOQggU0LtYouCp6Df8iLvZgtSnmfElO0BbYGCnZ8LL45/Tp/9IOYfIT3qNUitHFVzClR6ecn&#x2B;9mXaeO8DLybQBAFxSfGGG9kvClu3XmPtMA0/5tk6EcF2msm/KcrdD1gIFli5&#x2B;qMPfC418axQ8jPCuwsm2Fl4KYqSWwlueFUMmU28bYBQv/O6E/1qw1GGRCqX1nEawqTU/V22B7fWwkScOwJJMG0AHRNLQmtO1SS52KxyVDHrcPbP3AvM/yj5W2VXlsxOQ0mzwQrVzY09N9QgnwFaZkoyr5ZV&#x2B;f1qz/aIPh1WrIorbRbDGS79191y2V57lwrSphUYb/0RXnX0otQbQHZk2YATNdklfFP9crI0M9UTOZ6o07en04R5XfJ3IZddMwd1OdjOFgf7o3e6/dl58oGv3lD6Lr/xW42K&#x2B;vepe362Idwy7Oddwo2Z3OdWbA7DbjBFsXHxTevy8b3PA13d4cQ8A3EOmDRjTC&#x2B;PR7hoh0JGjZNINPaSBFX3uV/zRby6Gc&#x2B;f0kaNu6xd&#x2B;PQEBNabtBub93K9sFqT42A7a9OaF3Jo9w08/fassacFCsstjKLLPbIHobvfYMg748Ys2ANlk2oBBrKpSjFc5JEw4DvUE1swoO2R1tfOYw6gqMF244DzaR1azjyn7eZTjPD3IFlabA14uJj/xSFXJvC&#x2B;O1JqTuqq7ENNki8nUDpN/bfBZJC2hV2Sb3QNo5JW5Pj&#x2B;v&#x2B;JYANEWmDaAzIm/Ic70j5vqqbKWWc6h9HdgeZ6nO2UDasrZwich5rMbFnQNcceV6mLqG2SP5iewpbpHJNnFyXzJyD6VmDjVl7PN2zrLHX3PCA9pue7lKDQWbLl9NZQ0BqEGmDRjBFLDGFG0YLLQ1YhdixH9MSlUy3NbPuT7Ut6nZuqcv6VOXpoLT43aXfknabQvvFEDAg5OBkh53/vpL/WJd7SH1cWnHtmyJRlBx4VZz6mcnu&#x2B;rj9oGerevwuXCpdMEBeBWZNmBwLYzerUpTE0optWL5ctRq2cUqKl2&#x2B;Vgm83fXGtttnG&#x2B;wivOsNzxG4wfWJFEe3txM6po5gyE62zffKeFyetZp3Pr31GkFl1Ws1Z3/odq9UN3xynVQA5JFpAxhB2dXm4SVqr6zWuKQulaNu2cgl5aa7P/sq7Y6tPhqyvV348/PzK&#x2B;3uc&#x2B;nxNADGc/TttrwUN5Vsm8RUv5zyK0WO/PFvJYrInjjFUviiUfWhx1697CiSBGBIMm3AWyyX4Rk4xh34qUHY6Uc7si/mYp/Cqi293VsjH9L4FePCKaVtQctAZ03GcdYQmKV3epDtPztgYKeXmtOvsMYvVjcf3sAV5gezOrHDq/TJt6UKLEJcfGneWSMrE2/tjq/6XDivHpmWB8AjZNoAdnqKB9DgUGWoJD5pdLp9jevA3O/TxUUm5rox0iTa0/dl&#x2B;RwHeL7AGPK&#x2B;UI7WM27/62k5YO76rnb308XrwPVVb99sd&#x2B;zXNoVZKdoJD&#x2B;EayWoe22z4Jw6ATBvQk4zs0WoqW&#x2B;Du4&#x2B;XbRnoucNHRB7xgEarwBg9&#x2B;HsPTzkq9ApHjzRsUriQpuwZ0qsh1&#x2B;NkL&#x2B;/1T3Dr68nobb81FScUMrgQ/zy6uFj98Krzx9QPuNzAGIJtMG9CZiyUsIiuDCYVhJJEV/0p1MWz3/KD5iexe3CJX69ld0W2boHo8mxjpaE7e/B3Rde01gFK2F8nPc9fAStWYdy/7&#x2B;scZSaXikAFtrkwWM5M1KZ5seZgdAI&#x2B;QaQPGt4z1DVYFVvLyanOHY8vFYWIyRqfP/aja2JUDK&#x2B;u2g2nnnQXI1m8F4IIX4fiv/piEQZsLssKD7vkUxKf/b7jcKYQAgEwb0LfIqRipybajGRvAMEp9rlu7VpQdjbvUeFrxSNK7szuPof3nCDCruuDofMtgs75WLYXdbY5aEJZ8oyNHo6x6PGMjOwG2f8pOiZ0uGNnjywhAQV89fQAAV0V2nl5ZQPvrb741Qg048tOPP0w/Dx7DdJnavVJtjy1&#x2B;xfs26yju9vZuDyby0h1&#x2B;FjpNgMGEe4q3ttXVArUWR3Jlosyorwm3meO6gufSxZAmcCRNBUvLF61gTrGp5whAm8xpA4YSHqF2&#x2B;tfwNgaoAt3NYIsZgL973duthVXvKaeW59q9IIcnJaweYjUhQ&#x2B;0vYFS7AxHKPsRyncvAwLXdg2lZ0tyX1cartT/7euI85ahk92k4d3qC1VuSrcZus4VrnscPNQvvcNba0wfgWea0AaPZnbrxSe9TCOTbTkcXmgMHA2thBtsneJ1JOrZVz&#x2B;Djz&#x2B;vIxZ6O0xXv57e1hTcXoIaLF7ftFfKo93&#x2B;ASDi1gPA8HiWcaIRdp5&#x2B;a7UTSslNL46sFXHmUSuKPKv7SdDT3d3llEC4CsCLTBoxpN/bNbhvsTndrs6UBvEGpAj5JHYgPulKea/t10EVmEaCGgkMKVnOdd2cSPxgtP3h5zx7nB1fccL61EzVVmmq2vONRuCjHBsAR1SOB8WUveny6E/Uk4Q3a/5gnXeUCJXSma1prFTKX4sv&#x2B;tHbkAK2J/O64GO4&#x2B;GC3Xftxmvyvp3W6&#x2B;Z1WPtLijMtrdnd5XVme/vjEAbybTBrxCTMdxfEdAkdQd8HKRC7eE1w&#x2B;rtLj9g30KgTXkrtc9sxgbwFLqZfB0jczAHeMfIuPATqVG7wUThL5riJeXAeq6ZXr9I79b0vboI7/KVp5e0Hx&#x2B;AYgn0wZ0oEg3a9koeQ7Ba48uBB5x20D4i9usJB32bVetshMarhy27hKAXbuXx1W4e7RwUWBvuwUhjh5utVmNZFvZHYYfazsVCTIcrV9QMBMcWI1sML1UTQegUzJtQE9qt1Rj9n&#x2B;09nudIwKorvZ1tch&#x2B;TCYGeJArcKptAUDd97SpwbLhp7PKhIUANEimDeBnls2M05WWxfcwhjtTTZGPtepiCBTASdVIVZxw3Z55g6R5w67JQGtauN5WEj8Abjklbr5ltc39L87RI24LVwT24HuHMdxTyyEjBv4UHWurijgAVcm0AR1rbXzotju4teGBwJ12O&#x2B;C2/QXhftgaV49nr0ingxjCd9nt2dTXCbSvtcA1xu4Kl9t&#x2B;8KQd7t5l/nJs6vUp/uWio58Xig/8hHMAdO2rpw8A4KqCpcl2fz99OE0CaNDX33w7/ez&#x2B;tfYktsBDbzfe/nfgJH3GJfQoExkY4zze6wYMI/4LohE//fjD8ufz82XYauSiHnl95mf3Sf8SyT7g&#x2B;Dt2d9rQsuXH&#x2B;XE3nNtH9SerPijtc1EFipNpAwZRJEYv0uoI3107GWo7/ZT11bQuddFooUvl4hPZnQmxelItPE2AU6LBydF0lgdfn&#x2B;lr97avkvmZOiVgVjwXuBpTK1ZkNboRoAjVI4Gh3NkwrmTguSxQ2yMz2E4tx/7Xu0tf4pdei98bQMvKXvcet1tVMunugV3NHqy3uWxT5L1rpxOvAyU0IV7M&#x2B;em8&#x2B;ngR2OOsAMqSaQM6MzdBb&#x2B;iq2E6VWC6Qfv0AJNWgtkZybDGbFa9M2&#x2B;xibIEDO50TfOmYAJ42Ur5tGQxnfOPE37flgHnVOphv371x&#x2B;ddpVs12s/DSrRAwTEnt7g6YfhnfAJSleiQwssiqa1d6B/Luvt3bGH0u0I5eKsMcHeTFi8yDz/3ogra7Il14m8&#x2B;FtBxAs3r5hjqVXeEtr1DkPdHyKulV6fBiNtY64HOcaU5aFbiGxw9geSS7tw9zpQWgF&#x2B;a0AeOLGakUP/WkVHMiY/7KgyV0oBdjfEAGHtIeeRXNmxIHwNhunn&#x2B;Q&#x2B;nV8Wvdi&#x2B;deY52K&#x2B;BZGcJ5DBBwcoy5w2gDTbkpLz7y2M6YPXanzgat71If4ZPfX0V8OZA52Sy0pZ4R2ublk&#x2B;tZbfYoCA7eSPRqaDlJX6ZZRUZnlpnk8T87WS&#x2B;jpfeQqpM9vC33rZxju13ilyrn9T0VH8Z7O4pl4HWmYEM1CJTBvwIqXi/rlUzlGzP2NXu0d75SDhPRrPsX0uz1HLq7JV2/Jyd9QTFOh/DLwOu4WS2n&#x2B;XAU7t5tueOphHLF&#x2B;B3W&#x2B;KrdPNAq/h8nsqNUQP/De8ceD2eYW2&#x2B;ANIPUO2I2Dedo4N4yhqSjo5a1uNOr3z&#x2B;rYahiVKZCl87mlWAJWoHgn0Jy9k38b9BaOrglUlH38UoKDrn9ndPTzeONytf5s0A6/0EQF0Yx5Nvx1IcZpP6uv6GT7avGj8aJnPyOqOMQcWv81y48hv/DnZtltGMulZxB&#x2B;qKpTdOc0T3HYkkcfwSCu1hdeBZg35rQo0zpw24L3KtgfuKeU/uv&#x2B;PAAAgAElEQVQhEISOZPSFFd9DDacXz/A83emveTsB6FTklKyBx1QdfTVcecpNVXFfFr0IT5go3r37&#x2B;HOnlN36K21GRIFSMW0eMENqPycNvIpMG9CTIrUytm3yUmVVTlvU4QXSV23y66UpgeKuFKG90tg77barJ/Bkix9STAclQKcCF7eXBHilLvLhgPn0LitjvPinbQ061WBEFKgSKYTjfq57QDtUjwTeaLfAS5HhpYE1FYSA0LvsIrSpF5blNerZDovVSmy7B5ZR2LbNuXoAN1hliXYnr1xc3bMLRYqiZxQu3p1BWLWGWKDdsZX6jCIniGuG9KjNz75ziTatLuNtfnyA4cm0AS81N013R&#x2B;Rdj8yu9EHHeEMXDDTl/kls2fct5fQpX1w1c7o8tvBMAdpxNKpjvKtlkdqPMd8ju3PgLi44mqRsu2D57RnYYeryb7Sj/fcrfOKVfaCCe&#x2B;NVltfA3U6eSh01wJupHgkMomyPdnZ1uFTLsbTxD3dUrwOId&#x2B;VD16PI5xtfHjNyb&#x2B;ENdKAALxdTCDGy2vlt4WsLVlm6jl6ZIl98R6fNg40aimiq&#x2B;uL25AmXE5e3oB3LQdWr6csA9ZjTBnRgN2rPrsa2O171qLJKkcGt4RG728FWGcwLgSSBz1p4wujyWlF8ibKCe0sVXkUy5tK0utAdlUT7uF4Br3T0xRHouT76a9VSh0/JeDp5tYvD3&#x2B;z3fEOt3tzVI54eQ3blySHPnDEM8KYUyWEM8DpQSfbF&#x2B;aiCkawbUINMG9CHskVXpkBtt6VdO&#x2B;TafSLZDypGhLKOanZNXliF6bQ41dxduHqtwqm70ocJ0Iej5MqRmBJtg11UY57OqgrxfOM2ZbV735h5hDcIPHTVpMWoZw7t0ESlrJiREEkXNOcnUInqkcBoIrt3w3VUTpumleSN561xJPBCp72ZxesvVfr8XjzO&#x2B;P7fwJQLAD7HteBWJa2uGDhxEvOMYjpeu35lYtKHeVSVJE94bm5G4ZmuP6E8a/cKuTohnWPAbcxpA/pzcUm2yCZlINlWKlC7PtxPETa4aP4Q5a3Zlv0BrJdjS91muzb4lQNYXdZcoAA&#x2B;wVKQS4HahkkPNJLdZ7SqCX868frz86&#x2B;no9e5r7RT5DzyU/GtiYFzuu90GrCtPmjxtcT7&#x2B;ijRvun0iyyru7taR2DP1w8PYCbTBvRtN&#x2B;jfjcPmktynLe07hevGHP018imE&#x2B;9OB2bavYXXLMF0GxZ/Itt/NpQZg1&#x2B;r75foF&#x2B;agf/FXX4fiXMf7b/Nn1zNp/&#x2B;955pg0mXC8dGpTU7xH&#x2B;qj2qfg9wkUwb0L2Mlc&#x2B;aSratxA8YTH0KVkFnYEmdPgY2HrHCAUBt85V29c2V2vH9wi&#x2B;s1Kd8MSHUZj5plV79ZH0db5O&#x2B;V16ipl4fwmoHb4GsBmQreN6adglUJdMGDGU3TRWuhtGjuVnbbL4QehFYPiewWRdXj/C82E&#x2B;FVisA8SK/gMLJjKOAdvhCvnmRfN69WsgnHZXxKL7PDG2mJKnEu0yzlgMRtn964oiA15FpA0YTbjR2kZGKP8KYFnKpUavQo6QaqgUT8I98yi4uQhlp&#x2B;yq5pAAUtJ20FKP36DfDanbgDc9RVclJ1wMW3yNmGbbPWfQYSF2EtXO6MpLt19nyzEydUuksBYr76ukDAChvWoxt/ln9dZhxl6vW/u7QLSsn8VpT5f3tjZ&#x2B;9j8NqBcfdXSWtBJN4sJ0JX2MByBCOWpNkT37qNH1y9GW0DZKvPMHlTmq8UPHfqi188woA7pd01m2r0a42KNtIXO7EuUEjAqeiUxSoxJw24C22tRazG8ntFOQ5HaQ8TFoRkmTXhjrdpq9x3KPOYwAY1XTRLvVds5yzsvwKiyxcOZK8L8TApJ9nv2EbKWodGPBHKZVi2uIEnNzs6DyPPBWdsUAN5rQBL9Vjg3AelrWMC8PFgmI2&#x2B;yym7FQapQvPOm1KrdLnge3bSbQHKJMC0LvVHJHtBhenZ70k5IuMmeN30qajM&#x2B;S2t9g0phtEvsKBCg01Htf7ziOOCkU6IYFnmdMGvEiNySjtTBkpeBjtPCm4LulkPio/1dHC2pUOrNnnCzCq6xfeKaILl0d&#x2B;4eV9lX5LWiD5c1ac8/FV3PqafE/Y6VjJ6ZfI6qnbP6U6HQEAj3A2Ao0wpw14l&#x2B;1Ap7ywLDB09J7GbdIcnYwtNdEZQ94H/PT8b7A5V3wIMwCNW4adR19Mp6HpXFuy&#x2B;OE14uJMoNMdbhfEOt1V7UoStaOUl0yIvFn4Vd2edbvFSywcQBdSryHhch3OdqAd5rQBb3QxGttdQmP1&#x2B;w0BX2oJ8sjkQWABbVEsQwovGj9PCLj3oB5W4/nq/QFeqOClr&#x2B;zF82jm05Cz3MIT1i/W4Ty6PbLmZ2DlvCtuWEGt0pG/U3jgY/ayfJGLEEfuzXvN/S4uxgZwM3PaAK7aHZMV2Wip1/otUhUknIGA8bR5kicdVYMjzVs7HoCXOIoGt&#x2B;v&#x2B;ctHFQTlVWwRVBwxtJ&#x2B;dZ/rmI1FoFSXMrU9&#x2B;XF4454wYx03/vORKAUsxpAygpY2mE2mOHp/2XilOHHOnMqOLnfba5DNvNzcuq89giN2jhZQfowvLLK1xZ6xNX2OCoVMPAV&#x2B;ZtAHC97kXB9EZxjyzhljT1zTy5reuf7sBOHj8n4UibrTOAMHPaAArLq9ZSddRnxrjF03sZpsoYdk/jxxtyqZ&#x2B;vmDV4wm57yoFZswAkOZqutBuLplYdn419rX7qG3/73i2X2qq6hFvgKUc&#x2B;dGAnRQ577FMuRszEtfhP9JRhDU96ezz0pSPXL1CBNe/n31fbO0WBLpjTBvAzMTFcYF7XvKTTxSUfioSSVw5jd6D0vJrF6haBL11bzvt89mQu1bUUme&#x2B;/&#x2B;clmrzICQLZlx2XSvKLVLQMHe/c/teUjPjLPrIhwsLEatzf2KVRPuABs4MxJGtjkraG2K&#x2B;2sSudnC00/YDwybQCFxU8uCQ8pLZVs&#x2B;yziyEoteXEqA2j5BI4/tpafxTJ5v7oSdtrJCNCU4vmb7U6EfDXMr/P96aiCzY3599OveIWjw2I&#x2B;ufGf7tMas/e8/lKtY7j4tdLgadDgIQFdUz0S4DG3dS6XqrcQ3om&#x2B;cjoyn8zNViMpe1TNfjzbfPEBiitYErD2N9cqcVLvgZp1VJYz8r7XH/3iHp61eulOZ7Q3G6I8LulMaGq20Iq3eDyVzpzer34A5rQB5MhrMESW&#x2B;Khn91G2A2mzm0MGhdGRpgpFLjN/qw2uTGhrpCrmkYsXHIAe3RYsra6xGQ&#x2B;6vD6L8e704Opx13eSMWXN2TVL/dAt40YVI7nH1L5IzQTPHQ67G2yvG8UbCC23iYBhmNMGkOAoU7X8PWYM7HaDeiuf13b0fDt9OnCDowHdeW2/08XY7m9Sxk/dcKEAXmI7s&#x2B;eeC&#x2B;CV6VmrnXxe3Ed5WnlvuSBZ3v7nF7ng9MdKAsdmytptVifM6ca3HBSD&#x2B;&#x2B;nygvRh2wtp9ql79LlY7dlHAyjLnDaANLsDhHcjznDc1tTSRLujzK4c4e7erh0jXNLOGZiUf2rnsOPFPMHp8tLONRDgBqmR1YPfBatDXU5fODqY4aO&#x2B;IZ9Utusn5ypJeTQl6&#x2B;Uv&#x2B;9HMoRsKS8aLfLPMKBpV9sW/3mjd8E5MogXqMacNIMfRAOFlhukowususIvsN7/hSGAkzS4RtxWfFSvVPJaEA17l5iluxQ9mtf3w1/CjDuIaT7zxKW5Hx1Yqwmn2id/mNGcw/XI0QaeXUJMxnF6s5l6UmDOz6tnr2gLUINMGUFjBoC0cqpZtda8C2StxbbhQA7zH3DuWVAslsE3gU1&#x2B;vLZpdCCtyn/qAgNdqMEF1dH1u4diacjrJr4jVzMJn34VA5/jusQX605NetLede5Hp8M/BK7PMZLQQYr3t7RtezNdWxpt&#x2B;w7nqGw24geqRQAe6qB&#x2B;SUWvxennGsmK6/jN2GAjHW35D6VoLp1bxVcoCGz/yfFfHs1qx8hN3iWvhnQJoxP2lxWOWFo4/pGXgtyzPNXDVuPu7ayPrntVrPW2Xpiu1Q47svuktN6mOPvKtHSelnH5TxNfIqXpRbWr9DmBI5rQBPXl8LGdYZOOhqexaWJHm0LJB3uDYbUbybAN&#x2B;OYNte25vT/7wIND453L/sz49&#x2B;NO7T7/c0KIGaFMXg&#x2B;sv1pBc3RhTqqHZl&#x2B;JUzBSi7BzVncUq44Wf8nY2/5Wd93tipDqaK1kqXV11rlv4UyzNNoDVLNtPYjH8m9cXvD6hFiCVTBvQn8cblgG163Xc/9xrj0Zs9q2kL49XyKnUrdBgz2PZgwkUPir4KABdaCFxsroxI9kWTiJGTvhu6osvoFQqKGZxo8Ad2zlzVu/&#x2B;tl9&#x2B;&#x2B;ztHIheyaq1&#x2B;&#x2B;OruIrp21PjcxVyCkh73ekfK6Yl3T&#x2B;1f4J1k2oBeDdBC62VyW43hk7u9MKfPa4A3ncFcH717NGT78Y6zGNfziKWOBGAkSet0Fn/o1OW4Ppu47p0DJq5XhD7aw6rj&#x2B;Mq08npe&#x2B;I7fbDmF6IZl2B4/oyirUppte&#x2B;PqzHykKo/LEfAUmTagJ73HTDVKoNzc7VLwLTiqhHO0vfYe7YgZv3k6M2D6QMV3nrZ2ASx7NdAqBt7pqGjw4wUDY47nyPYgd4eVtDAfq6zT55I31KzgNjfI&#x2B;EIf7DQo6ObQKP6NOPrwCucGFnN92616Ov&#x2B;1ymEdcFUBHvHLpw8AIM0w6/oM8BSu212U&#x2B;MGIHE4FPrnxV6e8VQravGhkLC2&#x2B;uouPOUCSVYXGeuIfZZ5ts8wehSt0DVNLcPd7MPKli&#x2B;m5XiXkwnu&#x2B;7dw4dTqpZT7Urt/929zwtnaUzaWScHyeNFNtO77w8tFFaecaCLyTOW1Al/odLlfksAPDnO8c6XzlXQis3LDaLG//UMPFEzI1Z7b7Eev00rdyT&#x2B;EjgMcFLnSpty/NUV9rkVL44COv&#x2B;d19OwRqpO9unPSnwByR3UdvUKCAfGsncIMefH9Pz73w9vRiemdX729M6Y5VMH&#x2B;lnH5B8VlA1x&#x2B;gOJk2gLuVjTW3o0FPVySuHVPGVweKHzspDqZxeZ/r3aJhgRRUO10YkR3BNxwJQPvySi/Gz4u6baXbcKd/zKSrGJ0mYOJHkCS9s5FTNK7MgL&#x2B;ndRCe40hrUtNsSTr9jA8pvHbDaTGPo1saGVSX1/8AkE2mDejJMIFRUtyZ0XvS&#x2B;wsVeHF6f2r04nS6wMWmY8biFh31TAWeXUfPAqC4K/PYPte&#x2B;etqMoF77vbD6Tjx9HY7qtqUm7SLzsrcNywvcwrOWp0HZot9tXoteLnWExyMCVXDySvi2/GSBTsm0AZ0ZbARcvf6F&#x2B;1&#x2B;l3cGqR&#x2B;9XRjGl2UgnAHeKL7R1Wj6lxszUGnxYAFoTf82PqdV2ZSZTQaeBX&#x2B;TdtwaL/LdiQuKLkwXbHJMXX2/zDXoZjTTXDMy47/Cf5d5NZ2Dee3Tb2Rt/eIqdAo/45dMHAJBj2eAsO8juKdlx7Wonn2Bz&#x2B;oaCPwHb53h0wKf37WLYHZ2q2gtw9CmoIVwNpsbj3vnsAMYzX0WvXKUbDIy3T0eH&#x2B;&#x2B;MqRQJJHj8Akni/Wpbdll9&#x2B;75Q/rApirl1JRS8BCjKnDehb0sq9jTtNg53ajbDjl3CLf6AYkUPbro/SNUCSgm44l5brFtyfZps/L5U&#x2B;OBZiAYhRMCQ7qisY&#x2B;SgFl3CrtPHSG6K&#x2B;3fDg6IknvRrxu4VZ7XCReIHwPuNep254m4qv/1dwbwAZzGkDehI/Bapry37q3fr4AUl5tRusovPVYO3ls9tdsOGoal/eU2th9C73yJtZtTsPoIXPUSm7E14rTW4rvk&#x2B;AwexO0C9S5GD1KLddkwOx3EhfpveYy/QVKXoxnwbLQHo3L/tsCkT88Abe5StSpwhnV4PMuFeq1DncR9fD6fba1f4BYsi0Af05WkN7m8IRXbWseJ9LoFyS/p33OBrxHT4ltinhwN7yPHU5mi&#x2B;GPgUALxEYljTSqKOXRPtFKjMHloI7Kjs//AvLbZxLNwi/yKtBrtn76cWcexvj6QAdkWkDxrENHwdYzatU/3g70wEDM9WuOBqWe3G39CLp3M6YIXpFa&#x2B;dh8atBa08QoCPhAWRJtvmY3ejo5hgpnCi63hM6QLR/KqYPPbxBeOctNBCOtNOE6V2DKzgSFnOt7iuev365Pr1eObeBZ8m0AW/XfqsjsPzG7pbtt0ULNunDc48MZHuJ66fT6lRp/0MUdjQ&#x2B;/dPqVQ7gbU6vxoGgrvHUyNY9B/zmqK/gsLzdPT/&#x2B;wj5&#x2B;AL27fzUsb1kp4Svb/E1xtNnp5bfSxTnm0rEsbFvksRQrBh4n0wYMKD662g71bbxVsLuS&#x2B;e42uxnEdrpm6r3OgamNvEdM&#x2B;cejUfYXT5hK5/aVMQE&#x2B;FACdSprMlFRm8Oag954l3NofP3eDGk/cC9up&#x2B;JqBZTlJHnHlqn7zWxY&#x2B;1N2y/5FnsosV8Kyvnj4AgLpGDbBWHSvTL3NkeWX86TQmrruO&#x2B;N0XhLf56ccfpp&#x2B;YLT8RqetGzqXTz&#x2B;P8sT0tzXr90x35CgOwVO/aG7/nUS/ggclYLMWHSQFe2PYtY8Kjsh8Xd8udsocRF9/&#x2B;Bkfn7dGhHt1&#x2B;eqFzMgM1yLQBHbjYINztaF6GVp12Ohx1K6zybZ8LransY8tz/Y1ezt6bftlO5RFSc&#x2B;R0hZsjVa8hpyVfrszNrbElACvFJ2/FTN0&#x2B;ve/jihzJ0dCZT5OdyDXM&#x2B;bNwFq3g&#x2B;/6SF7ZHgZZOdpI1ptTtqFn828Q3Uft6nQNDGOtdRpyNwINk2oA&#x2B;hAOm17b35pflqCz7PYfRyFLMR9N6hNqsRHYZRO7qwRPsykdvVSqzRtcMAEtlr6UxgXHSAKNlHBW4V9l5LTW&#x2B;YrJ3OPZ4rDaLY1NQuGT6nUdCEZF5qfhiNtvxx7u3F7RbN/jiSJHdl2XuEnGqA8&#x2B;SaQNGFhlpjdGoLhVWpoa/8zDte7onIgtHJFXbG&#x2B;MEYOviO7u8&#x2B;&#x2B;MnyapVeVolMrCf6efxZwTwErvT64uEHwVLZ8eX6qrhtHs0qUJmiSMa08W5lV7be5S6OBR8v1a7ciYUFH674xvm8cUVb6juE5/8i7Q7b1JbBmjQL58&#x2B;AIBLfspdTX01n2OWVHitNbujxubX5&#x2B;J0sfADVVK8FtCQ7zu7lu9yxpubXfS/rNMRrB8VIAH6UbxncNsDXrxSZfE&#x2B;0yMxy&#x2B;rE7&#x2B;rlnbCrLOzFkvLL8uxFWhbsSpqBOv9&#x2B;zxsRmEhEhps/QUeP9dQ7ePESrYAN0CyZNmBAMaHbC9uHSeFsuE3e8quXHbi3/KRIcr1zrZE021LMNS1mJ0fJZgCq6iXGWH5NLEOjOd92QxKr9qJrY/TSdnrYHIk8w2PaZcXPjdvS7a&#x2B;yfOPCr238VTdm1lcLwyYytiy7B6c0UIlMG9C9IpmVgfudk16f1HDzzgGV8RmCGlvSheLtyWcbYOGEX15xyzG6FwF6dE/UdCUTFjOr7OaFcIon9vIGkPXeLSviHUOgQmC9k3M5&#x2B;NJs0SIqvYatFVeMuWzu5olPj7zI2T4/UL8XdqBBMm3ACJLCo9Vsrd0xgIN1Rsc3irYvyLZX6NmiMTV6ClTCGVizabbwyZaUJ7bgCkCzHunrLDJL4HTVnztriT/eZTzpPVDcLQC4uqXrJziGo7ZYRkKiyGEcVTpxqhSxbNvmvaSnk4C9U1vtfK0Ag/nq6QMAeEBMOzN8S3cKRthHu7rzVfppb1Xk5WFkF2BhGBmD7leLmpQ&#x2B;or8Ln3jxM/MiK0bu9gyGL4PA/8/e3etab2QHwuarlvs6utsNCB05nagDhYLC6Wsw2nAw0WAuxLDga9CEDYUKFE3qSBDQVvd12JDfL6DNj&#x2B;JPsVisKlaRzwNBOO853Nzc3Dz7LNaqtQqK8sF7SiDwu7jP8evF2/GGd6dybSKR5tfkYjbVOndS4h2M3KeL54oSH2iTxWXT5jsV&#x2B;Iyt8/H7hg954BYybcAzhYtFFuPOyY3X&#x2B;nI9pm95GCI5bRBZEnSlcojKrlznRW99R3U6xoQ32KzlbfNWHOAxbvyYjXzq8F&#x2B;ozb&#x2B;P63xAUbn&#x2B;Rh&#x2B;Wlb8q8BMANKVO67zN3Uqz1VRhCKLfd6pmzXSdJwJeQvdI4LFixp0DYetiluuUnKvfMye7jMm29Tlsfw5dgnXLlMe8tIe5kmDLeyTJ4q&#x2B;x8O/a5udbYJ/tnAGAl6jcq7zE/hcFN5X/lFRo/9V7u8h4eqk1ItDY4MY36CW/BfXFLxIZr/6bdbbB6WFr4oxHFT4b4xG6vIGM1LQBL3V9KYKn3o4uui/Gn6K9ac4Zj&#x2B;3wAE69oVfmdz/13X&#x2B;hG7sn5foFuX38BYCzNqOmW44kUszfyvovIcuKdIZZR07FXcIBoTflDfoN5vcanMaYPnPKdbzcO6TxqXs84UDj1LQB7xUZWr0wCAuEpAnrS1W2t&#x2B;TG9M35Bv3e1fB4kTecytQAHmOMTK7PBjsUqISOn&#x2B;B/GGh1ZN1ged7PoMdXdMXbXm9rDqtwiu6f6xaf4bk&#x2B;0m&#x2B;cGhj/1PO/YmF7&#x2B;zz7MsOn19UOVCbTBrxOxsxZ5bY/RZ2Kic8uhDY9quYpmh/q/NXttdSLXBRhPfJSYUSMjO59p9I&#x2B;fAK/O/LEAF3bC0LqRBeb&#x2B;09rVnb736O85&#x2B;qFM&#x2B;02OQ&#x2B;V9dhFlouu5KXq2FvkPu0vyOZUj2sHuP0sPruA&#x2B;nSPBN7oYjD31CHvddOYwOywcIeZvZ&#x2B;OrSEqt5QM/HSRftvcePFiA&#x2B;9&#x2B;5Evr/TrpV4NtkU5NEY3cW2uvEYBDLcSWhcLjUWvBz8XjmaK&#x2B;w/1UjntLOHxne3&#x2B;BtwsEqFmCOpHhLc5O4gxs1sI7GG7D2MgRPmkaNNApmTbgpfZyJ4HKp72Hzz3gVnMKl9fnZ35yYu6rA40c713JY/MdH4JHFT&#x2B;O8JJhF2LMR&#x2B;L2iiljvrm5280HuqUE6Nq94UHkjKtTpr9ZzS7fe/bAFhubZUVNm3cu4cmRNQ6LHLp4szbv6wN5uPJHtGs9diEVB5SmeyTwavNkUvI9cCM9c&#x2B;rI2N2i/roXaRPGI1NxsLB5tcR81Cwu1PZbygCwJ28Dq8NmwvcuBRQ5WeRwy6KdMxcr0mV5d161ltt7Xmnj3JU0K&#x2B;GDpeVfq8DLCSfYxszWjcvLDVsfzp9ZqR0oSaYN6EDldbDi78AXZVJ7KZmWQ&#x2B;dI5Rqd33WiSryixWpwD3jfSbZ5dUVeFZubra9YFxjAs&#x2B;21T/D5n0tCKLgIXBeB32GNEVy3FxC66tq0d9dZeYjjivnwSHiz8YsS80sOT1f4PIe/A5CL7pFAN&#x2B;LXwUqz2V7jsNpp85DWXWUeEM/Fr118mDyb2twltN/JKH5dusi97e2h9KVLIzY7k5y9qBb3sXu76uK2HIASKscVWVaQaqqLXca1r8LL9w5HL/wBwWFT7yw0Yp5zesCv&#x2B;aGinwPxJzCQ6vMxBdShpg3oT9HJvHtJoMNDitmm9wgv4/EHJp010lIysGXytfGGG61b3P6bFe6dklZAudd88ux&#x2B;AGjZlcjn8LF1WkqGaw42O0Bs9u&#x2B;6sbdBoaeeXuZhss3fdw5txpOunJYF4v8e7woDjfEPP/zLWdQWb26w96PBbxCQm0wb0KUKvVkO78AjF0/qMYzOKPKG8Ekn6kmv5bXih702r/DFw69fD24CAXo3Jl2yBwldTOTai9vXvQ1q5qVynbfwe6qfJBnpUHqjw9z89On0mDvBvaU02rz29k67HBtQk0wb0JPNfoOl69siN9uLQcM9Eh8W4a2nKkc&#x2B;KvmxNTV7YOR18fY4e09UVx1A1/Ymb0WufLO3z7QHXrdXo7a3/ani/vnAbnd//h4zvE7Luvu96M5mLjP&#x2B;tzumKUVH6dL4NNu9Xe4XxxnId7Z/zoGuybQB3Wsk/xE5f61mprCOmNXawmJOQiMn6uwYyvo&#x2B;yihM18Jp8kXvrLT32mxlgPdY/7FI&#x2B;PPRSIyU7Mas4fpIch3G3ot68Hw7aFxygJ38azt9Dsw/pVv4rEsTk2PL4vofNU34gbt8cvcBAJwznwjcyJFc1G&#x2B;0vSnttCzuQALbpB5XutuvNFoQf/nFNwfb2&#x2B;e4BxcewMMcjv2d6qbQiMiFedZ/19YpxuzHluDwMBLG2fc87BYAWnZ25ezNZPk8WxbeyfSJN19CbPGoRj70YtS/MUm78Y//AwRQiJo2oBubFSR7QXO40Co50trryR4eWN/rb/6eG&#x2B;zIE97sCck7x7nZl8ncYceYRW44sL03HeDlDgPFXLu9pe/iqYbhMQ0k9/5Z/3WFu2JeqYyBMImBjE796u2NMBwWpa3fshIf&#x2B;zXde5AJAwi9LCkHPJhMG/AQp7oyZm&#x2B;zEzMQP7e3hNszLGbwFQpwK48lhSdi8yQZL6p2OmIBcK&#x2B;Mf1xi2gDkeq5cYmLvw4Hs&#x2B;q/LKC307ux9&#x2B;hC3OMKpGQaRW7J2pSF/9oMBOKR7JPBYMXNmL96xJwdwi6ducEDkuvgOeP32c3jkG8fw89/QxU11zJqC08abG3R6tQNQx1P/TCR0Tmsn0NqsYl&#x2B;3g4vfW2Aov51XTWVP/d1vxNlbzkB9bcLDe5H8sZZR5DsV7sNf4LgAjqlpA56mcqHYumXcvJlkuLFk&#x2B;DhL14TdbnFm&#x2B;lom&#x2B;qlvCsOZnjDJe3P9ABCQ3Ha7wX4JWQ6phRrxmJq8&#x2B;PWfNi1m&#x2B;YgWXsXbfVF46ceE0xv4jY6cS3r2GR/sbEuhxWfg&#x2B;o1whwW0SU0b8EDrRn91JmftreJ2cbe3TyvLJaYRR9ornb/FTXUWEu7fLvJ62Lt4FgnvsxfYM35zAWhNePmf&#x2B;GqAOn&#x2B;nel&#x2B;vdy1LgHfYmbyjEwL3ytJyNnJj93cNUscGNEKmDXiaRdu3yveo8f0Swxs89dY6nGzL9aqbSraNnvqGNms&#x2B;gJjrc&#x2B;B60xh3gADkEv6rFI5IIyc5ZczGTU3F10e1OJhwEvH6keRyvWImhgASDu2txLa5cczUzz3vSedUWNI&#x2B;1wPf86YAXdA9EuhAoU445WKy&#x2B;NYx8a/rbMuFLszf2bxv8SNPF5ESVj7fk1bKtrkTACjh&#x2B;l&#x2B;ZmD&#x2B;RRSOrLDs/uwjcdYWepYVWmehUSTAAACAASURBVNCjcr877wnme3mlvRwn8DZq2oA&#x2B;XI&#x2B;lNqfQRq6UduVJw7N39zYI/PTGNoklZIyS25nRNj&#x2B;SeX/5x7xrLQvPzR8uvxExy7Sc2h4AatpcCTjmz2KuGGYKk84eQMDi4S1HXIfFiIsvgDoCt&#x2B;SVj4S&#x2B;VnAHmMi0AU&#x2B;zGQqv7&#x2B;cjlWs6lzDov97yGaFnrszE3urxD8tNErBeC/2WOfKBHlkAcN2VPzTzhwSipquHeP5g9r7TkeQ//YHW98JXCNicOkBNh38yEmY8A3RKpg3oz&#x2B;FN7O0D3IFJWBln72bcye1yZSbW6460MFrhxq&#x2B;ORUosy6zwdZrtGb9xALxZTMR1S7ItbxOLLLXsF48hjWFouCjvZDv2nFoLY/1F5MNNYQR6IdMGPMQiubVX3rSnXNlTONkWaR1chteTf7NxqY/ASb4r2ebeoJoSvV&#x2B;8fQA8xl7cG4iRikYye6Oo8c84b1&#x2B;x96iYUD/7vcBm9L6eDSbMgDTzT4&#x2B;Y399As5nN7/jdDKgwb9hNNNAXmTagb&#x2B;FV0OK7Mm7&#x2B;80pgFx4suNgvcTGOcPb1dm2zUm29lN34zb0hjLtOlFuFcurcpO09i7cVgAoCf27i/9LFREGtzejaDP8W4mvj0sbik4XvVmI2Bg7l&#x2B;rVVUZogY1uave8AdOHTuw8AIJtFZmVurHOK39W4/dlHxR/PUGxoPmZ67NmCvxbMT&#x2B;ZmZnRxthfv3ZSbbCFq7&#x2B;vMd6fCb1aFpwOATRX&#x2B;7gQCyDp/9Taf5bAW7dRTVHstC4ex6Lw3QwtRK3Qq4Xc8Syua97hS9hf5Eef8A91R0wY8ypVasVMTTk/ts8Tq6NP&#x2B;Yx6e8NPuhO&#x2B;mNAB5uby9YS0VAMADhP&#x2B;cXenBmNHz/tqeaokp3oBR/VIzv3ph8/46p96accJB4CEPG6YAXkVNG/A062Tb1HAmJlzenGraSBFYiaCzkZcWI6YiLab0bfpnF6&#x2B;aGIFMavbfGpcNAL24/W9WlnArV0&#x2B;CvSqK&#x2B;vOx1h3gF8ezONTb30doROAjJfxrtbfx9M/w2gQvt/dZtPmhGm6xI4sGPJtMG/AiFwO7mre78wRh8mPj9ZJ22lxrbZFMDb98wf175BqVM84FwCNNzdIv7mQI9nvMMqkrcgw9ZlHeRdy46D1&#x2B;5SATLFqdv2rpZShkb&#x2B;LsLSs7vM0663b4sby54Pr6&#x2B;wBd0D0SeL6zUdphn5aW736nBcnGfy76Tz5pheeENTxg0&#x2B;Gwnd5NADxGTDrqrEChWN4nCv9F7j0OFGxAOb1/Ptwu7e47sArG4vP8SSMVwGvJtAGvkP3GNSamvPgU62M&#x2B;1RMj4WC6i26nE7I3ZjTfwOAFAMDwgoxOfOg7fd3IOdmL/7uL0iGv&#x2B;N/Qw9/rRn7ZO5L3VnrzM033TuAZdI8E3mJvbYazO4nfw/WWjIcPL5HPW&#x2B;y5lzD3sGnkdIdgnOJV1m/6ldasAPAMgcApOYLdK1yo&#x2B;Qc37bmaCncDnat76fcOw&#x2B;XbyfXVvvdhcqpFrd&#x2B;gBIFPpMWWezODD0&#x2B;79wV4Bpk24F0CuZbF8uOBkrLFo8Ib5HVx/bb1A7MsntGIxd1X4EU94/USlvAuuzAAyKvlqUuLIdES&#x2B;bBqrzpLPq9yUjCgwasF6otJLR82qvXbVFn8p6i3BngemTbgjQKFXDHzrfaWK29znul6QtnhWhr9Ci/dsRhRavDN4i4uBgCKajNKHK27cJdbv62cCnmylvOm0I7rU1ETfpe1H6xgfUM9/9HmQ/YaeD5m/AFgzjptwHtN7QQzrgxfIWSMLLZjZJllDt/0jJ8AANC161Hl3oo&#x2B;dYLk6b/sTxpYUqgC0T6vMv8VntL/ovRc6pzJ8OpuPtOAR1LTBnSg/QqkytOyip6K9s/2WSbNvce6YmBzUu3h8oSBbQDg2S4GTuHqvWq1fWmvIv5RlYsUhbL0okTpZ&#x2B;D63/ydFcavLVbKyGVzn84/8Fpq2oBujBPZCt1npoWD85K4EpNns0hbHfph0wb3CgEf9jIZZr&#x2B;AizfXLR8A7Sga1l4XrkU4NA7pLsrL5j&#x2B;9dnSxDl/FxSVdm3374Eb1f0fmz3jxs&#x2B;vZ0t6OQFvIzVvsMffp4xF4JzVtQH8KzSG9kmx7qpbXFDmrhenVFLKYzXr91s71AABn/xouFjNePHxz/L3CH9xTTxETQoTXPC70isYnFZ/QhUDtVPw0uPUvmlaEt4ip9DUFAWCkpg3oUiMB3DQfuYV5W7lm8JkJyPPEV3a6/gEo5PZYMYv4Lg4xr7eRcxJ/GJtd1hfTfcJ7S75rEJ/Qu8WVH5nYFp/fzvkHiCTTBvSkcoRX4uluHFC4uORGIwlF2LT32&#x2B;rOEAAK2cwwnS1uqB9kbgYG8QeQJYMoooYh&#x2B;Ivgd6Qdpz6fZUaBN5NpAzqzuZxYa&#x2B;u3hdUZTdgbREjYVcL0w164DXiSxbvpzQWgTX2FUuuodfPP6&#x2B;JP8OFuM0aqCaYgIT5UWGcQAy3yIpnHxlPNG8kuvlhv6VegWd4dgFNk2oBuHC6oXi4KDA/ZJ8/bqpBsWw8iZHnShwXc8jFPYh4lAJR28e9sIMtVP8hMS7YNq0NdhB8Pi5Z5s7Ppls2N530gD3/p/PrcbvNNd4cFECbTBvTqcI3lzZ&#x2B;WiNovTmXNeCQBuZZwm74ej9w0NwCAF9obMd9cySxmb9mO7LyYcf/xv8MtN0&#x2B;INuww8ovQhc0cmzQbwKFP7z4AgAx&#x2B;&#x2B;Pabe&#x2B;P1mBvv8GPTRiVOuXiWptnH651cefkAAFQIBdOk5ZauP0VMy8qMpv3vleNM359/bT02Hu/sNRzoErn3kL1q0QY/Dx9s747euwAQT6YN6MY6&#x2B;FssCLFYlX1zsyymHZ66017voX7KKmY9icNj2Eu2zZ8CAICFwzHoQL6t/Vjr&#x2B;qSuQFxdbV5X&#x2B;FnGwwi/0vjz0OxbCRnt/To00j/2JeI/l7wFAMl0jwT6FtOAomiweOUOee/uos76bYXu7YXmAADxEmKnZsOtwKy4x0g7&#x2B;XudNpt9K2Eu733r3q1o0cmyDEkVhwDEk2kDerIIAfeK2AIVVyVcvw2ofMC5iNQBAGLEpKDCDQwXmg23phldex3hEvY230N4ml253NV6ueJDKkh4hoTis71cWiDlLM2W195HpXMLUI7ukUBnzjZprHPvempkJF6FNkG5unYE&#x2B;mHuPQsAAHN77dCfEUplWb9tsbfANu1EoZud5xce9l7ToLRrbH6XF3PPu7e&#x2B;w&#x2B;JuMXAMfgWSTV12cw1KeC8ATlHTBvRqEcTHbFbB9a6M48MDy86t5Zq9GzOccWoP88U2TNcFAAgIxH5dx1HJsfEUQIbTadXayK8PY11yF94eniemuO1wFfC9WlgmkTfU7rsBbiTTBnRjL&#x2B;yeUlOR249ajkE3p7tWLs67aPNomz3hAAAtiJxo1d1g9JUx9CtrQSU86nCfhymBXBGvyJlc5r9EJRY&#x2B;IKMSp1eWDqAOmTagJ5t3tglLIMxrrfIe4SQ8mpD2vNWSbaUHDgAA3iC8HlvyTqYWYd3JWLOyvh24K1Kdl7XlnW0m9ua6phqTKlzbFB6duJgAS36stwngLJk24AnC0ecioO9rseW7bkXmJ20xkJGwxkahdewAABq3GVBtbnbqp3Vai99rHQYvXlRgctgDXv7c814Rt4i/r8yeNibsSj4&#x2B;8oNx&#x2B;lHMZdD&#x2B;OAlAg2TagI5dXFdsWi54/l/O4ws69XTrUYbKx3xlRrb7MQCAsLFM7Ww79N7FBPPhaWcx56dCLPq2N46OHDaDCSxbsKiHc1t3o81Pwvhs6PUPUgAOfXr3AQAc21y3bO9HF28AbunGE3iBC53e3oxn9WLnHDcAAEDXIisJTgVOfXVrWIs/5sOx/vVJuxJ/nrU3L23qbJl3fawe32vuEvjdiVy&#x2B;a3OHZFFuZcdTb1PNT0uAp5JpA/oQMwNrPufucD358CJqbh7WEs7J/I0In9XAwMFiTqW3BgB4kkUy5tSSY&#x2B;sJZ8&#x2B;IlPbOSeSra/Mk5B3Ffsx7TQsCl5Psy&#x2B;3Gz8DwvXCWbOg0zyPhIAEYZNqAJ9msbwsEo4sf3T7pNW0nmznFNuPjvbfjqYNEAAB7YoKiITUu6jSUijwnfSl6ixET/Dd&#x2B;g0BfXEXZnfqIiPyLkPw2eX8BrrBOG/AogYXT96LG8SGbiwPfsn7bY2yet2c3yQQASHB9cHPR4&#x2B;EB4WveAd97z0bG1zK/2Tns4QGT9dJrZ4UX&#x2B;qIR3iaAG8m0Ac90ar3fmHRa5dvXw/h42uDeSDomlE87wnXrJLcNAMBTrXstnF3AbFPXCZgnBX4V4tiu32uKCq9uePhwd2HJNieeFvpV9TYB3E6mDXiseaAZ6EWzNxu0Zlg8/Ly0bn2QyerMaN5bAT68weZDEm4PDCsAAA8wRYN7HRoOH775/VMLv7Vmfk4eMIhc4lU84LTQmvmF6gJLlutTN7BC2/xtekApM0DvZNqAJ8tyW5737iLheK60YWzB4t5g78jXt3Pr9dv2dh7eBgCga9enXg2PaClZSOUzkzHftmiA7/1lLXBVBK5811IJV86qdwSgfTJtwButb27Dd7xpDScvOiwUyyXvC9mbi532FAlzut2EAADPcDbwe0bhV1i5F1g/htzsANF1DSJdiL&#x2B;TffznSWXZz&#x2B;f15fcAyOjTuw8AoJ7D3oxj14XwQxaP&#x2B;uzzL8K9eq7E0&#x2B;vjuSLmpeW1efxu2AAAIuWNBodg7DptMLQdsNVZ8KzOGTi814D6XIHl7M2mvdIluOWPa4BXUdMGMAwRTQjvWmp&#x2B;vTpFWn&#x2B;Yu/pPZoz7k5ctAQDo1/V26HsPf2o/ySwv6t4StxIq9OSgZXsX2OLzwRVyl/hFFsLbA3AXmTbgpfYaQq6/GbO3G8PcLOt2FBW5pLa29QAAAYGE2fRFICjaG6XtPfuyeVpOvaJ2KkLqHEnv7zinbE7ZHGa/OPPrYX5htPN78RhTtvswqbb&#x2B;/iIbOu3B2wTQDpk24L0uThC&#x2B;cSWMK8uezw970QYzy7HFPG8JxgsAgJdYz2E6Gwjd1e2gR5VLwa6XMMaTcnuhvQtscTHI31wXLkFLvhP3NgE0S6YNIDFCvXcRixLP292dtlsLAKBl5YKri1Vcgf107frLudhlIeM7nj3fttcksLtbALJIqKwir3UWP&#x2B;aXcbG0BADtkGkDGIatyX2LOcKbUe9eq4061rF1fLQd086xmislepusQgEANKJC24CLj8oeid1rcwx63SVv0&#x2B;HKzYHmb6VXbi6xq4S3Xoz9DIveg&#x2B;ulwbmF8w/QNZk2gJ8Jr37RmvByHeHDbjOIT7t7P1y2BADgLqXnAM1nUJ2ad9VmNJjR3lS5LHurnHOq&#x2B;X4dvi4x9pM8/nOgvs0Ph3Ai8w0fyACPJ9MGsLS5ZHTLkteB31wT&#x2B;xblntpAAADQiKLJtrPRVKA864UOz97eBs87ezEz9mjc4a92L/e5D7BoDrmXgat7UAAU8endBwDQqMPby6kLzdm9FY2kf/j2m05vjNdHfuVE9XseAIAH&#x2B;&#x2B;zzL1oYVE0Ikxo58jqmSHLzRK3jzMph53veCMpxFa0tmmpm3&#x2B;2CtwDgYdS0ARzY6/MwRswxc9Aq34rfUh&#x2B;WZUJ0rhUCFiWJUm4AwL0WgU3pSrJCRRJ9xVTrQfOL52RzhbPA83YhfE7mhY99vS64XbimUJoN4Hlk2gDSzee6noqVKyTbFuH7Ou2UdsPc9T22wQIA4C6b07YqpNzCPz074Nt1HJVrWtj0da7dXnd91D7mVbTwSqGEvB9rgd9HOTaAB5NpA9i2uHnea/84T1zF77OaEktKdD3CMveAlwAAtG9d0Hbjs&#x2B;c6kvbjqL11lxMC8qlp/N60rRaGzrOM4M8LAdt/i9lzvUfIa5U7b94RgMezThvQgYSisRIHcNF0tz&#x2B;l7hYrvYVHYZJf/nzibd4Vzuss13FqPbz1Y8Op0FetOAIANKu1tE2M9uOoxeFFHm2WF5Vx&#x2B;eEWSLzxEuGPtbMf1L3/4gNwipo2oBv17&#x2B;7CbR/iNx5t1oHNvxMuFGvz5rbaUR2uIXFqV2n3PG2&#x2B;BQBA48Kr9aw3KBdyTFHQvHnDxTjqMd0Oco2Jb&#x2B;6n5fNz&#x2B;ML3qgMf89bD3kU&#x2B;zD4kKy&#x2B;&#x2B;DkB3ZNoAQgIzYaemHKcyN/dG5IGXE39gz2h8kba0hhsqACCvHsOq8Hh0vyKj3MP4f6&#x2B;VwqWDK2&#x2B;v00bMAx/w7vNyCbeHe5e93wWAd5JpAziQkE67Irws3HWBl3N2RnPCo8o5dUdU8&#x2B;kAACLVjK8KRbaPiZGynJ9FyD3F&#x2B;TXzUhlvZHrMCkNe8b8Ffl8A3kamDehVd3MnN29xpz4Ve4F4/QC9u7Oa8KjxNV48tx2dJQDgXjFhw2b7sqIR7/X5ZHsH1l2gvinQUC5hP2uBUzSdwE7PYaeHzcuFr9vIj0oXP8BrybQBVDLG3OsAffrnXX14SiTzao4OZB8bmm8Q8xL6HQQBAKpJiCjiF/S9Llc&#x2B;6Ydvv1kcduAh7QdRgfg85sinzc62mjy1wVlFZ/LNF7Vq//2FyanfaABY&#x2B;/TuAwB4qfEWdy9SXwxS3HswgUfFNKa/Xj0WcyRXHr55hPGDRIGdAAAshMO86Uf1x3OzJNvWh/2YGCk5Pm9waH498y95kbb5Q/ZuDZ5xAfBO42/H5rUduIV0zQO8kJo2gFLWxWrzNdhiRlgqy3I/cO&#x2B;i0PGL2Ie3OTxg904AQB3z0KVOt4DscU6DqaY0189MwrrId4WdmtjThaKLcAdybNJsACyoaQMo6Hql1Nlqs5qTRmPSUc1Ox44/sXuvwh0UABApcjJQfEnQ4ZDuYdPCNPGhZlrLhPbNX/7FYHjzFC3&#x2B;2ULAmXB/sXhp4x4i8xBq4IiXXGZ6eBHu/Sh8gw/Am6lpA6ghHMqfWot&#x2B;vgRa&#x2B;M68kMhnWUzCvf0OZO9Iwmd&#x2B;byqxKbcAQF7j4O/ewmB7CZ7DhdAyHuG0z/jdLl5OzaV8K4h5sw6D/CtLuF23eDvCiduEVvOb/3zGu8/tKndzHX&#x2B;XDz&#x2B;&#x2B;5IkBXkumDaCS9a1muW6NLdiblF15hCXQ2WO&#x2B;WnuFIwEAGCX0uw7n4XIe3Bnx0exdU8RKm96U8FuTHPnfe5ZOFfCF9/CMt5vHCCyXvvnNQJHuNGu2ROtdADqieyTwBL20RA/MEo0vaMt6RBtijiTyMA43K9TXaM&#x2B;8a8382Bq/bACAToUHZ&#x2B;dfTxOA5pmJqYRi/p153LsubhPVNGt6g2IKYtbbPPX9vZ6M5G0Wn4RZ7F17UxGbixOAQzJtwKP0ewua1oxlPihz10TRvs528om68QwDAF07FSxtJs82pwoNP0/RLTYoFKFl2e06mdTLtLmw&#x2B;etavzWjU/Hk3vtb883Nu97eIqm8Pjkxq2d1fZFw0XqqQeSKa9NmkdnuxcPXPwKABd0jgQ4kr1fcvhLBeukTknGEZVT5HSx6g/SkpUcAgGrW8cmi6O3sDgUkd0lelW1v&#x2B;736tiwiu96V6IwXaDWf8Vl4qlNptitPAQCRZNqA5&#x2B;h0GYArazaEFy0vJ&#x2B;aefPOn80dtLp9WJ1N1YzN9wwcAwKZwXBdobhbYZ/2o4zCyaqdlemmlZ3eV23nA9RcVqJyDePO10xYFspvlpABQmu6RQE82O4oE&#x2B;j/00ogmLUe4uKNopL3h4jDCDWfC713j7xoAQF5pa/oe9vc7nKF1JehK3u1h7PqAaHDx1lx8OZtv9GFlT/YbouxvSu/vMr1Iu9d2fQIQSU0b8ByLu/HNtR8a96Q4fnM9iXnV2nr64d4e6stYH6mfJACQJq3b9l7J/jogmX/ncP8JnQA2Q6C8QVEXIVbePgqbYeotAWeg5WmWI9m7a4C1wwURz15CT7oxB6AOmTagM&#x2B;FFiQNTX3u5PYu8Dz/btrG0zSdNS3beuITbpoztR1p4OQBAR8LrtyUIl75liVVKtAfcW9Pryj770mbXzcB9R&#x2B;SRxD/8VW83pUXeccu3ARBPpg3owyL7Esi3PSDZNopZ5aJy6J&#x2B;QBUxLsLVwS9Nawg8AeKe9GGlejpbcgbyQvLHcNO3pGbVN12P4FkLlPeG7tkFcTW6LX4cGb6IBeAnrtAHd2FvLYWpOOB9umKLnw4UrWhZYlG56jW2&#x2B;wPDCG&#x2B;Ek1mauNFzLWEi5pe8OV9QAAJjkmkY2jyQzHNbRc&#x2B;09&#x2B;ymRsWJ3qr2ERs7VlfX8hvZudmhK5GfLuNkzPkAAaJCaNqAngQlrexHzM1Ia4UXO27zzDL9Z4cce3v9Ue8m9XzkAwPOkxSfheLJmzJMl29dmAFxO8kJ6t6zflr3FSGCHb7sSCNhsfrNeKNE1A0AJatqAzhzOeXxqi5J5lV61ycgXHQ7ZrG&#x2B;ENgsT92oZq1W2BQ7j7K4C16esHgAQKbny/rBLxNUji3v2hIOf1zYtFgMWRE2SS8dObZZ2JMlv&#x2B;p75jcPhxjxJTBOUwSUBQF1q2oDunUqEbOY5HrPqQ0f2Tnh4suG9XfUzPvX0QhbjRC5CACDSfBpWQpQS6AbRnU4P&#x2B;xaHAWedkzm/aNOe8anTKzkr5r4y/kcAkEymDXiUs/dXi&#x2B;17uT3bXPfiliM567AN5mJ&#x2B;Yviuqf77VeE8x7TW7OVCBQCKyjUJqWYkebH15fqLx1uHvllCwRsD6eztTyeC5Meb/zps3hate0Wuf1r2EAF4K5k24AnCE9ZOBdO93J7NO84vXmDjLyFmAnX2pR2yy3KHtvdy2nmZAMBrlZvcs45gF8mk8PMGFgN&#x2B;jNKLrk3n&#x2B;d4l3LLMn7ME12Nc7DQzXgna1QBwF5k24CHCuZnDfFv8QgJdBO6NH&#x2B;FejnCxzeb32zn/2ZtJPnKcCACoI2M4MQ&#x2B;3isZdmwccWEZu/sDAP5&#x2B;n6Aucn9vWzmT85dfakXPWoql&#x2B;eOP1J8DbPhMAaJBMG/Ac4RqvwELZ4zcLNWa5Sy&#x2B;z&#x2B;dZtZC629JwvvFdtnYn11zEzsiO1/yYCAO1LjijqB1TXPW8l5qLd41tOth2aDv7GDvNMIjvhX1/EYX3v/6TfdwB6JNMGPNZmF5HktE3OIyumuxvj0WZyNNc5r7&#x2B;oe8JTT693L93b13UIANwuuRd3oKSsdCgSGcqmxfNJR9SWzdldV/a2Gb7e0k8yvJbz4U4e8xb36HoJ7CLRO28CmXZInd4UA9A7mTbgyc7O/bx4j9eCrvsQBioOp68TXlr98YK0B8bM7uzlOgQAbndxNd9bMjGHS7itv15rvHrvilyhfps3C&#x2B;FUYlqSmDrOnvzx/d3rChvoRhP4fsxPAaAcmTaAZ&#x2B;r0HiPmsCPHF248A52efACAhc2opkK1fXJN3t5O5n0CAg95W7amtai1kUo7ytlL/19v/tnvfFMAnkGmDXi4eQP3hMh70fk999GV1enNxvot23sLDl/dje9d&#x2B;JJLeCE9vpUAQDsu9h4MdJUs5HA138MHfvb5F3uZwhwH2ISiIeK9y91FvjRxcnfuyt8DQFEybQAZGspTzXyZkIQpyfPxgmpLuG1&#x2B;f51si08cAgAk6LrNeJo3ROyF3tN1V/Nb5q7Fb/mqC/vxvJsAdEemDeBYlvY1XLFu/hO5ZfiB1ZJt4SXo5l1Tzi4uCACQJrn6v37Xh73F2yIPINxpQEjfssP2JAnT18ioxNn2DgLQI5k24NUWYwTZb7PdumeUdsc1JtvauVs7PJLwAuAAAEW1HITsZVzW8fbeWlDJ3hzVn81r1jkSqdOnavkjCAACZNoA/ku5HpJu9nJZ3Hfttfg/HFu5d/m9zTGCdX&#x2B;ew8cCAMQIzDp6ZGhRLtfynqg&#x2B;sKhw5O1PoXfBEl&#x2B;dinmDmpofCQBnfXr3AQDc7Idvv8lyVzZvAHh9b&#x2B;yJOb1jsu0wWZXrrU&#x2B;wN0awufE6dwgAkEtg3k84ArkxlIo8gPkG8QHVw6L6XG/Tej&#x2B;BbNxCoVN6&#x2B;xVILs/4XQPg5dS0AURVSh0&#x2B;KobpltUEVmhbvwXzIZj5f3UO1Y0lANCCqaBknntrPHANr&#x2B;A1XAu0Gn/t8S6WCkVeBrecrvBayNzibHMO7xcAzyDTBjAMEUttX9nt&#x2B;PUi2ZPxWdgTnlp72LDxxmSbG04AoCkdBSeL8DtLsq3EnUJfYlqd35Vsi1m/jStMGAWAQ7pHAuS0uUKY&#x2B;71bZGm6GNhJ3jd3b0Lu&#x2B;CzTYbi/BQAqeExfvrRXsdcp8QFRfXz3jshTt4hRm&#x2B;rNTmV7l007eVkAKEdNG8BVh/P73EXUdLhg&#x2B;&#x2B;F9eNqE5dLvsqsIAKhp3vKhuzTGlQNet9CcfvTCeCzy3T&#x2B;cmtbdJcRaxjfxhb9KADyeTBvAtrw3hPN7CbeapYVP71gfFpNvm7aPfN4Sd4yHiUMAANbE21lcT5VNsxK9I/1arIlwsZnk4tY4w/EBQANk2gDSuTFoVuTc283NWktoucwAABLMC/LyRn3Xkw3tiM&#x2B;ihQscp&#x2B;/vneoHnCsCy/XNFzXce6zLAIAHk2kDiHKla8qCu4s61i2P1mVqexNsW&#x2B;sIKtkGANyu006Sw1YSKGbEP9wRce&#x2B;fj7EZOYfPW6eXB5GyL7fmagHgSWTaAGJdX&#x2B;&#x2B;BduRacqPaxMx&#x2B;x7YAgMd7ebXK41948psrfH2k6&#x2B;&#x2B;pCwOA55FpAzjHLUHXHrDsmSsQACDZxVCq0wDy0GYurVDYOe&#x2B;9&#x2B;dTz&#x2B;Tzz5pDhusbDb7qdAeCRPr37AAD6c/HewK1F48Y3KHzbH77DLM0lBAC0oNOYZAr2NiO68ftDRDQ4bT9/VMBe3/KWVQh6ezwtb3PYDuTw7fP&#x2B;AvB4Mm0Al0w3n1duHua3K25CSlsPnQSmXsYs4HFqJXAA4D3ek0K4dxJSmuvFbZt7WJyH9Wpn3VlExdP6x&#x2B;sUY8wF3&#x2B;95eI/F&#x2B;xiZcgaAl5NpA7jk&#x2B;r3iek11tysVrE/yerwgcnRsb5DF&#x2B;wgADK/Jt3X6AmOyZXumdzawfS8x4fgqAocaWbE3RJ&#x2B;9RQJvHoF3ccYeZu9j6myjSAB4Leu0ASQqt66AmZ63O2yQcnYnAMDLWZLqqQ7jxl7e97OJk3nNU3KLjr1MZy8n7Rk2s6SBd&#x2B;GHb7&#x2B;RZgOABZk2gFa4Xbnd/C1Ivr3PshMA4AE2NPYDAAAAIABJREFUC0SEB83azB/Eh&#x2B;iLbJOYMNJel8Lxl8Wpa4ocGwDskWkDyODK/cb8sXvDMe4wezEtXHH3gQAATdgcmBbdtWz&#x2B;lgUSbzEph/jWlJ3G/HWC3h7PTL/UsQFAGpk2gESBO/A0684zWXoYcsr6HjLj&#x2B;9vpGAoAUIKQoGWHeYVpXauEWPFJb/0iMbk4G096pa8lxwYAMT69&#x2B;wAAOhYzj/XU7eV8AfD1Ay0PXs3187x469fNcLI8CwDQkfFPv9zDI738zV3PVNtc&#x2B;ivw8M3NFvsRPCebTmPkOXSqAeAsNW0AZZ1tLPPa&#x2B;3MAgDdQIPIY8y4Ue30Lxrd70S5e4VcMXdlzOXuBOecAkECmDeBm69vyxT/nd&#x2B;OHt0n6EzZOVhUAGOTb&#x2B;rEOrYVzMU5d3uHTGH8rxKHDW0WfSwCQRqYNoJL1hNb1BtPX6/uf9dRXSbUWxJz/wOgMAPBOQrgehddpzhLjPenC2Lz9kTarLKZvpNsTALhOpg2gIZs3OYdFb25T75Vw/g0xAADCgK5FJidiJsY9Ps&#x2B;x9wL9ClQzX/FOyg0ASpBpA7hZZNIlvKi429T60m5ElSECAHNig8aF0xLz/4b9wD7hLX5Y&#x2B;4p5cduik8djXmPLIu80AYBkMm0AB2r2abyyWvXh7ZM7qOySZ316LwCAOaFayw6bwG9Ke0PHZ5k/1rVBRqrWAKAQmTaAzK70Etz76d7yBoePvX5shMUMu7ihBQBiCNUeIH4m3CkPuzbKLXRHwN5SBYGfAgCRZNoAToi8xb2ebAtn1zY34F4xb4d3DQAIe1hC5Z3W8Z4IcG3Re9MpKmSzaefEBw4A5PLp3QcA0IeEdjFnHxJYKnxRxOaOqE2H7/j4Vq6bAgEATMaAYS&#x2B;YHEMIaYnGrSP2&#x2B;Bh&#x2B;vtk8bky4v4BN60vRpQUAF8m0AXRgsVRDwh7cO7VGvg0AmGwGBjIrXQvMogv8NGYPcFbgWnKZAUAWukcCRJlmktZMjWS87bGUen2by&#x2B;lN74J3BABYWMd&#x2B;Y8AgZni5dST5YBI/1y0&#x2B;NDbbmWraCQB5ybQBxJrnSAKb5b1dCS/zcPYG6Q03503Za/rkjQAAThE8PEChrMbzYksZoCsedjEAQC9k2gA2hOcAxsh4c&#x2B;g&#x2B;8xm8jwDAFQbQH6BcQPiq8sdXvVgAoAsybQDbppu3RdYtcorl&#x2B;sZvvbd44f4eZ/c53Zq6O61Msg0A3ulKDCB&#x2B;eJjDu4mL7/gjg3y/BQBA42TaAKJk6WFyJdm2OJhphxf39rz78MYtriKjBgDwElfaJAgY3mMenAvU57SUjOdcAUB9n959AAAdOLxRGW&#x2B;Da97P/PDtN7nuvT/7/At3YjU52wBAaQK8vsxj&#x2B;&#x2B;QgP7ATF8N7eK8B4BZq2gA2pN2fVJ52evEmav5wE2YBAGpKKzpZxGx7LcGFdj3K0iV&#x2B;76J62CUR39IfAKAONW0A27LfuZW4FZy3kTz72HGm88PuugEAXmIzuyb30LXx7VtE6cJ1AID2qWkDOJZ2f1v/rvjsM2orBABwL6U5LFxcnG/&#x2B;QJcWAEAdMm0AOe219Jn/s8TznuqgEtk3stzRAgAQIxCMTRHdIgI8jO4EeP06lTlbZOzm77srAQAgL5k2gCjxN6KbWy7ybdkOayVt4qrprgAA3ZkmWu1lU&#x2B;45LDJZzKXLFbG7SAAAspNpA4gVM6f48JsVHBa3uaMGAGjTOpCbT9ja/FG4iK3EQVJZxhaj60vi8CJR/QYAcEimDeDAXq/Fw3vOxtelj&#x2B;whOd/GPTYAQLyi4dNeZVIg&#x2B;Gw2LuVegnwAgItk2gCOLZJSgUUO1uMXLd&#x2B;4Joy2tPxyAAAadCV8mkdrZyO3zUKojNVRdC3tSrDAGwDAJpk2gCjrXj17t6a9jF8sSu5O3TAf9ily&#x2B;w0AkMVisa69DWJ2JU3Cwt4Kf64TAIBTZNoAYm1OCt77Z&#x2B;SQR7Wb2M0xmotP7fYbAAB6tHcbsteVFACAgE/vPgCAnhwm29Y/jVmjPlAhV8L8qHIl27oo4wMAuF0jS/mK4h7jyju4uBdY3xpItgEAxFDTBlDWZnHb7f1YzqYMD7kJBwCIdxg7HTYqn/f9uxKJieKId9jLFADgnWTaAGpo8I40&#x2B;/EYpgEAyKhc9HhYycTjHXbm2Nzg9vmCAABtkmkDqKe1fNs0KTX5qFp7RQAA75ExDJM&#x2B;eZLIEH2x2foa2NuJqwUAYEGmDaC2dc&#x2B;fZBVmlbqRBgC4qFxAFZg4FfOkpkxh5hwAwHUybUBPfvGb383/u/twLjl1Q9t4uivQW6bxIwcAqOOWuGjvGedrvMmyPN78LZ6/9dMX49ebV4LLAwAghkwb0I11aq33ZNtw5t41MDTTeFmbZBsAwKhoXJRWnCRUe4PkqsewaWqdCXYAwMvJtAF9mJJqH/74p&#x2B;m/4b&#x2B;r3G49tKvOjoms72MLTTUNL9twihtvAIBqItfoOnyIJMoj5Qry1491nQAAryXTBvRkzK6t//mAfFua0ssqXNz55sxZd&#x2B;AAwNvsxVTlUlnhKHF8xlMZFyHck5S7g4i8TlxOAMDDyLQBHRizaIs022gqbhvel2&#x2B;rM8s4&#x2B;T58fOB6KQgAgBc6nCBVIlg6fMZwNu7wOzE/ok2bRY1poXty21KXDQDwGDJtwBMs8m33HkwJ473r/F50cV9aYc2PjFNftSECAN4pXEbWZnR0WPrW5mFzaAryTyVcA3ubP8QSbgDAq8i0AX3YLGjb2&#x2B;bBxW3hqcelpeXbrty6uy0HAB4vPsTKlbSYJ0X2ypjmR3Vj/MldIi&#x2B;2&#x2B;Ev38hEBALRLpg14lDc0k5zfps5HQJ56&#x2B;/rU1wUAsDZFPiWKgTYLmMJPIcf2NlnecbWPAMDbfHr3AQDkNybbPn715TAMv/jN73768fu7j&#x2B;ic8S40Zo36cRryD99&#x2B;c3bt8Yu30NfvwKdjXs&#x2B;evrhnAIC&#x2B;TLHfPM02/2mJACkmgIyJMKVPnif&#x2B;5mL9wPGLxdTA&#x2B;YUt2gcAHklNG/BYvRe3bQ617IlpOrRe5u3eVRM2j9lgDQDwGKeSCoEoaK9CKHvFW&#x2B;TxbBLFPUn8pbv5vi/6jsquAQCPJ9MG9O3jV1&#x2B;O/23&#x2B;tNNmkvPZoHu9IifXVxovNCySPAnaMA0A8Bhpy9xOj52&#x2B;DgdIyRVIeVdiu3cWF3lt9ho9&#x2B;/D5P8cvXCEAwCPJtAEPsZdsG/rMt23e0x4OXty4zMbeAQ9JNXnuwAGAxwtkuRISYMnh02E2JZxx0aLg8U7l29YLDboeAIA3sE4b8Bxjsm1Kqi10t3jbYoGE9T&#x2B;H8wMZezfJ05IJ6yXiLu781BEmrwkBANC1dWgXjscaDJnmLyHX2sB0YXErsb44G7xcAQDykmkD3uXDH/80JduGYWg833Y4NrGoAzs7llFofXIJMwCAPetIaR6Gpc2mKmo8vKYOibssGkKWuJUAAOiR7pFAxwIdIwN6bCYZI1CvtvhnhS4u6yYzkffe3U3fBgA4ax0pTeHZ2WinXHSUsbO3FoJPpf07AMBITRvwWFMebrOfZHfNJIcy7XeKzpueJromHPl6Yux8&#x2B;MmcWQDgATZrxSLXuK2Q2MjyLPOyp0EU9zJScQDAS6hpA55gnUubl7sFSt8eWdw2ty5o29ysXL7t1ArqAe7MAYBHCkRKYxx1b2oq&#x2B;dnHIz&#x2B;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&#x2B;qjNYhTp1KJx4X/KtwEAvWs/lRU/cWr9/fZfHVl4rwGAB/v07gMAyCyhdu3QmGwb9zwm23768fvsz1LBlXnNn33&#x2B;RfjeeNrgcMs9aY86fBXjBm7sAYB&#x2B;XYlkpghtuBCnnXqWvQ0C/QkCYaoo7km8mwDAI6lpAzr28asvx/&#x2B;G6CXZpu0TdNpMMnA3u/5RzHeGYDvH0l2J1KgBAK&#x2B;1rgpKC43KLd6WpW6pTtNLbmTxNgDgYWTaAM7psZnk5n3s&#x2B;J35j/ZaTQYevv66WcZoAIA32wvY6sRIF59FIAcAQMtk2oA3morh0urbFsVtPebbFkMtgSml07hGlunJZ0dJDue6hjcwVRYAeKrkIKdaT4Ihes3g4aiPAgAAtEymDXiCKz0hkz0g37a3weI7exmyxWocpYdCAg0kD/Ntew8EAOjX2UlFi&#x2B;3j02BXJIeIUwOG8Z/TOnMiOgAAWiPTBrzdleK2odvF28I2B0QCi3mcGu/IMjiyTp6NX5j4DAC80KmU23yJrPWqbyXyWNMzbs7o2ntU&#x2B;EfybQAAtEOmDejYlOLK4mK&#x2B;bfyio&#x2B;K2sDb7Lh4O0BhzAQCI0Voea28612effxFoci72AwCgBTJtwNNEpt/yZumGbptJhq0zW&#x2B;F/1rGegm2QBQBgz7wHwLxLQThTVSi&#x2B;WpfTHSbMrvwUAAAqkGkD&#x2B;rBXbZY9YXZxvbenNpPca/hzdj&#x2B;5DqnQDgEAHmAzm3XrEaWIj/QCTc4BAKACmTagAz/9&#x2B;H3gp/Nk2/j19J0rDSGveF5x26G7kl4t1NgBALQvLRG1KIPLKxy5BfpGDhFNxQEAoJpP7z4AgAyuV7Z9&#x2B;OOfFjm5&#x2B;T8T9j8&#x2B;ZNzJmGwL5wt7tDmW8cO334RX1MhOdg0AYM8Ym&#x2B;39aPxivcH4o8X3SwR4m090aoOFmlEoAACM1LQB3ahZnRbIup3yyMXbNplBDADQpnnmKaYOLJCpKr14W&#x2B;AAwvkz2TUAAG4k0wb04WxB2LoKLVCXFlOydqUR5Xz/D062AQDQps01d&#x2B;PTZnXyWHtHOP9/&#x2B;OHzR62/BgCAQmTagJ7csuhalgN4T3FbCzbHkgAAGH6eNktIttXJXV1/umltuUKLzAEAwESmDejGlbK26wu5ZfGwfJtUFgBAj85GcQ/IVIXzbQ94gQAA3OjTuw8A4JyPX30Znza7nmAb95C3lm6&#x2B;z1/85ndnM4jtGIckEhbSuF3gyAEA3uCHb785lV6qn4saQ7XpeUtHbp99/oXgEACANGragJ6MSanbe0hm8aTitrPGOcU1x2uMmwAALHTRcPviQS4eq58kAAAlyLQBnWkt2fbxqy9fvnjbepxivZT93nBGzWGO9geSAABuEY6ROg2i5oe9efySbQAA5CLTBvQqLcVVaMG2K5m/TvNtCWMThw8x3gEAcItALq2pttunDuNwUpfiNgAAsrBOG9CfsaxtzEidWrZtlJBs&#x2B;/DHPx3m0qYN0pJ586foYvG2i6Mt86VB5qti1Fkho5GhIgDgVaYJVc1GeofFbS3kpSIDuXmoGbklAACkUdMG9GoaoUju39hafVunxW2HNjsOXc&#x2B;omYMMAPRiEdr1EunN50INMlIAALBDpg3o2E8/fj/PtyXs4TDZNu625rJwD863Lb6TZbDGiA8A0Li9cK6vSK/NoOt6l4VcRwIAwJvpHgl0b2omOebDKjSTPJTQ03JhfPj4irpoJhljHMtoc5gGAKCodXDYRaTXSMfIgMOOl9PXmy9kM0Btamk6AADap6YNeIi8zSTnX9csaFt4anHbZn1bnRXaAABqGkO4zTlYvUR6iwhtSk01noEbxa/WduUhAAC8nJo24Dmm4rYhtarsSiHavAptMv9n2s4XxW3DLKfYtcD04bX1tOL5llJ0AECneon09mKt1sKw6x0UZNcAAEigpg2orfSM3evFbaOL7R/XT33xYOazntMPqzFNDc0AUMGT/opBLk&#x2B;N9O6yiDDjy&#x2B;8Wm4lUAQCIJNMG3KBCsu1ivi1LC8q8ybahnxZDp2w2k9w0H/sw8AHQnSf98YJTIudvPTLSu9GVcDE&#x2B;QAUAgEGmDbhLhRGERb4tbScXK9uyW0x5fswoTMJwxri9cRCALjzmDxYU1VGk10UMVv8gNZ8EAHgn67QBd/rFb35Xei2Kn378flq5bTifOZvWe7tYjrbY4bQ3i7eNpkU&#x2B;NkdDfvj2m8XS9IGNAWhKy6kCaFNHkV4Xwdh0kFnSYIEuC&#x2B;OPpg26ODkAAGShpg24Wf3itrRmkhe32cuoBR51eKjzfXY9jjkflTARGOAxGq/IgduFgz2Lt2U3pr4C0eZhTm7xfYErAAAjmTagCa01kwwvt5ZXeJDl1BDM40dh1qMb03&#x2B;ndmJYBKC08J&#x2B;kD3/4fbUjgcYdBnvjF2&#x2B;I9CrI3k9SVAkAwCDTBtQXGFyrMHxwsbjt0N4&#x2B;59/f3CZ8MM/OtyWMdxjUAGhW4C/Rhz/8Xo4NNj040mtQIPiMjEvnm60bM&#x2B;gbCQDwNjJtwA0CA23tFLdt9nsML6tWofot8NOuWwyN84vH/9Y1Z5t5tchkW0LRGwDJAn&#x2B;A5Ngg7MGRXoMOi9sOm0yGHy7ZBgDwKjJtwG3CxW3V8m2BcrFwXq1Nj5nyPI1uSJIBdEEpG1TwmEjvGfbWdQuEr2aAAQA8kkwbcKfw0FsLzSTnybaiibeMO&#x2B;&#x2B;9xdB8zGLRhydhaQ0TigFKC/&#x2B;tkWODTcmdw3uP9No0jxjTosdTj5JsAwB4GJk24H6NN5MchzPOZsIW2wcenpBjGwdfHrx4W&#x2B;VuPFOHSbOMAc4K59ik2SDBFOA9NdJr0zrCFBYCABBJpg1oRePFbYfWCbN1sm0vqbb&#x2B;/vwYwnm&#x2B;wyU9pq/7GoJZDHas/xm/usZiy8WjjKEApNEuErK4GOlZvK0j87BTCAoA8CSf3n0AAP&#x2B;/cVTu49ffrX80jh1M&#x2B;bASxp2PTzQOalysY5tbZM4SknnTzteP/fjVl4c1c&#x2B;OjKpzGjGJq13749hvjFAD1aRcJuSzCzrOR3jCLLfuK9FoWjjA/&#x2B;/yLyg0YAABonEwb0JwPf/j9ZrJtuCPfVmJttrNptrS030K/&#x2B;bZDm2MZm4Mj4zfn28/r3socHcDTyLFBCRfDzgdHencRHAIAEE/3SKBF4a5TXTSTHGVM1F05jIkWQ8lUzgEM0mzQNpFeaVP6LSEyFEwCADyYTBvQrkC&#x2B;rcLC7z/9&#x2B;H1Mvi0hl3Z7ndx8CMYozMjYB0CYVdmgtEU4lxwxivTq&#x2B;OzzL9ICyCvpOgAA2iTTBrTu9uK2eb5tc5vwOvZpoySbj1qPv1wZgnn8lOe9nj/joMa6k2TAYhzEsAjwKiVybHttouE9YqK4wOJthw&#x2B;UbytEV0kAANZk2oDaEgbX7i1uGy43kxwHO6b/4h81lCmAWxzY8NBk2zofFh4ZOZU/k2wDXiJ7u0g5NpicDQ7T9j9&#x2B;/chgrx3SbwAALyfTBtwgbZQtXNzWSDPJvCok26b9v3b8ZT4yEpM/m7aRbAOeLXsp28evv5Nmg7ASEabitux&#x2B;&#x2B;PabeQAZk2ab4kY5OQCAR5JpA&#x2B;6RNtwWHtprpJlkj56abItMhp0a8pg2NlACPJhSNihtPnMrclpV8mQvzSRLGPNtZwPCcAPz5LXfAAC4l0wbcKfk4raum0kOEeMp457XOw8/3ZViuxcm2&#x2B;ZjGRcnIxsTAR5DKRvUlBC5XQn25NtaMA9B5zHk/JtiSwCAvsi0ATdLHoDrvbit3MocF5Ntz7DZE3JzzGIxlrG5zTq1pqANeJ7wyLtSNmjHxclVFm&#x2B;r7FR/8lOPAgCgETJtQBOyN5PspbitkL2SuMU2m99/5JjLIp22WZR2Knl2mJwD6Es4x5a9lC0tbwfMXQk&#x2B;FbeVcBhMprWaBACgfTJtQG2BwbUSxW2lxw4WxW3Z820Xd3i22&#x2B;RTy9rW3w90gIwc1DD2ATxDzXaRaTuEZ7sSQF5Mtsm3ZXe4ctv1DQAAaJBMG3CDwEBb9uK2oZNmkgvzjFfRZNvmBo8ZagkPVeQdyNhLvFlpA2hZzXaRcmwwl2t6U0wng/BhaCZZ1F5n8ikKjWldPsaTokoAgGbJtAG3eVhx29B5M8nJk8raRuNYxvTf5k/T9hw/2GFYBGjNvaVs1m&#x2B;DKzajNc0kG5cWcFq/DQCgCzJtwJ0eX9yWPd92MQ3WVP6vKVfybTr8AH0Jj6QrZYPs9gKwdVx3Y6SnmWQhp4LMzS0l2wAA2ifTBtS2HowrUdy2t89qxW3Xm0keDrWE97z38MjjeefwysVxEID2hXNsFUrZVLPxNlNMGGkK4W6ZICXfVkhk6DhPoe31Y1hvCQDA7WTagBusB9qyF7cNj2gmuciWPa&#x2B;vY4Pi5x2Pmx0Oc8jJAY3I3i5yOFnKJscGa1Nma57imiS3/rZ4WxfCS7Vtbi&#x2B;wBABok0wbcJvN4jbNJBfGkY75eMd8MCVtAOXwUVJ6AWYQAz0q0S5SKRvES2tFUPp5wxS3tWmRn/vs8y&#x2B;m/249LgCAV5NpA&#x2B;60OfRWopnk3o86aiZ5keRZRgYygI5kL2U7lWMblLLB&#x2B;QaSFy2izYzFbfJt5ayL1RbJs5gl3OTbAADuItMG3O8NxW1DjmaSF0m2XTQf4DCKAbQvPCxep11kICeX8OzwEuuY7XoUp5lkmzYTbIF/AgDQJpk2oAnVitv29nlLcduV8Y58B0WUw3GQNBr&#x2B;AIWEc2w3lrLJsfFOP/34/anAr8FgT3FbIevV1zYjw0V9W2DNNlElAEB9Mm1AbeF6tVMbv7mZ5GL8pcHhGA4ZBwFKUMoGzTqbbFss1ns7zSSL2sucRT72sP8kAADlyLQB9ziVP6tZ3Db000yynWGXVwnMIA48JP77BkSAK1ouZZNm4&#x2B;Uqr9Y2/DwxVmi38m15rYPDmLBz2mb6Yh5PHsaWgk8AgOtk2oDbnKpXU9y2qbWZzu&#x2B;RkG&#x2B;LZ7wDSBD4y5Wc5SpXypb2hxse4JbFevfkamYu2ZbRPMgcv7herHbYq1zwCQBwkUwbcLNT9WrZ823PKG7jLtfzbdMyG&#x2B;v1Oa4dGvAihdpFxlenna17g9cao77W&#x2B;hlcSbYpbitkrxtk4J/TAwO7FWECABTy6d0HALzOOBg3H3cbv94cpFtvPP5zb0Tv49ffJYzoBQ5gHDIo3e1n3P/4XONghzK17sSk3D77/ItylXDAO9Vckm1zn2fr3oZh&#x2B;OTDLxMODJ7hpx&#x2B;/vxLyJYSIH/74p8Nc2pX4c3zUuIc6kfObSZUBALRJTRtwj4uLsWkmuUknybvsdfUZR0MW/19375n/c69NEMBCoVK2wA6vlLIl/3WG57ke8hVysZnkvL4t30ExDEmVansVb1MserYFJQAAATJtwG2uL8Z2KjkX4xnNJOXbKktb92L6/jwPN5JmAw6Fc2wJabazHSATStmAuYshX0y8Vz&#x2B;Np5lkOev4MD5i3OxVPpJsAwDIQqYNuJnitrXFTOemJjuz53CcYnMxtnVxm/nFQFj9Urb1xkrZIIvrIV&#x2B;JfNvFyNPibeXMg8lFF4TI6FGQCQBQiEwbcL/SxW0JY3yNFLdpJtmRRRZtr59kYPbxfOzDOAiwSSkbPE/2ZpLz8O&#x2B;uCVuaSZazV502mmLIcMVbeCcAAJz16d0HAPBfPn793WKQbvzn5jjd&#x2B;M359oGNN3ceI7DPauu9//Tj9&#x2B;NzJa9UL9lW1LwJ5GayLbAkG0C87HVsQ760mRwbXHcx5Bu3v5JX&#x2B;/DHP60fPn0nLZ6c9lktcn6zhCBzXLatxMEAALyNmjagIdcXY9NMksqmdS/25gUnTxk28AGMCrWLzFLKdrbuDQjI0s8g7akXDxyffX4MyfGnZpKlKU0DqMZfMSBApg1ozvX82ankXIxnNJMc1LfdR4seIE32dpFD1lXZ4jeGZ6iQK5pCvuT5VYUCxYsFc/Jt5ayDTGEnQHb&#x2B;eAFhMm1AixS37ble3GbxthsZ9QDi3V7KlnEJN3iYOi0Nxi/u6mdQ4knnIajxyrzmLRZOBZyiU4BD5ogAMWTagHb1WNxWv5lk6acjL8VtQIzspWzhWSbXV2WTZuNtaha3DZmaN143HYZmks0SZwLk5U8VEEmmDWhas8VtLTSTHL9Q3NYj&#x2B;TZgT2DouVC7SKVskKxOvm38omhxW3jPmxFj&#x2B;HjCP5VvA6B9/kIBp3z4&#x2B;PHj3ccAvMgnH375nx//Pe2x12fcn9p5jPA&#x2B;p5GRouaRX945y3WOn88&#x2B;/2LvR8/Oxv3N3/7df/zbv959FNCQ8J18hSXZzm6fnGO7EgzAjQKXboWo6VTIt5flWjxwvtn4o80Hfvjjn6bvb262Pp71ng8PVeRZwhhnzkPKmO9wSBwLzxYIy8WxwB41bUA3yhW3bW4fo5HiNs0ku5arvi2QsQPal71d5JCvA6RSNpjs/TL20kwyzfzpNp86fDyRBXNKB0rYizPFjQB7sq&#x2B;UDLyETBvQk/U4YMLKbSWaSe79qNqQQZ3OQpRzMdlmuAT6Ff5LkZxjy5U2syobLNw7yyoy5Evoc1C6O6Vmkq0Zo0cxJMCkRBd34D1k2oD&#x2B;XM&#x2B;f1S9uqzPyIt/Wtcjits8&#x2B;/2JvTGTx/cCWQCP6KmWTY4NR4NezfnFbfMjX&#x2B;AK98m11rPtGAjAoZQMuk2kDunQ9f1aouE0zSS4K59umAZH4kRFjKNCmHkvZEg4JHuzeWVaHId88cdWR&#x2B;TFLthViSTaAOaVsQBYfPn78ePcxAC&#x2B;SffHYzaAn19BhckQVHo6ss977PFJM6yBkXfoGLdJmm7OSp2&#x2B;uv9MUK8nzWuGx4&#x2B;x1bJv7vDfHZiV5OvXJh19&#x2B;/J//Y/39wO9IhWjqSsiXNivrwx//ND1w/Hr9vHvJv8VPAwc834OgtIRAVMkhcSw8Q8J6i&#x2B;W9AAAgAElEQVS8tw//9/&#x2B;JY4FNatqAvilu26OZ5CMFKt7W3zdiAg2q3y4yvgPk2bo3YNRUM8m0nSwyXot6uHB5XDi9F07CWbztRmNUKVwEXku7SCAvmTbgCUqv3Jacb9v7UbXxgrTBF2m5No3rrp3qBrk5gDLuQVdJqKxyu8jNfeZawg1Yu3eW1RTyJc&#x2B;vmtJam7mxcZ&#x2B;RNXOLAwgn6sJHu8i3xTw7Z0m2AW&#x2B;jXSRQgu6RQFWlG0Zdbw6pmeTw30MeGvW0Zi83tmgXGR4uaadTkK47vEqJObNFWyUXzbHpHkmn9rpHLnTUTDLcxTHQAfLsA9d9Izd/GnOogxiVBohjoV8Xw3LdI4E9atqAR1lPwE8obtNMkr5srtCWUAAHlFC5lO1sB0ilbJDdvV0NsjSTHMWn3w5djzw1kwTgIqVsQFEybcADXW8OeWqlt0iNNJOcvt4b8lDQ1rjNKrRAUk2yDe5ymGMrsSrbemOrskF9t8&#x2B;y6mt&#x2B;VfwRyrcBkKDE1DeABd0jgaoqN4zqrplktfzWXmehaaRDpq1Bi&#x2B;aQ4WaSgS6R8x/pHgmF3N4u8uz2NXNsukfSqcjukQvtN5P8&#x2B;NWX8euopXWPnDae/2j&#x2B;z8gV4DafQtRKfeJY6EjesFz3SGCPTBtQVf3BtdKDj9krEoab8m23HACn7C3Dtk65rZNtFzNqn33&#x2B;RfacnBEKnipcY1Hir0bjq7KtybTRqbRM23B3sm2YfS6dTWiNFumx4SjTNuwk29apteRM2&#x2B;JZxK5UJo6FLpRo4S6OBfbItAFV3RWUdFfcNlQfean8vCTYy7QNO/VtP3z7TSDZFp88W68Dl4URCh5JKVsMIxR0arp0s6fMGylui3cqQzbfOG&#x2B;mbb5/ESw1iWOhfSXSbIM4Ftj36d0HAFDDx6&#x2B;/W8RS4z83hzzGb6633xsf2dw&#x2B;RmCfwzD84je/qzBkYFTiGTY7Rh6u0FaiUg1eSykbvMc6sIwRCPzGD5CiUdm48/GJxtTU9XxbI8YEXp3IGYD2FcqxAYR9cvcBAFTy8evv1uFRIMza3PjU9jHC&#x2B;7TSO6eE02aHiTcgzeES69lv6Tf3ebaUzZABXJH2S3QY&#x2B;F07qGM//fj9lI7aW03tuo9ffbm58/Az7j0qxpg1FDYDIM0G3EWmDXiXU/mzhORcoXxbwj55npj6sx&#x2B;&#x2B;/SZvmZr8HIQVKmXLlTZb/32RY4OMsgd&#x2B;dWZZzZNtacmtU00jY0wbl8v/AfBsgb&#x2B;haVPfhM3AKTJtwOtcz5&#x2B;VKG4LH4PiNk7Zy7edTZtJs0FAC6VsCTm5hEMCAq5MtNr7Uf3itoT81oc//qmp/pPK2gBe6zAsT9insBk468PHjx/vPgbgRZpaPPbsojVZto8RDuksQfFmCSurbWbLpnXdpr3VX7PNSvJ0LfvN/FD4D1BTgwVNBQMQ75MPv/z4P/9H9tgvsMM6Ud/0gZYrczbP242LqK23GZ/rMMO3d0jTAxcbfPzqS6EyFYhjoR01c2wf/vD7D//3/4ljgU0ybUBVDQ6unR2OvL59DMk2MgqUpk0ptyGuO2VGRijoVIl2kUO&#x2B;tNnZnNwtGgwGIMaYaRsKTLS6PfCbf7JlybfNM2FXMm17x7NI5i2&#x2B;L1SmNHEstKByju2/vpBpA3Z8evcBANxsjKXmcdj49V6M9fHr7xZB29ntY4T3OQaUBhGINE&#x2B;nAVcoZQOGYJy2Diwv7nAYhl/85nelo75x/&#x2B;NH3MevvszYFtK6awCUcEuaDSBATRtQVcvT2EsPaJYYhJVs46zD&#x2B;rbhvztJlu4naS4wfSlRypaxhLqLUrZJy8EABEw1bZPKXcQ7Km7bq2NbdH08m4ebDmmvpm3QQJIqxLFwo3tzbGragD2f3H0AAK3YXNA&#x2B;EKhtbnxq&#x2B;0iBfYYX/oW1H779Zi9/tk7Czb&#x2B;jJI7XOlxivcgKENfSbJt/0YDrFr9ZgU&#x2B;A5F/DcOCXsMNTfvrx&#x2B;ylN9fGrL5Mr0g6zdOE9Hy7PBsALHYblCfvULgLIRaYN4GdO5c8SknPJYy7ybbmMp2v67&#x2B;7Ducdevm1Kpy3yatJsvFahHFuutNnZnBxw3cWJWTECHy91opdFvi1tJ6dK4jL2qxyqpCQBqCx7WH4qxjaPDTgk0waw1GNx22BMIc76LL0837b&#x2B;ZiCpJt/Gq5SYMzsoZYNHWP&#x2B;u1S9uq5NvG79ILm6b58/Gr&#x2B;MzasllbXmTdgDcLvBXr1B7ifiNASaf3n0AAI36&#x2B;PV3iwArsFj9&#x2B;M2L28cI7HP47zSSpSkSvPbUzddmu/dIeJ75RVV0zb8SKufYNnf7mFXZ4Kmux4qHDgO/0qHLuP/xI3FMcZ3NYwW2j8/ezRd4A&#x2B;BVtIsEeqGmDWBXluaQtzSTTNjnGxyemTefunAipLs0CbfrN3fbQilbxvaSQFHXGyHEeEYzyYtUqgG8TfZSNi3ZgaJk2gAOXG8OWb&#x2B;Z5Js7Il705lO3uXjbZ59/0W/KBE45zLFlX5UtoV2kIQBo0PVVfmPcPsvqejPJkZwZAGElpr6ZxwaUpnskwLG95pB7sVeW7WNoJlnIm0/dmGxbZNck2zhlumB&#x2B;&#x2B;PabXi6e8Dh19vv5zX3m3R4oYS&#x2B;cS4j98gZ&#x2B;dUKX680kASDs3hxbYPtx4w8JRwC8g5o2gFjraU3tF7cN7&#x2B;6IeNGbT512kZwy1j4uKiDHq2izVrIp5UrZTu0zY3tJoKhwvdqpjUsUt3XRTHKRn5OuA2Bou5QtuYc88B5q2gDOWc9BDswvVtzWuzefus3iNlgLXCSfff5F&#x2B;2m2vR&#x2B;VWJJtc7e5ptkCNWUsbltvH/PsQzDwqxC6/PTj91eK22TXAJhrvJQN4JBMG8Bp1xsEhcdH5Nta8&#x2B;ZTJ99GsvGyGf/fYL6tRLvIIWvaTLtIaNypuVaHsV9a4Hdv1KeZJADXVZ76dn3eG8Am3SMBEl1vEKSZZF/qdGRqzXzBrXuPhDb1eIWUaxeZsTuNNBu0aTOcO7Vx3maS4Y&#x2B;sXppJAvBOhdpFxsfYAnIgI5k2gHR7&#x2B;bOi28doYdjlqV516uY1Se23AaSOzSXZOnJLKdvFmbNWZYOmnFq4NyH2Szikw8AvYZ9nzZNtWRZvA&#x2B;DZ6q&#x2B;UfHFjATkQpnskwFUJzSEvbh8p0FNoqLWGxyO9tpmkZBt79i6MH779pp2EXP0c2&#x2B;ZurcoGz7AZzmWJ/a50EW&#x2B;qmWRC5kyyDeANSoTlRXNsCccDvJBMG0AGCSu3Xd8&#x2B;hpXbynnD2WsqTUILAtfD&#x2B;kdN5WUr389v7jPv9sDtTi3Gdn2V3xiHgV&#x2B;FuOWnH7&#x2B;3chsAe0q0izy1Q2k2oBDdIwGyub4SW7mV2zSTDPjtr36d/NiXnLoxZdJU4oQbza&#x2B;EH779pvGMbLlV2U7tM&#x2B;P2QFPOLsZ2auPkZpJ7P7pl5TaLtwEwBP8GVWsXmWUJN4BNHz5&#x2B;/Hj3MQAv8smHX/7nx3&#x2B;/&#x2B;yiKK13KUKjL2bPLs4ZVVmwzwfbnv/4lbeePP3vZ/c3f/t1//Nu/3n0UHJu6hk7ptCm1NqXcNjNt80fdkqZtv11kwvbP8JJggOcJX7pFm1OVKL2tE7pMH8XXi9umjN2HP/5pnr1b7/njV18KzChKHAun3N4u8uz2gY3FscAe3SMB8quwctuQFI9qJnloTL8l5NucPR6p8Z6QAfXTbNdv6cPbA427uBhbiVV7NZME4HbZ20UOVmUDmiTTBlDE3mocQ/SAS3j7IXXMZQguCjLUGnZp3G9/9eu04jZnjwc4rELbS7&#x2B;tv39LV0mlbMBdri/GdjZWjBE4gDrzhMb9y7cBvE3LpWwmvQHZ6R4JVPXOQnvNJBsxD/Rj1mZL7iQ5PPHsZafrTrOmTNu8XeTip&#x2B;vvD/t5tZplcErZuvDOYIAHiL90i/atKvFRVi1uud5M8uNXX&#x2B;oeye3EsXDoqaVs4lhgj0wbUNVrg5LSQ7HJoWp4t8OzMkZnM23DtWTb8Kyzl50RimbFZ9rCP9rcphylbB15bTBA785eutfzZ9ljvxaivvnH9ZV8W2AnMm2UJo6FgNtL2YpOehPHAntk2oCqXh6UKG67VyDTNmXU1hm4i8m24UEnMC8jFG1ap9mGiHTavHvkLQu5VZ4zu7dbi0BEenkwQL8SLt3uituGfvJtU7JNpo36xLGwJ3tYnnHMJEtALo4F9si0AVUJSir0Get62KWoddA/5tUWuTTJtjqMULTpMNM232y&#x2B;wWYBXAXtl7JpF7kmGKBTyZdug8Vt4X121Exyk0wbpYljYa2vdpHh7QPEscAemTagKkHJSHHbLcIj8nN7FW8X9X4C8zJC0YJ1Oi0y0zbc3StyaCbHFn6IUrZNggE6dfHSLTrv/uXNJBdk2ihNHAtzt7eLPLv9lYBcHAvskWkDqhKUTBS31RefaRt&#x2B;nmzLlWkb9XsC8zJCcbvNFdfmmbYp3xafaXtwmq3Ch/Z7CAbo1PVLt7tmkp0Wt8m0UZo4FiYvKWWbiGOBPTJtQFWCkoUsE5brL&#x2B;Ax9Jku2useOezk0iTbijJCcbtwpm2&#x2B;zfyf882GO/pGNlLKlnf7txEM0Klcl26DzSRbmGWVsbhNpo3SxLEwvKyUbSKOBfbItAFVCUrWFLdVM78TWC/GNppn1DYzbf/0z/&#x2B;yeMg//sPfpx1PdycwLyMU91qnyg4zbevGkpWXZBuUsj2FYIBOZbx0uytuG7rKt8m0UZo4FvoqZcsYjYtjgT0ybUBVgpI9pQdzk4Pd8G6HrtJFMZm20ZhXW2fa1mm2iXzbWUYoKlusu5acaZurmWlTyvYkggE6lf3SbbC4LbzPXppJyrRRmjiWN3tnKdtEHAvskWkDqhKUhJUe1e16jvN18Zm2tcNM2yDZdpIRipo211QbrTNt8/xZINPW&#x2B;5Jsg1K2&#x2B;wgG6FSJS7f0AOI7m0nKtFGaOJZ3qpxj29znjTm2kTgW2CPTBlQlKDmkmWQ5FzNt4TTbKDnZNvRwAvMyQlHBut9jwCLlttjD/J9D/2k2pWz3EgzQqXKXruK2PWn5Npk2ShPH8kK3t4s8u32hgFwcC&#x2B;yRaQOqEpRE6rS4bWg7XbSXafvzX/9ymHiLzLQN15JtQ9snMC8jFBWsq9Dii9vme6i/HtvQTI4t/BClbGkEA3Sq6KWruC3gVDPJj199ObwpoOIW4lheRSnbnDgW2CPTBlQlKImnuC27QKZt8/tz8Zm24XKybWj4HGZkhKKCxdpsw8&#x2B;L0vaybi1k2hpJsyllK0QwQKcqXLrdFbcN7TWTlGmjAnEs73F7KVtrk97EscCeT&#x2B;8&#x2B;AAC2jQHiInb88Iff7wWOe9sP&#x2B;7Hmx6&#x2B;/SwuOw7sdY/FOBzhism6jeTotPgkX6Re/&#x2B;V2nJ5AuzDNnkb0lq2kkxxZ&#x2B;iFI2oJB1OBcIus7GfpvbxzgM/CoELeNTjH8jxlzaZr5t/BEA11UuZWu2XSRApE/uPgAAQtbB4oc//D4Q1G4Gl&#x2B;Htk&#x2B;PRcGwdjst7t6haW/wzS&#x2B;LtF7/53bPPIdl99vkX43&#x2B;RG09f39Icci18zYc/&#x2B;sLCt&#x2B;ibd&#x2B;ln7&#x2B;rd2AMZbYZ/gY3Pbp92VIF9Vgtafvrx&#x2B;ymrF0iqma4EcEWhsDxXgL0XwCccEkBGukcCVSm0T5ZlNY4SDYUOj6SpwY7phmFRrzYvZZvMt/lf//v/zH&#x2B;02R9ynmC73kByrqlzmIuuOxmt12Obf3&#x2B;zG&#x2B;TiR7cn3hopZdMusg7BAJ2qf&#x2B;l210yy/spt9x4GryWO5cFubxd5dvvKAbk4FtijeyRAH9adHg87Qw6rMPRs88lIgd0OrTaT/PNf/xJuDhlwKou2qG9Ly8BpJknAuojts8&#x2B;/2MyW7ZW73ds9slCObSg/Hi3NBpR2KvyrFvsF9lkt6ps3k9z8EQBnVW4XublPATnQLzVtQFWm/1xXYYC4UPlICwMf85uHdaZtUdk23&#x2B;DPf/3LlDMLZMsW2&#x2B;y1kUyueGvhHOZiLnAuU55svuLaumpt&#x2B;HmJ2/rr6YGVjnsYBqVsbyUYoFM3XrrdFbcNd9S3PSlMonHiWJ5HKVskcSywxzptAJ3JshJbOFa&#x2B;soBHC2t4BMyHYNYdI3/7q19P2bXkirfhKM0W/lFYC&#x2B;eQpsxTa0MwT9ZaQVu55R8SVmXLtT1AIacW7k1YuS3tk&#x2B;0w8EvYZ4Jx8TZpNoA0h2F5wj4zLnssIAd6oaYNqMr0n4wUt6VZ3EVEZtTmNW3DUVnbP/7D38fk0q6s5faA4SRzgbPYLFxbV63t/XOuWjXb4dirUrbHEwzQqRYuXcVt0AJxLM9Qv71Ev6VskxaCAaBNMm1AVYKS7EqPHRdaJGm4ddglIdkWn2kbRVatXUm2DZ0PXRmhuG5R0Lb500V/yL1MWyNptmo5tvBDLAJRmmCATjVy6Zb&#x2B;TCvxUdx1xAJr4lgeoLtV2RqJxhsJBoAGybQBVQlKSui3uG24b&#x2B;TlbLKtUKYtZleHOh29MkJx3WambUqwhVdlq7we21AsxzYoZeuQYIBONXXpFv1wU9wGYeJYutZCKVu/AXlTwQDQlE/vPgAArhqDzkUw&#x2B;uEPv98LRve2H/bj182HxAjvdhiGX/zmdy0Mu/z5r3&#x2B;5sjDboXk6LXmRtj3jnVILp5FbBBpCLty1JNuglA0gt49ff3c2lovfvlDgJ2IBuF32JdmGp7eLBIikpg2oyvSforIUq72nmeThYlGL3Nv/&#x2B;t//Z/7PcC1auABukWy7XtY26mvoylzg6zb7Q47mNW2bCbbe20UO5St33dWXIxigU21eum02Em8t6oO8xLH0qPFStl4mvbUZDAAtkGkDqhKUVJBlAOWWZpK3DLuE7zcCybYrmbahWLJt6Gf0ygjFdYFM22gvCVfl6I6T2dVK2bJ/BnKRYIBOtXzpFh3NfFLgB1mIY&#x2B;mOUrZcWg4GgHt9cvcBAJDZOiT98IffB6Lnj19/t/mQU08RKXwkv/jN7w6H5rNLHuW52AQyY2pt4ZbTSCMOs2iNpNnCHwUBm59X4d0mpOWavbEH2HMq/Dsb&#x2B;yV/MDYY&#x2B;AG8TfjDtlBMHr99QgAP0CbrtAE80NmV24ak1T7WTxEpfCT11/AYn2vz9mOxfts//sPfZ19lbZhl3TZ3npaTa2QBPHKZl69t6iXHNihlAygjYeHeiyu9RToM/EQsp8z/zjp1QEAL7SLPbi8aB/qleyRQlUL7yqzcdtbm3ciUbPvzX/8S2fXxsHvkfLNxg3AOL7kGrtkhGF13TtnMtK2/eVejyEn9&#x2B;/m93T5gEYgHEwzQqV4u3dIDnZpJ3mj9d9Z5u4U4lvZVbhe5udtHBuS9BANAfbpHAjzZXnegcIOgs9s/vpnkn//6l/G/YZXxWqTH/umf/&#x2B;Vs0VtkCi25lk5rJuo47EtT85b&#x2B;kXf1AJGuN4csFPuF/xAIVw5tniKRHrBQol3kcJQ2u5hm078deAA1bUBVpv/cqEJrtUIj6cMd03UDNyd7PR6n7y&#x2B;aTMbk0iITaVdWd2ttyrO5wKd89vkX6wK1qYJt/NH8n4fdJvNSysYpggE61d2lW/pzUnFbZYcZNaeuGnEszVLKVlp3wQBQjUwbUJWg5F4VBqbf0ExyiOj0WCjTFrm3gHaGYIxQDBGrr8U8fK1m08hCObahfJ/bvm7pH0YwQKc6vXRLf2DKt9URX7jm1FUgjqVBLazK9oaAvNNgAKhApg2oSlDSAsVtp6Ql2&#x2B;bSMm2LdN3ZHYa1MARjhGJYZdrmmbOYbNlmpq2ROrZBKRv7BAN0qt9LV3HbA5xqEenUlSaOpSkt5Njybt&#x2B;yfoMBoDSZNqAqQUkjsiTPFLcFkm1ny9oWu5pvv5mEC&#x2B;8t0r2jMEYohp9n2hZps8iEWdqjrrullK3CBxd1CAboVO&#x2B;XruK2riUsxubUlSOOpR0lwnK9JQJ6DwaAcmTagKoEJU1pubjtcM&#x2B;N5NsCZWfJmbbNjQOpuCtuHIJ55wjFYrm165m2&#x2B;tppFxl&#x2B;yJNmzj6PYIBOPePSLbqgjmRbOQmZtpGzV8I741ha02Mp2wOi8WcEA0AJn9x9AADcZh3mfvjD7wMR&#x2B;cevv9t8yKmniBfe8y9&#x2B;87vkEYdk66GKf/yHv8&#x2B;7DNueXKm1hVtO4zt99vkXe8uqDbM022YnyXaUu58P36Jv3qWfvat/wI09wHWnwr&#x2B;zsV/yh204BBWuXOHUwSMFfrXDn6gBeQPsR6bZAALUtAFVmf7TJsVtZ0WOWcSXtcVsuVfW9ttf/Xr84s9//UvMUe2pfCbfNhd4cw22qaZts7htUda2qIerrJ1StuyfTtQnGKBTD7t0ixa37T0kRoOBXwuuJ8xee&#x2B;pKeFscS1OUst3rYcEAkJGaNgCyFbeVmOM8tFrcdna0okJZ25RyS2PKc8tuLHE7/BWrXMp26kiUsgHsyVLcFo790g7sMPBL2y1KA6F34d/iFkrZEgJ4gMeQaQNgGPINoBRqJnl423DLwMFhsm2RG1sn266k366n7tYMwdSxSJu12ShydJhjK1SykNCdxl09wFlZmkNqJtkXpw46dUsp28XqZ5PegFf59O4DAKAhH7/&#x2B;bh0ff/jD7/fi4/H7i4eM/zz1kEjhPY/3HpUb44xPFz9mMabHxgxcQqrsH//h7w8fNa9sS&#x2B;sn&#x2B;Yvf/E5/oRbstZGs4/CqrpZjS3iIW3qAeOvw7zCWu7h9pEAIOghXLrglZgaS1c&#x2B;xbe42b4dhgOdR0wbAz&#x2B;TqDFmouO1wz3c1k9z70WbLx3/653&#x2B;ZEmZ5S9MWDSR/&#x2B;6tfp7WUNN&#x2B;5tMM6tnV2rWa&#x2B;TSkbwKsobnshZw&#x2B;6UCLNljfAVsoGMFLTBsCGvWK1QMScMMF5/RSRwnse7pjmHChuiylEa5Cp4k2plmYrNGd2yF3KZuYsQHYtF7cFdvvaCq3FbCqdDOBhbmkXWXR7gGf78PHjx7uPAXiRTz788j8//vvdR8EJdTq5FaqPGW4adtm8KQok29apuM1KuM1d/eM//P1h1Vr8yMu4q/n25U7g3/zt3/3Hv/1roZ03KGYxth&#x2B;&#x2B;/WbeMXL8upEc29B2u8jDh9COTz78chgGwQA9ek8cezaWu759pPBun50xWvyZ3gv/0vJtw9PPXnZvi2OprP12kQnbP8Z7ggHgLJk2oCrja53KMoBSaMzlcM89JtvuzbTNHyXTlss6hRZWeW02pWzUIQyga68aXKvw&#x2B;Szfdkpkpm0k31ba2&#x2B;JYalLK1rhXBQPAKdZpA6oaI5JPPvxyHGujF7lWbiuxgMfQ6spt66GKcP6sNeMIjgU8Krh9SbZy9/MJK0BYBOLBpNmgI2djubTYL&#x2B;3YDgO/tN0&#x2B;SdoyvYPF2&#x2B;BW4V/A5JWS8wbYAnKAPWragHsYbutU18VtQ5P1bVP6Lb6BZLimbT6Led4NMmYxj81tCp20rucCJ/R1nNe0DT9vJrmocqucZgv8tGYpm3aRzzZNr/F3n669dhq7ZpItmP/JjkykJVe2DY87e9l1HcfSJqVsvXhtMAAckmkDbmPcrVN1FlV6QzPJtchkW3ymbRiG3/7q13/&#x2B;618iF/PY21WJk9b1CMVmpi2cfgtn2godZ0A7ObaEh7zwlr5r5tbwGG8eXCs9IPuwwK&#x2B;EQKZtc07V/EfJHnP2sus6jqU1VmXry5uDASBM90jgNv/58d&#x2B;nZpJ3Hwsn5OoOFL5nuBK499JMMk1gsbdhazwlkGYbhuG3v/p1cn8hJp99/sWUOYtZg224Kbs2Ktcucki6RU/oMJl8eFQ2NYs2HgG92wv/im4f6YXNJOfx3vT1n//6l4t5tTXNJKGou9pFngqwBeQAkWTagJtZua1TZ5Nn9Vdua3DY5TDftihi&#x2B;6d//pdwXi0XybYrIlNrjTjMsVVelS18MKeegtZMOTZpNniM63OtCsV&#x2B;4d0&#x2B;Ml20l1cLtytI87yzBy1op5Rt7yEJyyoDvJnukUArTHvvVJ1ecIXuNIYmm0mus2t7a7kNq&#x2B;6RMauv7VlXv&#x2B;keOfrs8y8CJWjrTNvmxovukfUdDpOV&#x2B;y2zKtsL&#x2B;ZvOI2kYNbFyW32n0l2HwWGark9gXh3FsTSokRxb&#x2B;CHq2PYIBoA9Mm1AQwzM9avCSHq5jnZDY/m2U3Vsh5m2&#x2B;LnMgUzbUOAU9TJCEV6Sbb36WuQ6bZW10y4y4SHu6vtiEVYezODaXOmV2/YeEuOR&#x2B;bazhWWFkm1Dtycwr17iWBpUP81W4eP6VQQDwB6ZNvj/2Lt/XduNK0/APFduPYekFtBQ1KkjBR12bD2DAcPBRIN5EMNAP4MUO3SgSOlEhoE7lp5DA&#x2B;tMwGl6e//hn8VicVXx&#x2B;6BAuneTZ2ufc8hV9atVJBczdO0qNYFyVt7WYtg29rptTdqm1yyGcJK2YWPStnieNa8s66xWtjoXBLKxYoa&#x2B;mVx7dPRaq84Kvz3ubugzBd7jC27/6rbIvNu3fL3mPr3iWqljSSVJK5tFbzspBoBXPKcNyGV6oIvHtu335Wef13z&#x2B;1qsnsc0f8viHgUNWWnxyW/2nULx6clt44mPR7VTLqyd8sNVZG0LOW/yR3vlUtvkzbzrEQyA6MD1v1dQDXEqRJ7Ed99Temb9t&#x2B;tljTyv8NZX/3Vqu8COBu3z0HRzqlFa2TbFZ4LHKANzS0wYkpbltv2mwXTlN0dwW8zj6Wpz7CPS0bXqQm562YV1P2/S3r/68vqa3i1w8hGxkbFyEZewzjt6drL/Cb6vbO/vWtXRjRTdTWO5Z49XKB1hWK3UsGWhl64xiAHhF0gakZvJujzURy3E8uS3g6TDs1bTINCeyPmmb&#x2B;Rl4OmUjaRtCSdsk4SPZhroxm4ztCtypuQ6Ta4uOntu98pPbdiZta3rX5G3rtVLHcq5Tlr55KtvRFAPAK786&#x2B;w0AzPnl/edxQyqlzFY194186v3b7&#x2B;&#x2B;q9vE/X1Xt45/vP2Sl&#x2B;TMP/z0uqjxrMH65uyHZOOtxNz9y3PaShN3FbKfQykZNus&#x2B;BO4Hyr07tN3/aU6q&#x2B;hP7wx/8KV5iffPGVDxBuaWUDuBpJG5DdFLYN5vJaUyo8e/vm65mK/&#x2B;i8rf6swUzedpyPP/14ejrLHse1si2Ot7WyXZP7MvDU1louVvsdUfg1mrdNOxCcXsg1&#x2B;gFCcV7fF5QAACAASURBVEkytvlDFOQAxX04&#x2B;w0ALPvl/edxLm9aPs&#x2B;800fat57W6/MDjMdDnj6fefGrrDR/5rMe&#x2B;W6eoiH/9h//OTW0TTtG1tw6cnE8f9yQvsjKWaP6tlj&#x2B;AizaWssFXh&#x2B;&#x2B;dywWfrHTnu7jTz&#x2B;O/6x58e9/99vxn7s/X7PJ5LyzKmdIIknMNn&#x2B;RVJADHMFz2oCW2Khq0UzGVvk5bY/q7C933P54Z0Vfi7MVRZ7T9vjiwXPahmFY95y2W5WfzaaVjcpkbFyZ/cwDjr5Z9Ff4vfLqOW2vqru719xGaHcB22O6VmQrhWwfYFmt1LHUlCRjmz9EQb6fYgB4RU8b0BLNbTO&#x2B;/OzzVK1sj4o0t8UOWSltc9ueqYrb&#x2B;ZfkPyEdqNzHppWNmrSyAQH7m9uG2QrtOs1tr6rB/dXdQVuUa27jOuZ/2g&#x2B;qyV8V5FrZAM7iOW1Aezy5rV0Fn9y29ZCV1jy5bThjle7f//YXsxX7PW1Q22M8VfHTLjpozexQq83UkL457rlAWKkntw2ztd&#x2B;lntxW/PG6v//db1/tGzn&#x2B;eTiNS/sZQilJWtkU5ACnk7QBTZo623Tut2jrhMvwYgJl8ZDHr7LSmrztlLBteDaWG7vW9KstetzpcSgUkuXJ2Ib0MZshfYvEbMB&#x2B;j7VcbK3VQQutEq6yWu/Lzz7fv0v8Y9h2&#x2B;5/Tv8cit1MqZzjaKUvfbBcJkJakDWjY1Nxm&#x2B;q9FpSZcZg55&#x2B;lXWyznt8qq5beUMS5G5mBY9xmxPg7etJ6lMKxuVeTwqUFCRZrWDNjbIucrqzm0ReNfWNv77VOPtWYA1ZmnFW9zyB5awSaOtbKpxgON4ThvQttvmtrPfC5s93Rd&#x2B;8TFsRQ5ZaXFX/Sae3HbNaG30b//xn3fx2O1&#x2B;j1tPVextbbfmqWzhk9dpZTOwb87UyiZmAwoq8iS2g57aO1/45X/w2PjY5nDMtj4/e5XDLcr/GcKig57KtviItU2xWeCxygDs9Pb&#x2B;/n72ewAowN5Wi4Pq9T1P619cSp2OmeOiiOG8JborZyvufjxefX9nXlb8f/Bf/vXf/&#x2B;//&#x2B;d9lz3lnysb&#x2B;&#x2B;uc/3e4S&#x2B;ZiZzWz/&#x2B;DRgs11kwUNISCsbPGUfhbIq7IF2UFvJcGpv1m1hsDJU&#x2B;/jTj7fZ2GKitjJICz&#x2B;8bdR0f1uFOpaEjivLtbI1RDEAvKKnDeiE5rayKj/069Vq5eILnA9tbjurv23Ny&#x2B;6itcs&#x2B;1O2uxS0WmOWJ2cJrZocVvw5b&#x2B;9JerZw1sG&#x2B;OVjagjq21XKxcjL23nLsaPDp334JwZ9soyWcIKx1UlmtlA&#x2B;iGpA3oxzQtKGwbdgy8bx/wUD9ve/zDrbsDLQ5y9ow0ck67bN1McnTZsG0SCMz&#x2B;&#x2B;uc/VYvZzt0ucv/K2cVDyEmDOFBZkfBsaz63UhOrrD7&#x2B;9GOFvO33v/vtzg62p2wmSRMO2i5yKL0fu0VvAOeyeyTQoWtuezUFJ6&#x2B;ehb5&#x2B;EB4&#x2B;sBSbSYbNz1Y8pmu339z5v82/e&#x2B;S//cd/3sZgi49Vu91JcnH3yJp9bMNhj1gfVvzoytgu65q3TtjEhlGHqnADOmg2/JSq72mpMLOO6n/8z/91&#x2B;5/zsdlds9rdi&#x2B;f/NqytzSTtHnkdB5XlZa9vCvKaFAPAK5I2oFsW5pdK2jYdW0q1B0T1l7dtDduGYfj404&#x2B;v/nz69&#x2B;RJ2&#x2B;0j2e7&#x2B;5Nb0wLZhddJWmaeycQp3TFjD5NrRityJzlpoVb/qW6wZ7qq727BtfdL29JWbnvq2XkNhm6TtCk5Z&#x2B;lbhMshOigHglV&#x2B;d/QYAjvLL&#x2B;8/jY9uUQS0ahwd3w4bxP1&#x2B;NHAKHjH8VHia9ffP1/DDmky&#x2B;&#x2B;qj9lMH7FTVvxtL6T5GL72qOn0dq5qZuMjVNoZQPyeFXLbSrkAuXiSvPvZLyP1yz8AiXfEf7wx/8qFbbV/wzhqePKcq1sAB3znDagZ9Nj2zy5rVFPd5YPPIZt8ZA9D/BI&#x2B;wyPp/MU9dsTM8jTsvZK6zGbh0A0amplE7MBeQSe3FakXFwj4SN7Z57Xe1f13eZhdztAbvUqWvvDH//r9p/YyT28jXMttrLFyvLFR6x5KhtA6yRtQOemCURhW7tKTbgcNOey5uRnzRcI2/JbnE7a&#x2B;ZT14kN6G9R0w46RQFqBWq5IubhSwlVWK8O2W6XCtulfHk&#x2B;4M28LvzeIWVOWx85cdhGbghwgJ0kbcAma2zZJmMTEVisXOWS9hNMuw4uVzh9/&#x2B;jHhd7mmcaPIx20nK3e/nZWxDVrZrm26G4rZgMy2blRQJJ9bKeEqq5n9DKaq764X7Wk2FvvqMwdqbqMJqVrZ5t/Jpi8BQDVv7&#x2B;/vZ78HgHouNbd49/CtTcnK44O7kgQzdR4otWenvsWTD&#x2B;c9f&#x2B;LpAHLmIW233/Ti77ngk&#x2B;TvArO//vlP0xPXXv3LnfrbS7a&#x2B;XeTiIaR1qfsglOXpv2ep8Oyi42679au&#x2B;&#x2B;RrjMfe6a0r7/e9&#x2B;e/ualc9gWxOn7XmcW7aHtxWsYzndQX1sQygz2/pOFOT1KQaAV3519hsAqOqX95&#x2B;t5W/a0&#x2B;fYj//5aphR6pD13r75en7M88kXX50yX/D3v/3lcSR5G6fNpG6UcmLG9vTkRxxCTlNXt9sf0JZXtVyS2m&#x2B;&#x2B;8Bvv&#x2B;zULv/Frvao37oK0Yfc2kuvP8Ic//lc4bKv/MXIFx5XlZTMzGRtAE&#x2B;weCVyOJ7d1YOtuQuFDDt1TKM9mkpdSv33t1rmtbIGVs2K2bkxLTMRsQKOK7Ax50FN7G9pMcljqLdsfvB3HZpIUdOgu7vNnfnz9ppjNdpEAOelpAy5qam4z57jf1AhVc4fJOs1t419dpLltGIaPP/14hba227Dt6WaSR9DKxlm0sgHd0Ny21auSb95t31ugEe329Y/9c3v2kBw0t1GCVjYAjqCnDbiuqbNNc1sp9UMazW1hr1Y6f/zpx8fEtNfpjCQx2541s4NWNmZpZQP6E2hue3rIpi&#x2B;xUivNbb//3W93Jl4rPX6VIj1zZ9XPdOCUVrZX1bVWNoCevL2/v5/9HgBO1utj2&#x2B;5yr60NZ&#x2B;sPfwzYaja3jQIr/kodst7i0OisQGtxquKIN1bwSfKvArO//vlP4189/svdy4q8jafO3S6ywiFk1uvdDc5iL4RsAktJHv/wuNpv/synVH2PZcnT3OvxWW7rN5x8&#x2B;spNZ9vkrOK5YB1LNYsZW/jMWtkuRTEAvKKnDUBzW3mtNLcFFjjvGeQsjt/OWpzbZcvauc9jGx26ZlbMxozpjmYiAOhYnea2Pf1tM397SlfWmua28T/Ldrzdne02ePvys8/3DBw0t7HSQTHbYl&#x2B;aVjaA69DTBvAPnc1Llu1pmznD0&#x2B;Hx&#x2B;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&#x2B;hpA3hOc9spwVhxpVYrH9fctnjywWY426WK2fasmR0qtrKF3yHnsmMkwJ1Sm0lu&#x2B;hLrJdzVYGYng6fJ2RF7Pz4V3hhD8XxZWtkAOIueNoAF7c5g7m8pW3OG5D1tE81t2RzU01bkhOtla2U74hAya/cOBS2yjL05mtu2elrYzOdqdz1tw8a2tsUsLWdbm562hA56JNtQ&#x2B;rrhGcmtUwwAr0jaAJZNbW1tVVTFk7bHk8zEbEXeQFmxUU2RMGO964RtxZO2VH1sw8Gxa53kmMwavTFB02TbLaqzn9tBXTJDI3nbng0kyyZt49mmQ4779CRtqTS9XeTiIaSiEgBm/OrsNwDQgNudJBVV7RrHMHfDm/E/Z4Y3799&#x2B;Hzjk8QuttHjycSTZTd5WxKVa2aoFxmRmkA&#x2B;n&#x2B;OX9Z9Vgc16Vf8Vrv&#x2B;MKv/pV39//9pfHUuexdy2tKW875dOjMq1s1GGVG7BITxvABm1Nbuppe6VUVrF4lM0kZzS6FjjbdpGLRxnV96etOxH0x1xbo/JvJN7oZpJjB9v6DSQXe9rudqEP9LTdHnjQ59ZoHduZplvZVONtUX4Da0jaALZpaHpF0javWmhhM8mnWpyhaKuVTcbWn4ZuQNA9k26NavrJbUOmvO3Ryg0k55O2x7HG08c/P75yev3jC4740FqsYzuTp5VNQd435TewnqQNIKKJ6ZUiQdfi6Pfu9TMvyJa0jUo9ikNz21ZtzVBoZeN0Tdx34FLMvjVKc1vAmrBtZVvbTNL2arAw8yy3NUMPSVtn8mRsgUNU421RfgObSNoAgvJPrxydtM03tD2eJGfSNmhuO0krMxSHZmyDVjZWyH&#x2B;7gSszDdeoCpPm/RV&#x2B;i0XRYtj2&#x2B;ILFpG0mZns8StLWt1TbSyjIu&#x2B;f&#x2B;Dmz14ew3ANCqX95/HquuaQ70ChbHuk&#x2B;lzdhG799&#x2B;/zjsmR&#x2B;nvTpk8ajYO1xz8k&#x2B;&#x2B;&#x2B;Grl3j6sd/R4XszGommQb5wPOV2wGuzD05vj1kJuvjxbvNHPWFP4xc68x9//9pdNqdVdrnaQ2PCE5iy2su15KtvMr&#x2B;rTMwdiOQV5Qz68fSpmAwL0tAHslbbb4IietuH1Y9gev8r0ZIVWNNHctub8TfS3JV8LrJWN06W9uQCP/MK2q86OcHsygPkXZGtue5qu/f53v3315/t72m6PfXW24p9S8jq2M8eV5YHfXAV592RsQJikDaCMhAVZhqRtz5c&#x2B;SxN5W85pl00yz1BkeyrbEQ9yI7mE9xRgkd/cdlWYT&#x2B;&#x2B;v8HtVL61vZVtM2l6NRF4NQyRt/fFUNqqxaAbYSdIGUEy26ZX6SduaZ5I3oWBydtycy5q3lDlvyzlDkS1jWzxKxtalbHcTYD3zdO2qcxc&#x2B;rpA4q&#x2B;p7WjutCdvGp7htStpmxhqDpK07Z7WyKcivSfkN7CdpAygp1fRKkaTt1XkWG9oKvoGzaG47VLYZiua2i3x6lCF961LdRIAwE3b7nbU1gua2gFjYtj9pe3zBqxdL2tpy4tI3rWwXpPwGSpG0AZSXZHpF0raf5rbjpJqh0MpGBknuHUARZu52OnFrBM1tMY/V1EzYNsZsw&#x2B;6k7fE1T18saWtI09tFLh5CNspvoCBJG8AhkkyvFJmkeLpL5EWStlETzW1rzp8qb0syQ6GVjQyS3DKA4kzhxSxuUV5Bhea2V0etkbPqW9ncNsVsw5akbeZnYHFgImlrQkOtbDK2PrhHA2VJ2gAOlKF027/3TqqkbTznKaFdIN6wmeSMDDMUWtnIIMOdAjiO3/GADEnb0H5z25Apb3ulSNI2LP3MSNry08pGTVa5AUeQtAEcK0kN9&#x2B;Vnnx&#x2B;dtMX2ewm/mY4nXF4dtV7OaZc7585QaGUjCVPwcAVJqsFWrFnOVVOd5zZdYTPJpyRtHFeWF6&#x2B;uZWx9UH4DB5G0AdTQdDE386TxW5WTtoLn3KqP5rbh7LztrBmKNfM&#x2B;WtmowMw7XE3T1WA1a565VZ/mtpg1Rdf&#x2B;57StebGkLa2mW9lU481RfgOHkrQBVNL09MqasG3r2Di2L1C7uwnFjuq4ue2UGQrbRZJE03cEIMwc3yuLpWaGx/3K22Lmq6/FrrVwW5ukLTmtbFSm/AaOJmkDqKfd6ZXiSdvMCffsDFOZzST3qDxDce52kU/Pf1ArJMm1eyMASjHZ96iJpG1UYY6&#x2B;v7BteF2JSdou6MSlb1rZLsudF6hA0gZQW4tFXmz6I5a0vTrbqwOb200odlR/YVvNGQqtbCTR4vUfOILQ/U5DSduguS1qMWyTtF1B09tFLh5CQm64QDWSNoATNFftVU7aXp3w6YEZZl40twXUmaE4t5WtWhBLE8RswB2XhUlbSduozgZ0xwUPCZvbtg4o5l8sactGKxv1uc8CNUnaAE7TUNlXNmlbsxflynO&#x2B;ell9NTOVQ9c4D7VmXirMUGhlI4nmVlcA1TRUDR6qxaRt0Ny2w2KRdivW1iZpS0UrG5Upv4H6JG0AZ2ql/jslaXt62rRJ20hz23qHzlBoZSMP0&#x2B;jAvFaqwUM1mrSNijyK9dyFVqk2k3y0vq1N0paQVjbqU34Dp5C0AZyviUIw8GS1CyZtQzvNbWvOf&#x2B;i0y0EzFOdmbK/Ob&#x2B;XsNZk9B9Zroho8Tqmkbf6JX8fR3Ba2Mm9b09bmOW3ZtJ6xLR5CThe/nwInkrQBpJC/HJyZAQkMd8NhW/6kbVQtb2s3bDtihqK57SLDR5Ff/qs6kM2V4/mCPW1nhW2DvC1qTdi2pq1N0pbKWdtFPj25jO0irnwbBTL4cPYbAGAY/rsW/PD26VQd9i1nPFbQ&#x2B;7ffPw7PFoeUT0d080c9/ULrvX3z9fz5P/niq00P0jjL4vtc/D&#x2B;dd1BK&#x2B;nQiwMC&#x2B;ddOV3CAf2OSX95&#x2B;ngvDs93Kmjz/9WKRQ/PKzz9cv7SoiVsgVOWSlNYVf&#x2B;ORhf//bXxaTsMW1d&#x2B;SxpiwPnzxWXW99M6rxFk3ltwocOIueNoBc0s7Plu1pu3vB/MaS881wyUO7bprbhtLLgQuuBe6jlc2Qvg9pr&#x2B;FAQ6zKH7Y8mmv&#x2B;wE3HlqK5LWymqJsfJsx/3/W0VaOVjfrcNIEkJG0A6eSsFI9I2qbXrM/SMsyeBFR7VEBDm0kWmaHwVDZSEbMBBV38ktJ00jY0UvvlzNu2hm2vSNoq81Q2TnHxeyWQiqQNIKlsJeOrke3M5EVsiqTLpG2o&#x2B;xCvQ&#x2B;dchkKzFTtnKNbsbpStlc2QvmM5V0gArctWDdbUetI20twW9qrSiz3sWdJ2KBkbp1B&#x2B;A9lI2gDyyja9sri14/zrw1MkfSRtoyYWOK85//4Jiz0zFOe2stUMTWlCtms10JPLziT2kbSNAltGFzlkvbbytpVhm6StjtZjNtV4o5TfQEKSNoDUUk2vSNqKaKW5bc3590xbxGYobBdJKqku0UDHLjilGC4jdx57kPzNbYsnby5sk7QdrfWMbfEQ0rrgPRFogqQNoAFJSsmySdv6OK2zpG3UTXPbEJ28CMxQaGUjlSRXZuAirhbtd5a0jUp1qtlMcjSft0naDjVfluffwl013qir3QqBtkjaANqQp6ZcP3mxKTCbNx3bTdI2XL65bdMMhVY2shGzAae4zsWnYNK29fBDNbHWqq287dbtt17SdhCtbJzlOndAoFGSNoCWJCkup0Hs/LTFqymSrTHb/LF5pk5iWsnbije3rZyhWBzMD/mWzYaPogl51j0A15SkGjxar0nbKP9mko2GbZK2Q52YsT09&#x2B;RGHkJPyG2jCh7PfAAAbjJXlh7dPp1rzFNlmK5r2/u33j0O&#x2B;xWHq01Fi7KiV3r75evH8a1KxTdaM57PFbE/f0tPvMi2aJriN84GzJKkGu/HlZ58HFoHtFCjkYoeEy4/FEuuTL74qXvit8fe//eWskO/izm1l25qZBQ4hLeU30Ao9bQBNamI5s562TVppbltz/jUzIPNrgVvcLjJ8FE2wlhbIpolqMKxaT9urLqg68je3LZ78xNzrVbk4fk/1tJWilY0T9X2nAzojaQNoVf6iU9IW0MTTO9acf1ia1JiZoWgxZpOx9S3/9Ra4po4XAexJ2jYdvvML7ddE7dfoZpKjI97bdZK2&#x2B;U/40JpcQX5xHd/ggF5J2gAalrz6lLTFXKS57ekMRYsZW/goWiFmA5Lr8jJ1VtIW&#x2B;3L7ddDcNmTN2yRtMeduF1nhEDLr8r4GdE/SBtC8tGWopG2PJhY4rzn/8GKC426GYs2S5GzLZsNH0YrkqxkAJv1dr8ombTNnSJK0jepslHep5raD3k/fSVu27SIXj1KQ96S/2xlwHZI2gB7krEfXJ2130xkzL7hO0jb03tx2O0PRTSubIX1P0i5iAHilpwtXnaRtJmZ7fNZXHU2stWolbzvubXSctGll40Q93cWAC5K0AfQjW2EqaSui17xtnKE4upXNdpEE5Fy7ALBGtmowLEnSFvjSRZTqVDtxM8mzwrY6ukzatLJxrm7uX8BlfTj7DQBQzFiVfnj7dJompgNPh4uLA92CR623eP5Pvvjqdgy/ZjyfcEj/dPLLqL4b0yDfOB9okWqwuC8/&#x2B;zyw8/lOj3XFYlEUqP12FjDzJ7&#x2B;r&#x2B;kju3Fa2rdW1grwz0z1L&#x2B;Q00TU8bQIeS1Kl62srqqblt8Ue0le0i1xxFK7SyAT1JUg2G7expW3mGNT1t4TdQRJ1Gn/q7iLeup542rWycq/W7FcBETxtAh6blzOe&#x2B;jY8//XidGKyCnprbDj1cKxsBWtmAzmhu60OsUy1wyHHNbcOKLIezzH9rDt1eQisbWtmAzuhpA&#x2B;hWnv6Mx0fKz7em6Wmb10Fz26sxVcKMLXwUDTHIBzrW6CWueE/b40lmGtqKvIGyNLel0kFPW7ZWtiMOIbNG700AMyRtAJ3LWcJuytLm//b0iY&#x2B;z1Nxrpfi0y9Mfy4Qxm4yte3lWJAAcp8VrnaTtUakFQ4cutLpI2NZ00nZoxjbUCoAV5O1q8ZYEsIakDaB/CWvZrQ&#x2B;Wl7Q91W5z213SljBjCx9FQ3IuRAA4SFsXPUnbK9WCCnnbjHaTthNb2apFxWTW1p0IYBNJG8BVZCtqN4VtkrYZLeZttz&#x2B;N2Z6yHj6KhiRcfwBQQbZqcIakbUa18sZmkq&#x2B;0mLRl2y5y8SgFeX8augcBBEjaAC4k1eSypK2g5sK28Ufx/Te/3n&#x2B;qGWI2njLIB64sVTU4o0jQNX&#x2B;S&#x2B;aTt7gUJC07NbSdqLmmbj9mybRf59CjVeNNaufUA7CFpA7icPLPM68M2SdsaDeVtb9/9MOxI2mRshOW5AAKcKP/F8OikbTFmu3tZ2oKz1GPYNLdt0lDSppWN0&#x2B;W/4wAU8eHsNwBAbWONOy0rO1HaOYtGPR2CLg6eCx5Vh5iNmA9vnxrnA4ymajBDQVjN1ucED8Pw8acfk9erj7XK2zdfzxdygdrv/dvv9xRFi4XlJ198tRgIsdXip7r4ozJvMTB7GgPPHBU4hOSU38Cl6GkDuKgkGzisnPLQ07ZJ/ua2WE&#x2B;bjI0wg3yAp9JeHo/oaRtmS8rhoemtrSLTZpI15e9p08rG6dLeXwAOImkDuLQk5e9i3iZp26py5rR1rB5I2qrFbIb0nUmyqgAgrZzXyQxJW/jrnqVaLWQzycxJ26EZ23BAYCZj61KSeQaAmiRtAFeXZ3rldkbj1fSKpG2TtM1tm5I2rWyEGeQDrJTtglk/abv7ErcvaKva1NxWQdqkLVsrm4L8gvJMLwBUJmkDYBjamV6RtAUUfO59qTmX9Umb3WkIy3ZZA0gu1WWzSNL26jyLDW0F38Apqi1CumxzW8KkLVvGtniUgrxLqe4jAJV9OPsNAJDCWA1PC9DoScHn3i8O0QsOjxeffx57arpR/RV4&#x2B;jpAwFQNKghb97Qcelo43R31&#x2B;IexinGlxcLyky&#x2B;&#x2B;WgyQWPyUFr/18xTkrKH8BtDTBsA/pNrq4emmPXra9sizmeR8T1v45Ib0DNbSAuyW4UKqp60IzW0HydPTppWNDDLcNQBOJ2kD4F6eQnma45C0lZIkbJtJ2jyVjbBUawUAmpbkivpYCobPMPn404/XSdpGTTy5bc358&#x2B;RtGZK2QzO2odZPiGq8A3lmDwDOJWkD4Ikk0yvDwwyLpK2I0/O2p0mbjI09DPIBistwaR1rv6OTtsfzH5G07Q8O9wiEHPXztlbCttOTNq1sZJBn0gAgA0kbAC9lmF65I2krpXJqdXfgY9ImZiPMIB/gOAmrwU2etq89qpy0lTrhVprbSjkxadPKRhKt3x0AipO0ATAn2xS2pK2ss5rbbpM2GRt7GOQDHC1bNbjVmrBta9IWy&#x2B;GS1LFN5G1rarYT87ZTkrbFjG3QykYVrd8UAA4iaQNgWZ657CQzFD0pO3Wy8sApaROzsUeeSxNA99q95FZI2l6dZPGdnFXHVquvem1uq5&#x2B;02S6SJNq9FwAcTdIGwCp5SuqeHlCfR&#x2B;XmtjFpm/9xkrExw1pagPoavfYuJm1Pi8mZgnP&#x2B;hDOlaZ6kbdREc9ua89fP22ombeduF/n0/Arya2r0FgBQjaQNgLVS1dbnPlK&#x2B;Szvb1DYdtRjcitmYkSf4B7ig5i7ClZO2Vyd8euDpdazmtphqSZtWNpJo7soPUJ&#x2B;kDYBt8hTZ42zF6TMUnakz4TLzUyRjY0aqvB/gstq6GtdP2lae89XL6tPctlWFpO3cVjYFObfyzAAAZCZpA2CztqZXCDh6dP10tBZrqjOkvw6DfIBUWrksl03a1sRsK8/56mWnqLyR&#x2B;Po3tvXkQ5W87dCkbTFjG7SyUYuBP8B6kjYAglqZXiHm0AmXxx8eK2eZ54IDkFArF&#x2B;fAk9V2Jm1PT5s5aRtpblvpuKRNKxt5tHKFB0hC0gZAnDVu3TtovH07bDOkZ57rDEBmTVylZ&#x2B;Kxlc9U27p75NOT50/ahnaa29ac/7i87Yik7dyM7dX5tbJdUxMXdoBsJG0A7GWxW9/KTp2MB04/M2I25rm8ADQh&#x2B;eW6bNI2f8JNRyVM2kbVKrRGw7biSduhMVvNoFRB3oHk13OAtCRtABSgHO9e2RH4&#x2B;APz/ptflzrh/FG0yFpagLZkvm4XT9puXzD&#x2B;1asvMd8MlzZpGz3WXZrbRgWTNq1spGJcDxAmaQOgjMzTKxRRcOrk7bsfhoekTczGxCAfoFE5L&#x2B;BHJG3Ta&#x2B;Yf4dZ00ja0s5nkmoKwYN5WKmnro5VNeV3LDwAAHHhJREFUNd4Hw3mAnSRtAJSUc3qFgoqMye&#x2B;SNhkbt1xGAJqWcLr2oKRtzRdqPWkbVWt7aqW5bX/SppWNVJTfAPtJ2gAoLOH0CmXNP4NtzYG3SZuYjYmrB0A3ss3bLjaczb/&#x2B;4knb0E5z25rz78/b9iRtixnboJWNipTfAKVI2gA4RLbpFYrbM0ofk7bFHw8Z26W4aAB0JtWFvU7SNn9g00nbSHPbKJy0ndvKVjMupQmprtIArZO0AXAU6&#x2B;OuIDb2XjOoM6q/DtcKgF7lucKXTdpu/3bmr4bukrZBc9swDKGkzXaRZCNmAyhL0gbAsVTw3QsMwud/KozqL8UlAqB7SS71m4KuTYHZ7WtmvkofSduoVGwTPmqlNQVkIG/bmrRpZSOVPGsgAHoiaQPgcEmmVzjUptH4zI&#x2B;EUf2luDgAXESSid2ZXrSZVw7rkrZXukzahms3t61P2rSykY3yG&#x2B;AgkjYAakgyvcKh1g/Lnw7wjOovxTUB4IKSzPCOiVcsadsas80f23TSNmolbyvb3LYmaVvM2IaD/4&#x2B;0snFH&#x2B;Q1wKEkbAPUkmV7hUGvG53c/CYb0V&#x2B;NSAHBZrUz1Sto2eazlEoZta86/MmxbTNq0spGN8hvgaJI2AKpqZXqFPRYH6rcjPaP6S3EFAGBoYc5X0rZVK81ta86/mLfNJG0tZmzho2iC8hugDkkbACfIP73CfjMj9vEH4P03v371ArrkFx&#x2B;ASfKbgqQtplor1dF51TCbt71K2lqM2WRsfUt&#x2B;pQXoiaQNgHMo&#x2B;q/g1dD9VdJmVN8ra2kBeJT57iBpC7tCc9tj0tZixhY&#x2B;ilYYcQPUJGkD4DSZp1co6HEM//bdD8M/J22G9B0zyAdgRs7bxPqk7TYte5rDXS1pG/Xd3HabtC1mbMPBb1LGxiMDbYD6Ppz9BgC4rl/efx5L/2kkQJcWB&#x2B;1G9R3LOX8KQB5TNdhBQdhxcrbV0&#x2B;puPnB6//b7x6Pevvk6cNR6i&#x2B;cfZrO0Na1se2K2xf&#x2B;7UjHbzo&#x2B;RVKbyWwUOUJOeNgDOZ83dRUyj&#x2B;qmnzZC&#x2B;Y36vAdgk1eKMWE/b/Asu1dM26XIzyX/5139f84O6M2MLnFwr28UpvwFOJGkDIItU0ysc5&#x2B;2br8ekzfe6Y36dAQjIc/uQtBXUU9g2rPspTfhUNhlb9/JcPwGuSdIGQCJW4V2EcWDH/BYDsEee&#x2B;8htMCZp26&#x2B;bvG2&#x2B;jk2YsYWPoiGGVwCn85w2ABLx5DZomsdCALBTnmrw408/PiZhj3/ymJ/xVODJbWWPWi&#x2B;cliWM2Z4&#x2B;KM5T2XoyPeRS&#x2B;Q1wLj1tAGRktNA3398u&#x2B;bYCUFCq5rbbgG1T19r8316qp23SenPb04InYcYWPoqGKL8B8pC0AZBUnukVijMm7IzfVgAOkrBmmInTJG3r1XzSWNkY7PFnMmHMJmPrnvIbIBtJGwCpJZxeYT/f1p74bgJwqIQTypt2jJS0vdJoc9tt5ZMwYwsfRUOU3wAJSdoAyC7h9Ao7GRz2we8mANWkKh4kbQU1l7dNP4p7ziZjIyzVxRCAyYez3wAALPjl/edxIDFN6wOnmwb5xvkAVJCqGpSQFfQ0B1oMsQoetd7t&#x2B;cVs1Pfh7VMxG0BaetoAaIYGmm4YIrbOdxCAU&#x2B;SpBte3telpW6mh5ra37354/82vAwfK2AhTfgMkp6cNgGZoboPTWUsLwInyVINCsuIaam6LEbMRo/wGaIKeNgDaY6TROt/BRvnGAZBEkua2NZ1tetq2yt/ctrWnTcZGmPIboBV62gBoz7SW&#x2B;fTlzHAR1tICkEqS5raPP/14m5ZJzoqo3Nx2dDRVLWar8P9CTcpvgLboaQOgYcYejfKNa4vvFwBpJWluu3XXu6anLSxtc9vKnjatbIQpvwGaI2kDoG0Jp1dYZOjYCr9fADQhVWkhaSsrECy9is1K5W1rkrYjAjMZ20WkuqABsJLdIwFoW5K9g6A/0yDfOB&#x2B;A5FSDHQtsC/lqH8XYFpRbLe7i&#x2B;PbN14G9H8VsV2DHSIB26WkDoBOabxpiAJmf7xEAzUlVDU4dbHraSsmzmeSrnrbwaWVsDMpvgMbpaQOgE5rboAhraQFoVKpqcCZgI6Zgm9oRzW3hzE/MhvIboAN62gDojVFKfr5HafnWANCBPM1tY8w2pm562ko5vbntrqet5peWsfVH&#x2B;Q3QBz1tAPRmWsucYTkztMJaWgC6kae57eNPP4rTiqvc3DYfbonZ2EP5DdANPW0AdMu4JS3fmmx8RwDoUp7mtkFP2wHOam4be9pkbOyR6uoEwH6SNgB6ZgCTk1wnFd8OAPqW5053F7ZJ2vYrmGatOXA89u27HxZ/nMRszMhzUQKgFEkbAP0zksnGdyQJUTQAF5Gn9rgN2yRtpdSMtRZ/lmRszFB&#x2B;A/RK0gbAJeSZXmHw7cjBdwGAS0k1wT3mbZK2gsJtalsjrvkKSszGDOU3QMckbQBcRarplYszyDyX3wUALksR0rcKQderHyEZG/NcfAD6JmkD4FqMcDLwXTiRDx&#x2B;Ai7PipHuHhl6PpVSsnU7Gdh2uOQBXIGkD4HIMdU4n7DmLTx4ARu6JfTsubLv7ydHKxjyXGoCLkLQBcFHGPCfy4dcnYAaAOwqS7h0Rg00/NjI25im/AS5F0gbAdRn8nMXEVmU&#x2B;cAB4SjXYvYJ52Hjg&#x2B;DPz/ptflzqtmK1Lym&#x2B;Aq5G0AXB1RkH1&#x2B;cyrMYEIAItUJt0rm7e9fffDXdImY2Oi/Aa4pg9nvwEAONk4BJpGRNCNad7QOB8AZkzVoIKwV08zrVdB2u1Ra8IwMRsT5TfAZelpA4BhsPawLivHj&#x2B;bnGQAClCjdK9LcNvW0ydi45QICcGWSNgD4B6OjOnzOh/LxAkCY1Srdm3kG28oDx6RNzMbEdQMASRsA/BPDpApEQcfx2QLAfu6n3QvHYG/ffP323Q/zPxsytktxuQBgkLQBwFPGS4fy8R5BSAwABSlXriAQiS3&#x2B;YIjZrkP5DcBE0gYAzxk4HcfUVXE&#x2B;UgAoTjV4BVuDsZmiS8Z2KcpvAG5J2gBgjhHUEXyqBZkEBIBDqVuuYH1I9urnQcx2KS4LANyRtAHAAuOo4nykpfgkAaAC61quYGVU9lh9ydguxdUAgKckbQCwzICqLPlQET5GAKjJnfcKFmOz2x&#x2B;Dpy8exGz9chEA4BVJGwCsZWRVik9yJ9EvAJzCLfgK5sO2qY7VynYpfvcBmCdpA4ANDLGKkLTt4dMDgHO5F1/BqyBt/O6//&#x2B;bXj39V421xBr/yACyStAHAZsZaO/kAYwS9AJCEYuYKXm0O&#x2B;fbdD3dJm5itY37ZAVjjV2e/AQBozy/vP394&#x2B;9Sgi5r8vAFAHqrBKxjzs1d52&#x2B;1r6JJVbgCs9&#x2B;HsNwAATfrl/edxxDUNwOA4JvIAIBvV4EW8f/v9qzhNzNaxqfxWgQOwht0jAWAXEUiAD209a2kBIDk364uYmtvevvvB97pjfqMBCJC0AcBeBmNbSdpW8kEBQCvctS/i7ZuvJW0d84sMQIykDQDKMCpbz2e1SHwLAM1x&#x2B;74CdWyv/P4CsIfntAFAGdODOjyrg508FgIAWuTJbdAo5TcAO0naAKAY0yvsNCW1BvkA0CjVILRF&#x2B;Q3AfpI2AChMcxsx1tICQB9Ug9AEq9wAKEXSBgDlaW5jK4N8AOiJahCSs8oNgIIkbQBwFNMrrGEtLQD0SnMbJKT8BqA4SRsAHMj0CvOspQWAvmlug1SU3wAcQdIGAMcyvcJT1tICwHVYfQUZKL8BOIikDQBqML3CLWtpAeBqrL6CE1nlBsChJG0AUInpFUYG&#x2B;QBwWapBqM8qNwCOJmkDgKpMr1yZtbQAgK0OoBrlNwB1SNoAoDbTK9dkLS0AMLLVAVSg/AagGkkbAJzA9MqlWEsLADyy&#x2B;gqOo/wGoCZJGwCcxvTKFVhLCwC8YvUVFGeVGwD1SdoA4EymV/pmkA8ALFINQilWuQFwCkkbAJxPc1t/rKUFANZTDcJOym8ATiRpA4AUNLf1xFpaAGAr1SCEKb8BOJekDQASMb3SOmtpAYA9NLfBJspvADKQtAFALqZX2mUtLQCwn&#x2B;Y2WEn5DUASkjYASMf0SnOspQUAyrL6CuYpvwHIQ9IGAEmZXmmFtbQAwBGsvoKnrHIDIBtJGwDkZXolP4N8AOBQqkG4ZZUbAAlJ2gAgO81tOVlLCwDUoRqEQfkNQGKSNgBogOa2bKylBQBqUg1yccpvADKTtAFAM0yvZGAtLQBwFs1tXJPyG4DkJG0A0BLTK&#x2B;eylhYAOJfmNi7FKjcAmiBpA4DGmF45i0E&#x2B;AJCE1VdcgVVuALRC0gYATTK9UpO1tABANlZf0THlNwBtkbQBQKtMr9RhLS0AkJZqkP4ovwFojqQNANqmue041tICAPmpBumJ8huAFknaAKB5mtuOYC0tANAK1SAdsMoNgHZJ2gCgE6ZXCjLIBwCao7mNdlnlBkDTJG0A0A/TK/tZSwsAtEtzG81RfgPQAUkbAHTF9Moe1tICAB2w&#x2B;opWKL8B6IOkDQA6ZHplK2tpAYCeWH1FcspvAHoiaQOAPpleWc9aWgCgS6pBclJ&#x2B;A9AZSRsA9Mz0yjxraQGAvtnqgGyU3wD0R9IGAJ0zvfKKtbQAwBXY6oAkrHIDoFeSNgDon&#x2B;mVRwb5AMClWH3FuaxyA6BjkjYAuArTKyNraQGAa7L6ilMovwHonqQNAC7E9Iq1tADAxV28GqQy5TcAVyBpA4DLuWZzm7W0AACja1aD1Kf8BuAiJG0AcEVXa26zlhYA4NbVqkEqs8oNgEuRtAHAdV1kesUgHwDgKc1tHMEqNwCuRtIGAJfW9/SKtbQAAPM0t1GQ8huAa5K0AcDV9Tq9Yi0tAMBKfa&#x2B;&#x2B;og7lNwCXJWkDAIahr&#x2B;kVa2kBALbqdfUVdSi/AbgySRsA8P/1Mb1iLS0AQFgH1SCVWeUGAJI2AOCfNN3cZpAPALBT09UglVnlBgCDpA0AeNRic5u1tAAApbRYDVKZ8hsAJpI2AOC5hqZXrKUFAChOcxuvKL8B4JakDQB4Kf/0irW0AADH0dzGHeU3ADyStAEAczJPr1hLCwBQQf7VV9Sh/AaApyRtAMCybNMr1tICANSUefUVdSi/AeAVSRsAsEqe6RVraQEATpGkGqQyq9wAYJ6kDQDY4PTmNoN8AIATnV4NUplVbgCwSNIGAGxzVnObtbQAABnk2eqAQym/AWAlSRsAEFF5esVaWgCAVDS39U35DQDrSdoAgKA60yvW0gIA5KS5rVfKbwDYRNIGAMQdPb1iLS0AQHKa23pilRsABEjaAIC9DppeMcgHAGiC5rY&#x2B;WOUGADGSNgCggLLTK9bSAgA0R9jWLuU3AOwhaQMAiikyvWItLQBAo&#x2B;wk2SLlNwDsJGkDAEraM71iLS0AQOvsJNkW5TcA7CdpAwAKi02vWEsLANANzW35WeUGAKVI2gCAQ2yaXjHIBwDojOa2zKxyA4CCJG0AwFHWTK9YSwsA0DFhWzbKbwAoTtIGABxrprnNWloAgO7ZSTIP5TcAHOHt/f397PcAAFzCNLC/nWQxyAcAuIgOWqna/V&#x2B;YKvAW3zwAJCdpAwDqkbEBAFxZ63lPo0lbo28bAFph90gAoJ5peG&#x2B;cDwBwQWue40tZYjYAOJqeNgAAAACqarS5ra3UqtEPGQCao6cNAAAAgKo0tx1tCgXFbABwNEkbAAAAACcQth3hw9unbfXeAUDrJG0AAAAAnGMK2&#x2B;RtRWhlA4D6JG0AAAAAnMZOkqVoZQOAU0jaAAAAADiZ5rY97BgJACeStAEAAABwPs1tMXaMBIBzSdoAAAAAyEJz23pa2QAgA0kbAAAAAIlobltDKxsAJCFpAwAAACAdYdsMrWwAkIekDQAAAICM7CT5yI6RAJCNpA0AAACApOwkecuOkQCQkKQNAAAAgNQ0t2llA4C0JG0AAAAAZHfl5jatbACQmaQNAAAAgDZcsLlNKxsAJCdpAwAAAKAZ12lus2MkADRB0gYAAABAY7oP2&#x2B;wYCQCtkLQBAAAA0J5ed5LUygYAbZG0AQAAANCk/naS1MoGAM2RtAEAAADQsD6a27SyAUCjJG0AAAAAtK315jatbADQLkkbAAAAAD1oNGzTygYATZO0AQAAANCJtnaStGMkAHRA0gYAAABAP1rZSdKOkQDQB0kbAAAAAL3J3NymlQ0AeiJpAwAAAKBDOZvbtLIBQGckbQAAAAB0K1Vzm1Y2AOiPpA0AAACAnmVobrNjJAD0StIGAAAAQP9ODNvsGAkAHZO0AQAAAHAJ9XeS1MoGAN2TtAEAAABwFTV3ktTKBgBXIGkDAAAA4FoqNLdpZQOAi5C0AQAAAHA5xzW32TESAC5F0gYAAADARRVvbrNjJABcjaQNAAAAgOsq1dymlQ0ArknSBgAAAMDV7QzbtLIBwGVJ2gAAAAAguJOkVjYAuDhJGwAAAAAMw/adJLWyAQCSNgAAAAD4h5XNbVrZAIBB0gYAAAAAd&#x2B;ab2&#x2B;wYCQBM3t7f389&#x2B;DwAAAACQ0ZS0/fL&#x2B;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" />
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>